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CHAPTER I 
 
INTRODUCTION 
 
Leukemia, perhaps more than any other cancer, is often associated with the 
aberrant function of transcriptional regulators resulting from chromosomal translocations.  
These chromosomal translocations frequently target genes that are required for normal 
hematopoiesis, including Mixed lineage leukemia (MLL), Runt-related transcription 
factor 1 (RUNX1), T-cell acute lymphocytic leukemia 1/stem cell leukemia (TAL1/SCL), 
E2A, B-cell Lymphoma 6 (BCL6), and the Notch receptor 
1-8
. While these factors were 
first identified through their respective translocations, knockout mouse models and 
biochemical studies have shown important functions for these proteins beyond leukemia.  
In fact, they all regulate multiple stages of hematopoiesis, not just the population targeted 
for cancer transformation.  Furthermore, many of these factors interact with and/or 
regulate the expression of each other, creating a network of critical modulators of 
hematopoiesis
9,10
.  Mutation of these targets may disrupt hematopoietic lineage 
allocation, cell growth, and survival, ultimately leading to leukemia.  
The Myeloid Translocation Gene (MTG) family was first discovered through the 
(8;21) translocation that leads to Acute Myeloid Leukemia (AML)
4
.  This translocation 
fuses nearly all of Myeloid Translocation Gene 8 (MTG8, also known as Eight-Twenty-
one or ETO) to an N-terminal portion of RUNX1, also known as Acute Myeloid 
Leukemia 1 (AML1) containing the DNA-binding Runt homology domain (RHD), thus 
redirecting the normal function of MTG8 as a transcriptional co-repressor
4,11
.  The t(8;21) 
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accounts for 12-15% of de novo AML, which is of the M2 subtype.  Two other MTG 
family members have since been identified: Myeloid Translocation Gene 16 (MTG16 or 
ETO2 or CBFA2T3) and Myeloid Tumor Gene Related-1 (MTGR1 or CBFA2T2), both 
of which are implicated in leukemia
12-14
.  MTG16 is a target of the t(16;21) that, like the 
t(8;21), fuses MTG16 to AML1 to produce AML, though this rare translocation develops 
primarily in response to therapy.  While not a direct target of a chromosomal 
translocation, MTGR1 is frequently deleted in myelodysplastic syndrome and in 3-10% 
of AML.  In addition to their well-studied roles in myeloid leukemia, MTG family 
members have been implicated in other cancers as well: MTG8 is mutated in colorectal 
carcinoma, breast, and lung cancer while MTG16 is mutated in ovarian, breast and 
colorectal cancer
15-18
. 
Given the precedence for targets of leukemia-related chromosomal translocations 
acting as critical regulators of hematopoiesis, we generated an Mtg16
-/-
 knock-out mouse 
model to better understand how Mtg16 functions in normal development and, ultimately, 
cancer
19
.  In the absence of Mtg16, B- and T-cell development were decreased, 
particularly after stress such as a competitive bone marrow transplant.  Both early B- and 
T-cell development were perturbed in vitro and these developing Mtg16
-/-
 cells showed 
altered cell growth and survival, though different mechanisms contributed to the B- and 
T-cell phenotypes.  Mtg16 deletion also negatively affected mature B-cell mediated 
immune responses. 
Hopefully, basic development information generated from the Mtg16
-/-
 mouse can 
be translated to disease, leading to a better understanding of how both the AML1-ETO 
fusion protein and the more rare AML1-Mtg16 fusion protein produce leukemia.  The 
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work presented here highlights the importance of Mtg16 in regulating multiple stages of 
hematopoiesis, and provides a framework for future studies on how the loss of normal 
Mtg16 function may contribute to phenotypes seen in AML.  Additionally, this work 
provides a new understanding for the importance of the interactions between Mtg16 and 
the Notch-intracellular domain, Bcl6, and E2A, which are all master regulators of 
hematopoiesis that are mutated in leukemia.  
 
Myeloid Translocation Genes 
 
MTG family members function as transcriptional co-repressors by binding to a 
variety of DNA binding transcription factors and recruiting histone deacetylases 
(HDACs) and other transcriptional co-repressors such as mSin3a and the nuclear receptor 
co-repressor (N-CoR) and silencing mediator for retinoid and thyroid hormone receptors 
(SMRT) and to repress transcription (Fig. 1)
20-24
.  The list of transcription factors that 
regulate hematopoiesis and that also recruit MTG family members includes the mediator 
of Notch signaling CSL (CBF1-Suppressor of Hairless-Lag1), growth factor 
independence (Gfi)-1, Gfi-1B, Promyelocytic Leukemia Zinc Factor (PLZF), Bcl-6, 
Transcription Factor 4 (Tcf4), Tal/Scl, GATA1, and the basic Helix-loop-helix E-proteins 
E2A, HeLa E-box binding factor (HEB), and E2-2
25-32
.  These transcription factors are 
critical during specific stages of hematopoiesis, and function in part by recruiting MTGs 
to repress transcription, suggesting that MTG family members can directly regulate 
hematopoiesis.  Roles for Mtg16 in hematopoiesis are becoming 
 4 
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more apparent and will be covered in more detail later in this introduction. Chapters III 
and IV will introduce new information on Mtg16’s function in lymphoid development. 
In addition to regulating hematopoiesis, MTG family members also regulate stem 
cell populations in the gut and nervous system through many of these same transcription 
factors
33-35
.  In particular, Mtgr1 affects self-renewal and lineage allocation of stem cells 
of the small intestine, at least in part through Tcf4
28,33,34
.  While neural phenotypes have 
not been well characterized after deletion of MTG family members, MTG proteins are 
well expressed in the nervous system
36
.  MTG function is necessary to terminate specific 
stages of neurogenesis in concert with the basic-Helix-Loop-Helix (bHLH) factors 
Neurog2 and E47
35,37
.  With their ability to regulate multiple different transcription 
factors in a given cell and the importance of these transcription factors in stem and 
progenitor cell populations, MTGs can potentially serve as master regulators of 
development. 
 
Structure and Function of MTG Family Members 
The mammalian MTG family members are closely related and conserved with a 
single Drosophila homologue, Nervy (Fig. 2)
38
.  The homology between the mammalian 
and fly counterparts is concentrated within four domains termed Nervy Homology 
Regions, or NHRs
38
.   Nervy homology region 1 (NHR1) has some similarities to a 
domain in hTAF110 and contacts many DNA binding transcription factors including E-
proteins such as E2A
26,31,39
.  NHR2 is a tetramerization domain that can also contact 
other proteins such as mSin3A
22,40,41
.  MTGs can homo- and hetero-dimerize and 
MTGR1 was the most robust interacting partner for ETO by immunoprecipitation
31
.   
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Figure 2. Structure and Homology of MTG family Members  The three
Myeloid Translocation Gene (MTG) family members, Mtg8, Mtg16, and Mtgr1
are highly homologous with the drosophila protein Nervy in four regions, titled
Nervy Homology Regions (NHRs).  Two proline/serine/threonine (PST) rich
regions exist at the N-terminus. Adapted from Davis et al 2003 38
NH1 NH2 NH3 NH4
70%46%51%50%Nervy
97%66%79%95%Mtgr1
90%84%88%98%Mtg16
NHR4NHR3NHR2NHR1
Mtg8 PST1 PST2
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NHR3 is the least conserved of the 4 domains and binds to Protein kinase A and CSL
42,43
.  
NHR4 forms a ring finger motif and is the weaker of the two binding sites for the nuclear 
hormone co-repressors N-CoR and SMRT 
22,40
.  
When MTGs are expressed as Gal fusion proteins and thus tethered to the 
promoter of a luciferase construct driven by a Gal-thymidine kinase (Gal-TK) promoter, 
they repress downstream luciferase expression
20,22
.  Transcriptional repression by MTGs 
is contingent upon histone deacetylase (HDAC) function, as treatment of cells with the 
HDAC inhibitor trichostatin A (TSA) abrogates the ability of MTGs to repress 
transcription
43,44
.  In the context of Gal-fusion transcriptional reporter assays, NHR4 and 
a domain between NHR1 and NHR2 (which is the major contact point for N-CoR) 
contribute to transcriptional repression, and NHR2 contributes in a stochiometric manner 
in that deletion of this domain has a 2-4-fold effect 
22,41
.   
While all three family members generally have similar binding partners, some 
unique contacts exist.  For example, mSin3a interacts with MTGR1 and MTG8 but not 
MTG16
33
.  Additionally, the effect of different MTG family members binding to the 
same proteins may vary in degree.  While all three MTG family members can repress E47 
mediated transcription, Mtg16 is more effective than Mtg8 or Mtgr1 by luciferase 
assay
37
.  Given that MTG family members have similar binding capacities, it is possible 
that they can perform some compensatory functions in knockout mouse models and that 
deletion of more than one family member will reveal new functions for MTGs.  In fact, 
double deletion of Mtg16 and Mtgr1 leads to a novel embryonic lethality by an undefined 
mechanism  (Moore et al, in prep).   
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Targeting of each MTG family member’s function relies in part upon patterns of 
expression.  Generally, MTG family members are widely expressed
38
.  By Northern blot, 
Mtg8 is well expressed in murine brain, lung, heart, testis, ovary, and developing gut
11,45
.  
Mtg16 is expressed in heart, brain, lung, skeletal muscle, and hematopoietic lineages
12
.  
The final MTG family member, Mtgr1, is expressed at the highest levels in the heart, 
brain, and skeletal muscle, and at lower levels in several other tissues
46
. Mtg8 and Mtgr1 
are both expressed in the developing gut, while Mtg16 is not well expressed in this 
tissue
33
.  All three family members are expressed in the nervous system, though the 
timing of each family member’s activation is unique and tightly regulated36.  In 
hematopoiesis, expression of MTG proteins is varied: Mtg8 is not expressed at detectable 
levels in any population except for erythroid progenitors; Mtgr1 is expressed at low 
levels through hematopoiesis; and Mtg16 is the most highly expressed family member 
and is expressed at the highest levels in early stem and progenitor populations
47,48
.  
 
Hematopoiesis 
 
Gene targeting studies have implicated MTGs in regulation of stem cell 
populations, and the stem cell phenotypes generated by loss of Mtg family members 
reflect their diverse patterns of expression.  Specifically, Mtg8
-/-
 and Mtgr1
-/-
 mice have 
defects in the gut. Mtg8
-/-
 germ line deletion yielded perinatal lethality with an associated 
deletion of the midgut
45
.  The Mtgr1 knockout also produced an intestinal phenotype: 
most notably, these mice have a decrease in the cells of the secretory lineage (goblet and 
paneth cells) and increased proliferation of undifferentiated stem/progenitor cells in the 
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crypts
33
.  Interestingly, no defects in hematopoiesis have been reported in either mouse 
model.   
In contrast, Mtg16
-/-
 mice have striking defects in hematopoiesis, implicating 
Mtg16 as the critical family member in this system
19
. Mtg16
-/-
 mice have profound 
defects in erythropoiesis, particularly in response to stress such as treatment with 
phenylhydrazine, an erythrolytic drug.  Furthermore, they have defects in lineage 
allocation as well as changes to stem cell function, phenotypes that have influenced the 
work presented in Chapters III and IV.  As hematopoiesis is a complex and specialized 
developmental process, a framework is presented here to enable interpretation of the data 
in Chapters III and IV.  Additionally, the function of MTG interacting partners and gene 
expression targets in hematopoiesis will be highlighted. 
 
Hematopoietic Stem and Progenitor Cell Development 
Hematopoiesis is the classic stem cell system, and has served as the model for 
subsequent work on tissue specific stem cells and cancer stem cells
49,50
.  Early 
hematopoietic models depicted a common stem cell giving rise to two different arms of 
hematopoietic cells, namely myeloid cells and lymphoid cells
49
.  This model, which 
persisted for years, showed one common early branch point for myeloid versus lymphoid 
cell fate decisions, then development within a myeloid framework to develop erythroid 
cells, megakyocytes, granulocytes, and monocytes, or a lymphoid framework, to develop 
B- and T-cells.  Within the lymphoid framework, common B and T-cell progenitors 
remained in the bone marrow to give rise to B cells or traveled through the circulation to 
seed the thymus and develop into T-cells.  This model has undergone significant revision 
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in recent years, adding layers of complexity with multiple early branch points and 
increasing lineage plasticity
51-54
.  The current models are still under intense debate and 
consensus has not been definitively reached, but a summary is presented (Fig. 3.) 
The one constant to all models of hematopoiesis is that hematopoietic cells begin 
in the bone marrow as long-term hematopoietic stem cells (LT-HSC) Lin
neg
Sca-1
+
c-
Kit
+
Flt3
-
).  These cells have self-renewal capacity as well as the pluripotent ability to 
differentiate into all hematopoietic lineages.  LT-HSCs are functionally defined by their 
ability to repopulate lethally irradiated recipient mice for at least 16 weeks, though 
stringent conditions suggest true LT-HSCs should be assessed at greater than 6 months 
post transplant
55
.  These stem cells will gradually lose their self-renewal potential, 
becoming pluripotent short-term hematopoetic stem cells (ST-HSC) (Lin
neg
Sca-1
+
c-
Kit
+
Flt3
lo
) that can repopulate after transplant for several weeks, but do not have long-
term capacity
56,57
.   
From this point, models of hematopoiesis begin to diverge.  While alternate 
versions exist, generally stem cells lose self-renewal capacity and become multipotent 
progenitor cells (MPP) (Lin
neg
Sca-1
+
c-Kit
+
Flt3
+
).  MPP can then follow one of several 
hypothesized pathways through intermediate progenitor populations.  All of these 
progenitor populations are lineage restricted, but not lineage committed, and thus have 
potential to develop into some types of  hematopoietic cells but not others.  For example, 
one model suggests that MPP cells will lose their ability to give rise to megakaryocytes 
and erythrocytes and gain high expression of the transmembrane receptor fms-like 
tyrosine kinase 3 (Flt3), becoming lymphoid-primed multipotent progenitor cells (LMPP) 
(Lin
neg
Sca-1
+
c-Kit
+
Flt3
hi
) that have granulocyte/monocyte and lymphocyte potential
51
.   
 11 
Long-Term 
HSC
(LT-HSC)
Common Lymphoid 
Progenitor 
Granulo/monocytic
Progenitor
Megakaryocyte/
Erythroid
Progenitor
T-cells
B-cells
Granulocytes
Monocytes
Dendritic Cells
Erythrocytes
Platelets
Short-Term
HSC/Mutli-potent
Progenitor
Early T-Cell 
Progenitor 
Lymphoid-Primed 
Multi-potent 
Progenitor 
Common Myeloid
Progenitor
Self-renewal potential
Figure 3. Model for Hematopoietic Progenitor Development Hematopoetic
cells begin in the bone marrow as Long-term hematopoietic stem cells (LT-
HSC) that self-renew and differentiate to form all the lineages of the blood.
As self renewal decreases, lineage commitment begins.  Cells can become
Lineage Primed Multipotent Progenitors (LMPPs) with granulocyte/monocyte
and lymphoid potential or Common Myeloid Progenitors ( CMPs) with
megakaryocyte/erythrocyte and granulocyte/monocyte potential.
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As part of this lineage potential, LMPP cells can give rise to granulocyte/monocyte 
progenitor cells (GMP), common lymphoid progenitor cells (CLP), and early thymocyte 
progenitor cells (ETP).  Alternatively, MPP cells can lose lymphoid lineage potential and 
give rise to common myeloid progenitor cells (CMP) that have granulocyte/monocyte 
potential as well as megakaryocyte/erythrocyte potential
58
.  These intermediate CMP 
cells can then develop into GMP and megakaryocyte/erythrocyte progenitor cells (MEP).  
During and after lineage commitment, cells undergo various stages of lineage 
specific development before becoming mature functional hematopoietic cells.  Many of 
the changes we see in the absence of Mtg16 are located in these early stem and progenitor 
populations, as this is the location of the highest levels of Mtg16 expression
47
.  
Additionally, the work presented in Chapters III and IV focuses on early lymphocyte 
development.  Therefore, in addition to this overview of stem and progenitor pathways,  
T- and B-cell development will be covered in more detail, while the development of other 
lineages is beyond the scope of this work. 
 
Early Lymphocyte Development 
Early B and T-cell development share many common features and precursor 
populations.  Like all hematopoietic cells, both B- and T-cells begin as long-term 
hematopoietic stem cells and travel through short-term hematopoetic stem cell and MPP 
cell populations.  Lymphoid lineage development begins with the production of LMPP 
cells.  These cells have both myeloid and lymphoid, but not megakaryocytic or erythroid, 
lineage potential and are the first cells where lymphoid associated gene expression is 
initiated
51,59
.  Loss of the LMPP population leads to a complete less of B- and T-cells; 
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this result is shown in Hdac3
-/-
 mice that have no LMPP cells and no B or T-cells as a 
result (Summers et al, in prep).  Flt3 expression and signaling is a functionally important 
characteristic of LMPP cells in lymphoid lineage development, and contributes to the 
upregulation of IL7-Receptor expression, the critical cytokine receptor for early 
lymphoid development
60
.  In fact, loss of Flt3-ligand expression in mouse models and 
thus loss of Flt3 receptor mediated signaling leads to a decrease in both early B cells and 
early T cells
61
.   
Lineage plasticity and myeloid skewing are hallmarks of the LMPP 
population
51,59
.  Granulocyte/monocyte specific genes, such as Colony stimulating factor 
3 receptor (Csf3r) and SFFV proviral integration 1  (Sfpi1), are expressed throughout the 
course of early hematopoietic differentiation and into the LMPP population.  By contrast, 
early lymphoid specific genes, such as Recombination activating gene 1 (Rag1) and 2 
(Rag2), are only upregulated within the LMPP population.  Lymphoid expression 
programs are not completely activated at this early stage, though, and genes that are 
expressed only in committed lymphoid cells, such as Paired box gene 5 (Pax5) and Cd3e, 
are not expressed in LMPP cells.  Using single-cell RT-PCR assays, it was found that 
nearly all LMPPs express granulocyte/monocyte specific genes while only roughly 30% 
expressed lymphoid specific genes. All cells that expressed a lymphoid program also 
expressed a granulocyte/monocyte program, highlighting the myeloid and lymphoid 
lineage potential and myeloid preference of these cells. 
The next step in lymphoid development beyond LMPP cells is the production of 
B- and T-lineage specific progenitors.  Early models of hematopoiesis focused upon 
Lin
neg
IL-7R
+
c-kit
lo
sca-1
lo
 Common Lymphoid Progenitor (CLP) cells that were 
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hypothesized to precede both B and T-cell development
62
.  CLP cells are capable of 
generating both B and T-cells in vitro and after transplant and have limited potential for 
other lineages
62
.  More recent work has found that very few common lymphoid 
progenitors can be found circulating in the peripheral blood, decreasing the likelihood 
that these cells seed the thymus to generate T-cells
63
. Instead, LMPP cells are much more 
numerous in circulation and capable of generating T-cells in vitro and after transplant
51,52
.  
Therefore, they are thought to contain the thymus seeding population
63-65
.  Newer models 
of hematopoiesis suggest that common lymphoid progenitors remain in the bone marrow 
and primarily give rise to B-cells
66,67
. 
Upregulation of the IL7 receptor (IL7R) is an important hallmark of lymphoid 
specific lineage programming and is a common component in both B- and T-cell 
development.  IL7 signaling is crucial for all lymphoid development and in the absence 
of either IL7 or its receptor, both B- and T-cell development are lost to varying levels
68,69
. 
Expression of the IL7R defines the CLP B-cell precursor population and IL7 supports the 
in vivo differentiation of CLP cells into the earliest B-cells, though IL7R
+
 CLP 
production was not compromised in the absence of the IL7 cytokine
70
.  Additionally, 
IL7R
-/-
 and IL7
-/-
 B-cells arrested in the earliest stages of B220
+
 B-cell development
68,69,71
.  
While the IL7R is not well expressed on the earliest cells of the thymus (Early thymocyte 
progenitor or ETP cells) its expression is upregulated with the transition to the next stage 
of thymocyte development and the initiation of T-cell commitment
66,72
.  IL7R
-/-
 
thymocytes therefore arrest in the earliest stages of thymus development prior to T-Cell 
Receptor (TCR) rearrangement68.  Loss of IL7 cytokine expression also leads to a sharp 
decrease in thymocyte number, though normal developmental stages exist
69
. In addition 
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to regulating the development of lymphocytes, IL-7 signaling also regulates the survival 
of T-cells, and the expression of a Bcl-2 transgene rescued T-cell development in IL7R 
deficient mice 
73
.    
The important role for both Flt3 and IL7 in early lymphoid development is 
highlighted by the ability of IL7 and Flt3 to instruct in vitro lymphoid development
70,74
.  
Though T-cell development requires the addition of a strong Notch signal, IL7 and Flt3-
ligand are sufficient to induce B- or T-cell development from uncommitted progenitors in 
OP9 culture systems
74
 .  Furthermore, loss of both Flt3-ligand and IL7R had an additive 
effect in vivo, and resulted in a more severe B-cell phenotype than either single 
deletion
75
.  
Lymphoid lineages are grouped together in part because of the common process 
of germ-line chromosomal rearrangements associated with V(D)J recombination that 
contribute to the development of mature, functional B and T cell receptors.  V(D)J 
recombination is a unique feature of B and T-cells that, briefly, consists of Rag1 and 
Rag2 mediated rearrangement of either T-cell receptor or B-cell 
receptor/immunoglobulin loci
76,77
.  Ultimately, T-cells must rearrange two T-cell receptor 
(TCR) chains,  and , to produce a mature receptor, while B-cells rearrange two B-cell 
receptor chains, the immunoglobulin heavy chain (IgH) and the immunoglobulin light 
chain (IgL)
78
. V(D)J recombination facilitates the production of a diverse repertoire of 
these receptors, maximizing the capacity for the immune system to recognize foreign 
antigens.  Rag1 and Rag2 expression can first be seen in the LSK compartment, where a 
small fraction of cells with lymphoid potential begin to express Rag1 and Rag2 at very 
low levels
79
.  This expression leads to a small level of B-cell receptor V(D)J 
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recombination in cells prior to B-cell commitment.   Rag levels increase throughout CLP 
and ETP populations and V(D)J recombination plays an important role in the maturation 
of lymphocytes, which will be discussed in more detail in later sections.  While common 
processes such as V(D)J recombination and IL7R signaling contribute to the maturation 
of both B- and T-cells, B and T-cell development diverge beyond the LMPP population. 
 
T-Cell Development 
Once in the thymus, LMPP thymus seeding cells become early thymocyte 
progenitor (ETP) cells characterized by the expression of low levels of the progenitor cell 
marker c-kit and the lack of expression of maturing T-cell markers CD4 and CD8
66,80
.  
ETP cells sit in the first of four populations of CD4
-
CD8
-
, or double negative (DN) cells 
(Fig. 4).  The thymic microenvironment is rich in Notch signaling activation, a necessary 
component for T-cell development, due to high levels of Notch ligand expression
81
.  In 
this context, ETP cells then progress through distinct stages of T-cell development, first 
the four DN stages (DN1-DN4), followed by CD4
+
CD8
+
 double positive (DP) cells, to 
produce mature, functional CD4
+
CD8
-
 and CD8
+
CD4
-
 T-cells that exit the thymus to 
contribute to immune responses
80
.   
DN cells can be further subdivided based upon expression of CD44 and CD25 
into four populations: DN1 CD44
+
CD25
-
, DN2 CD44
+
CD25
+
, DN3 CD44
-
CD25
+
, and 
DN4 CD44
-
CD25
-82
.  ETP cells that seed the thymus are a small subset of the DN1 
population
66,83
.  These cells are not T-lineage committed, and retain the capacity to  
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Figure 4. Transcription factor regulation of early T-cell development T-
cells begin in the bone marrow as LT-HSCs and differentiate through the
Lymphoid-primed multipotent progenitor (LMPP) population.  The thymic
seeding cells arise from the LMPP population and become Early thymocyte
progenitor (ETP) cells.  Thymocytes develop through four Double Negative
(DN) stages, including the -Selection checkpoint, to become Double Positive
(DP) cells and CD4+ and CD8+ cells.  Transcription factors and signaling
molecules that regulate T-cell development  are depicted in blue.
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generate myeloid cells both in vivo and in vitro in addition to dendritic cell and natural 
killer cell capacity
84-87
.  As cells travel into the DN2 subset, they begin the process of 
committing to the T-cell lineage and upregulating T-cell specific gene expression 
patterns
87-89
.  Final T-cell commitment occurs in the DN3 stage as thymocytes undergo 
V(D)J rearrangement and produce a rearranged TCR; in the absence of successful 
TCR rearrangement and cell surface expression of TCR with a surrogate preT- chain, 
cells are not able to move beyond this DN3 stage
76,77,90-93
.  The process of stalling cells 
that do not express the TCR/preT- complex is termed -selection, and serves as a 
critical checkpoint in thymocyte development. 
Once cells bypass -selection, they traverse into the DN4 population and 
upregulate expression of CD4 and CD8, ultimately becoming CD4
+
CD8
+
 DP cells.  From 
this point forward, they will undergo further V(D)J recombination to rearrange the  
TCR chain, then positive and negative selection to identify T-cells with appropriate TCR 
expression for antigen identification and response
94,95
.  Cells will then become either 
CD4
+ 
or CD8
+
 and exit the thymus to play diverse roles in the immune response.  
 
Transcriptional Regulation of Early T-cell Development 
The process of early T-cell development is highly regulated by a number of 
different transcription factors, many which are Mtg16 interacting factors and contribute 
to the phenotypes described in Chapter III (Fig. 4).  First and foremost on the list of T-
cell regulatory factors is Notch signaling, though other critical factors include Gfi1, 
Gata3, Runx1, Sfpi/PU.1 and basic Helix-loop-helix (bHLH) E-protein transcription 
factors E2A and HEB
81,96-104
.  These transcription factors work together to activate and 
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repress genes to form the T-cell lineage program.  The gene targets of these transcription 
factors are varied, but some of the most important early targets in T-lineage specification 
and commitment include Hes1, Ptcra, IL7Ra and other T-cell transcription factors such 
as Gata3
9,89,105
.  Given the importance of Notch and E-proteins in mediating the Mtg16 
functions discussed in Chapter III, the biochemical properties and functions of Notch and 
E-proteins in T-lineage specification will be covered in more detail in subsequent 
sections.  A general picture of other factors important in transcriptional control of early 
T-cell development follows. 
Gfi1 is a zinc-finger transcriptional repressor that functions by recruiting 
corepressors such as MTGs and HDACs to repress downstream transcription
26
.  Gfi1 
regulates several steps in the process of maturing thymocytes including survival of DN1 
and DN2 cells
98
.  In fact, in the absence of Gfi1, mice have a severe reduction in 
thymocyte number to roughly 10% of their wild-type counterparts.  This reduction in 
thymocyte number resulted from an increase in apoptosis of immature DN1 and DN2 
cells, reducing the number of T-cell progenitors in the thymus capable of generating 
mature cells.  Gfi1 also regulates the selection of CD4 or CD8 expression in favor of 
CD8
+
 T-cells, though the mechanism remains unclear.   
Gata3 is the essential GATA factor for T-cell development, and its expression is 
tightly controlled to the T-cell compartment within mature hematopoietic cells
106
.  While 
an interaction between MTGs and Gata3 has not been previously shown, Mtg16 can 
interact with the GATA1 family member
32
.  Furthermore, Gata3 is a potentially 
important target of Mtg16, and deletion of Mtg16 leads to increased Gata3 levels, as 
detailed in Chapter III.  Gata3 is necessary for development of the earliest ETP cells of 
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the thymus, restriction of the T-cell fate in DN2 cells, and passage through the -
selection checkpoint, in part by regulating TCR expression.  Gata3 deletion is 
embryonic lethal, and therefore the effect in T-cell development was shown first by the 
absence of Rag2
-/-
 thymocyte repopulation by Gata3
-/-
 ES cells
100,107
.  This finding was 
corroborated by the absence of even DN1 cells generated by Gata3
-/-
 ES cells in chimeric 
mice
101
.  Recent work using bone marrow transplant as well as Mx-Cre driven conditional 
deletion of Gata3 showed that Gata3 is necessary for the development of ETP cells, 
confirming the requirement for Gata3 in the earliest stages of T-cell development
108
.  
Additionally, mice with a conditional Gata3 deletion driven by the Lck promoter (active 
in early DN3 stages of thymocytes and beyond) developed a strong decrease in total 
thymocyte number, largely due to a block in DN3 cells at the point of -selection109.  The 
appropriate amount of Gata3 expression is critical for regulating T-cell development 
though: over-expression of Gata3 was also deleterious to developing T-cells, and caused 
mast cell diversion of both hematopoietic progenitors and early DN1 and DN2 
thymocytes in in vitro T-cell assays
99
.   
Runx1, also known as AML1, is a core-binding factor transcription factor and a 
critical mediator of definitive embryonic hematopoiesis
110,111
.  Runx1 is also the 
translocation fusion partner for ETO in the t(8;21) and we have preliminary unpublished 
data that Runx1 is a direct target for Mtg16 regulation, suggesting misregulation of 
Runx1 may contribute to Mtg16
-/-
 phenotypes
112
.  Runx1 functions in T-cells to regulate 
CD4 expression and the generation of DN3 cells in part by regulating repression of the 
PU.1 transcription factor.  Loss of Runx1 was embryonic lethal because of its crucial role 
in definitive hematopoiesis
110,111
.  As a consequence, analysis of the role of Runx1 in 
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adult hematopoiesis relies upon conditional deletion models. When Runx1 was deleted in 
DN3 developing T-cells using the Lck-cre conditional knockout system, Runx1 mediated 
silencing of CD4 expression was lost and CD4 was aberrantly expressed in early double-
negative thymocytes
113
.  Furthermore, Runx1
-/-
 thymocytes arrested in DN3 and 
insufficiently upregulated CD8 as they became DP cells, which collectively led to a 
reduction in total thymocyte levels
113
.  Using the Mx-Cre inducible deletion mouse model 
to delete Runx1 beginning in early hematopoietic stem cells and sustaining throughout 
hematopoiesis, Runx1 was necessary for both megakaryocyte development and full 
lymphoid development, a phenotype that was exacerbated after competitive bone marrow 
transplant
102,103
.  Runx1
-/-
 developing thymocytes arrested at the DN2 population, which 
produced decreased DN3 and DN4 levels. One factor contributing to the mechanism of 
this phenotype was increased expression of PU.1, a critical regulator of cell fate decisions 
in hematopoiesis.  The T-cell phenotype seen in these mice was reverted by deletion of 
one allele of PU.1, confirming that the enhanced PU.1 expression seen in the absence of 
Runx1 contributed to the DN2 arrest
114
.  
PU.1 is another essential transcription factor for regulating cell fate decisions in 
hematopoiesis and T-cell development.  PU.1 is necessary for initial T-cell development, 
though PU.1 expression is detrimental beyond the DN2 stage.  Deletion of PU.1 was late 
embryonic/early neonatal lethal due to anemia and septicemia
115,116
.  Deletion also caused 
a block in early lympho- and myelopoeisis, with no maturing B and T-cells or 
granulocytes and monocytes, though this disruption could be somewhat bypassed in the 
T-cell lineage by keeping the neonates alive with antibiotic treatment.  Therefore, PU.1 
contributes to lineage commitment and development of multiple hematopoietic lineages.  
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Given the partial rescue of T-cell development with survival, the role of PU.1 in later T-
cell development was less clear from these early mouse models.  Expression data showed 
that PU.1 was repressed sharply in the thymus DN2 cells as they began commitment to 
the T-cell lineage
117
.  Constitutive expression of PU.1 in hematopoietic progenitors 
blocked T-cell development at the DN2/DN3 stage in fetal thymic organ cultures 
(FTOCs), and instead promoted macrophage development
104
.  If PU.1 expression was 
enforced in committed DN3 thymocytes, cells were reprogrammed to myeloid dendritic 
cells, an effect that was antagonized by the presence of a strong Notch signal or the 
expression of Gata3
118
.  Therefore, downregulation of PU.1 at the DN2 stage is a critical 
step in T-lineage cell fate specification.       
 In addition to DNA-binding transcription factors, transcriptional corepressors 
have also been shown to play an important role in regulating thymopoiesis.  Conditional 
deletion of Hdac3, an MTG binding partner, had severe impacts on many different stages 
of T-cell development depending on the population where Cre is activated, including loss 
of early LMPP cells and impaired passage of cells from DP to single positive stages  
(Summers et al, in prep).  Deletion of NCoR, another component of MTG repression 
complexes, also negatively effected T-cell development
119
.  NCoR
-/-
 mice have defects in 
fetal erythropoiesis, and therefore deletion was embryonic lethal.  Using in vitro FTOC to 
allow for continued thymocyte development past the point of lethality showed a near 
complete block of NCoR
-/-
 cells at the DN3 stage and an increase in apoptosis of 
developing thymocytes.  Together, these results highlight the importance of 
transcriptional repression in T-cell fate specification and development.  
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Early B-Cell Development 
 In contrast to T-cell development, which occurs in the thymus, B-cells remain in 
the bone marrow and arise from CLP cells. Developing B-cells can be characterized 
according to Hardy Fraction subsets, based upon cell surface labeling of B220
+
 cells 
developed by Dr. Hardy that use the cell surface markers CD43, CD24, BP-1, IgM, and 
IgD to characterize the different stages of B-cell development as Fractions A-F
120
 (Fig. 
5).  Fractions A through C’ are CD43+B220+ early B-cells that are undergoing 
rearrangement of Ig heavy chain loci.  Fraction A cells, or pre-pro B-cells, retain germ-
line V(D)J loci, and are characterized as CD24
-
BP-1
-
.  Fraction B cells, or early Pro-B 
cells, are CD24
+
BP-1
-
 and are the main location of D to J heavy chain rearrangement.  
Fraction C cells, or late Pro-B cells, are CD24
+
BP-1
+
 and are completing rearrangement 
of the Ig heavy chain.  In the absence of functional heavy chain rearrangement on either 
chromosome, cells undergo apoptosis, leading to significant cell death in this population. 
In the event of a successful rearrangement, a pre-B cell receptor is expressed at the cell 
surface along with the 5, VpreB1, Ig and Ig accessory molecules.  Pre-B cell receptor 
signaling leads to a halt in Ig heavy chain rearrangement and a drastic increase in 
proliferation.  Fraction C’ cells, or large Pre-B cells, are CD24-BP-1+ that have completed 
V(D)J rearrangement. 
Fractions D through F are CD43
-
 B220
+
 and are undergoing Ig light-chain 
rearrangement.  Fraction D cells, or pre-B cells, do not express surface Ig, and are 
undergoing rearrangement of one of two immunoglobulin light chains,  or .  Several 
attempts at light chain rearrangement are possible, and therefore, while non-productive 
rearrangements will result in cell death within this population, levels of apoptosis are  
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Figure 5. Transcriptional regulation of early B-cell development  B-cells
develop from LT-HSCs in the bone marrow, becoming LMPP cells, and then
traveling through the Hardy Fractions A-F.  Transcription factors and signaling
molecules that facilitate B-cell development and commitment are noted in
blue.
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lower than in earlier fractions.  With productive light chain rearrangement, a final IgM 
molecule is produced and expressed at the cell surface, producing Fraction E, or 
immature, B-cells.  This population then undergoes negative selection for self-reactivity.  
Fraction E cells travel to the spleen to finish maturation, and become Fraction F cells that 
are recirculating naive B-cells expressing both surface IgM and IgD.  
 
Transcriptional Regulation of Early B-cell Development 
Much like T-cell development, B-cell development requires the coordinated 
action of transcription factors in a network of lineage commitment
121
 (Fig. 5).  The three 
primary effectors of the B-lineage program are E2A, Early B-cell Factor 1 (EBF1), and 
Pax5, of which only E2A is a known MTG interacting partner.  All three factors work 
together to not only activate B-cell specific genes, but also repress alternate myeloid and 
T-cell fates
122-127
.  While initial data suggested that these factors were activated in a linear 
fashion, with E2A expressed in stem and progenitor populations, which then activated 
EBF1 in early B-cells, followed by E2A and EBF1 concordantly activating Pax5 in later 
B-cells prior to lineage commitment, more recent evidence suggests that B-lineage 
priming is not as linear as originally thought, as EBF1 can regulate expression of E2A 
while Pax5 can regulate EBF1 expression
122,128-132
. Ultimately, it appears that these 3 
transcription factors, together with IL7 and Flt3 signaling, regulate each other in a 
network of B-lineage priming and commitment.   
As cells commit to the B-cell lineage, they upregulate the expression of B-cell 
specific genes such as EBF1 and Pax5.  Gene expression data suggested that E2A, a 
critical transcription factor for all lymphoid development that is expressed in stem cell 
 26 
populations, activates the expression of EBF1 in the context of IL7R signaling
122,133,134
. 
Expression of EBF1 was sufficient to rescue B-cell development from CLPs that were 
deficient in IL7 or E2A, suggesting that EBF1 expression is a crucial component of B-
lineage commitment downstream of both IL7 signaling and E2A
133,135,136
.  Furthermore, 
in the absence of IL7 or the IL7R, E2A was expressed, but EBF1 was not, suggesting that 
the action of both E2A and IL7 is necessary to activate EBF1
133
.    
EBF1 then, together with E2A, activates the expression of multiple B-lineage 
genes including Pax5
129
.  In fact, EBF1 and E2A often bind in similar promoter/enhancer 
regions of genes that need to be activated or repressed to specify B-cell fate
121,128
.  
Finally, Pax5 facilitates finalization of B-cell commitment
125
.   Expression of Pax5 was 
sufficient to rescue E2A
-/-
 B-cell development, further confirming its role downstream of 
E2A
136,137
.  The biochemical properties of E2A and its role in early lymphocyte 
development will be discussed in more detail in subsequent sections, as it is a known 
Mtg16 interacting partner that contributes to the B- and T-cell phenotypes discussed in 
Chapters III and IV.   
EBF1 is essential for B-cell development and mice lacking EBF1 have early 
B220
+
CD43
+
 B-cells that express the IL7R, but no more mature B-cells that express 
surface immunoglobulins
138
. In addition to activating B-cell specific genes, EBF1 also 
represses targets necessary for B-lineage commitment.  Downregulation of Id2 and Id3, 
negative regulators of E-proteins, is an important function of EBF1 in specifying B-cell 
fate.  Deletion of EBF1 led to high levels of Id2 and Id3, which prevented E-proteins 
from functioning
139
.  As a consequence, E2A expression in IL7R deficient cells was not 
sufficient to upregulate EBF1 and induce B-cell development due in part to impairment 
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of E2A function by Id2 and Id3.  Overexpression of Id2 or Id3 was sufficient to impair B-
cell development after transplant, highlighting the importance of EBF1, E2A, and Id 
proteins in a network that specifies B-cell fate.  
Pax5 is a member of the paired box family if transcription factors and is critical 
for B-cell commitment.  Pax5 functions as both a transcriptional activator and repressor, 
interacting with repressors such a Groucho to repress non-B-lineage gene expression and 
activators such as p300 to activate B-lineage specific genes in early B-cell populations
140
.  
Deletion of Pax5 resulted in a block in B-cell development of uncommitted early B-cells 
that retain myeloid potential
125
.  These Pax5
-/-
 early B-cells began the process of B-
lineage development and contained rearranged immunoglobulin loci, but were unable to 
complete B-cell development and therefore were capable of developing into myeloid 
cells. Furthermore, deletion of Pax5 in later, committed B-cells reversed their 
commitment status and allowed them to revert to multilineage myeloid, erythroid, and T-
cell potential
141
.  
Other factors that are capable of interacting with Mtg16 also regulate early B-cell 
development, including Bcl6
25,142
.  Bcl6 is a BTB/POZ transcriptional repressor and 
MTG interacting protein.  Through its N-terminal BTB/POZ domain, Bcl6 interacts with 
NCoR and SMRT, while its central repression domain facilitates interactions with other 
corepressors
142,143
.  Bcl6 plays a role in maintaining the survival of early B-cells as they 
accumulate DNA damage due to V(D)J light chain recombination
142
.  Bcl6 dampens the 
response to DNA damage by decreasing the expression of CDKN2A/Arf, CDKN1A/p21, 
and CDKN1B/p27, thus blocking the p53 response.  This allows for cell survival in the 
presence of DNA damage, and in the absence of Bcl6, Pre-B cells could not repress these 
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genes and therefore could not grow, self-renew, or survive in vitro.  Due to low levels of 
Bcl6 expression in early cells undergoing heavy chain rearrangement, this phenomenon 
does not appear to be critical for repressing the DNA damage response in earlier 
populations, though it has not been specifically investigated. 
 
Late B-cell Development 
 B-cell development is not confined to the early fractions of the bone marrow, and 
further maturation and lineage decisions occur in the spleen.  Fraction E cells that have 
completed their BCR rearrangement and are ready to emigrate to the periphery, are 
known as transitional B-cells, or T1 cells
144
.  These cells do not have the capacity to re-
circulate, but they do travel from the bone marrow to the spleen.  T1 cells enter splenic 
follicles and gain the cell-surface expression of IgD to become T2 transitional cells.  T2 
cells can enter circulation and travel to lymph nodes, but are not mature functional B-
cells and cannot proliferate in response to B-cell receptor activation.   
From the T2 transitional population, B-cells can then become either marginal zone 
or follicular zone mature B-cells
145
.  Follicular zone B-cells organize into lymphoid 
follicles surrounded by T-cell rich areas.  These follicular zone B-cells are recirculating 
B-cells that participate in T-cell dependent immune responses in the spleen.  Along the 
periphery of these lymphoid rich areas lies another B-cell rich region that contains 
marginal zone B-cells.  These cells do not re-circulate, but instead stay localized to the 
marginal zone and self-renew with an unlimited life span and facilitate macrophage 
associated innate immunity.  Marginal zone vs. follicular zone decisions rely upon 
several MTG interacting factors, including Notch signaling through the Notch2 receptor 
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and the Delta-like 1 ligand, which is expressed strongly in the marginal zone
146,147
.  B-
cell receptor signaling influences this cell fate decision as well, and a weak BCR signal 
and a strong Notch signal favors marginal zone development over follicular zone 
development. E-proteins also play a critical role in this decision: decreased E2A and 
increased Id2 or Id3 lead to increased marginal zone B-cells at the expense of follicular 
zone B-cells
148,149
. 
When foreign antigens enter the spleen, B-cells mount a germinal center response. 
This phenomenon is characterized by high rates of proliferation and rapid DNA changes 
in an attempt to improve the efficiency of the immune response, including variable region 
somatic hypermutation and class-switch recombination
150
.  After the germinal center 
response has taken place, the high-affinity antibody producing B-cells become plasma 
cells, which are the immune effector cells, or memory cells, which retain the high-affinity 
antibody locus in their genomic DNA in preparation for the next immune challenge.   
The process of germinal center maturation relies heavily upon the Bcl6 
transcription factor, which represses the expression of genes that function in cell cycle 
arrest, including p53, ataxia telangiectasia and Rad3 related1 (ATR), Chek1, and Cyclin-
dependent kinase inhibitor 1A (CDKN1A p21)
151-156
. In addition, Bcl6 regulates the 
maturation of germinal center B-cells by directly repressing genes that lead to terminal 
differentiation, including Prdm1
156,157
.  In the absence of Bcl6, these genes are not 
repressed and attempts at somatic hypermutation lead to DNA-damage induced cell cycle 
arrest and apoptosis and therefore loss of the germinal center response.  Deletion of 
Hdac3, a corepressor that interacts with Bcl6 to facilitate transcriptional repression, 
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recapitulates these findings, with drastically decreased germinal center reactions in 
Hdac3
-/-
 mice (Bhaskara et al, in prep).   
 
Notch and E-Proteins 
 
Mtg16 interacts with several transcription factors that regulate lymphoid 
development mentioned above, including Gfi1 and Bcl6.  The two most prominent 
regulators of lymphoid development that bind to Mtg16 are E-protein transcription 
factors and components of the Notch signaling cascade, specifically CSL and the 
intracellular domain of the Notch receptor
31,43
.  Notch signaling and E-protein mediated 
transcription are important facilitators of Mtg16 function referenced in Chapters III and 
IV; therefore, these topics and their relationship to Mtg16 and hematopoiesis will be 
covered in more detail. 
 
Notch Signaling, Mtg16, and Hematopoiesis 
 The Notch signaling family consists of four different transmembrane receptors, 
titled Notch 1 through 4, that interact with ligands of the Delta-Serrate-Lag2 (DSL) and 
Jagged family of cell surface proteins.  In mammalian cells, five ligands exist: Delta-like 
1, 3, and 4 and Jagged 1 and 2
158
.  Notch receptors are proteolytically cleaved in the first 
of three cleavage-processing steps for activation by the furin protease as they are 
trafficked to the cell surface.  Receptors exist at the cell surface with these two resulting 
parts non-covalently linked together and heavily modified with N- and O-linked 
glycosylation of the extracellular portion.  Upon ligand binding, the second proteolytic 
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cleavage site is exposed.  Cleavage then occurs extracellularly by the ADAM protease, 
and the membrane bound remainder of the receptor is cleaved by -secretase to release 
the functional Notch Intracellular Domain (NICD).  The NICD subsequently translocates 
to the nucleus to activate Notch-driven transcription.   
Once in the nucleus, the NICD binds to the transcription factor of the Notch 
signaling cascade, CBF-1/Su(H)/Lag-1 (CSL), and recruits the transcriptional coactivator 
mastermind (MAM) to activate downstream transcription.  This completed complex 
recruits general transcriptional activators such as p300 to regulate chromatin acetylation 
and transcription
159
.  This complex can bind to promoters as either a monomer or a dimer, 
a phenomenon that appears to be promoter specific
160
.  The Notch signal is terminated by 
ubiquination of the NICD by Fbw7 and subsequent proteosomal degradation
161
.  This 
degradation process involves phosphorylation of the NICD on its C-terminal PEST 
domain by cyclin-dependent kinase 8 (Cdk8)
162
.  The strength and duration of the Notch 
signal is also regulated by acetylation, and loss of the deacetylation molecule SIRT1 led 
to increased Notch signaling
163
. 
In the absence of a Notch signal, CSL functions as a transcriptional repressor by 
binding corepressors such as NCoR/SMRT, SMRT-HDAC Associated Repressor Protein 
(SHARP), Groucho, and/or MTGs
164-166
 (Fig. 6).  A number of different CSL repressor 
complexes have been identified and appear to be target specific in their formation
167
.  The 
first evidence suggesting MTGs regulate Notch signaling identified an indirect interaction 
between MTG family members and CSL, facilitated by SHARP
29
.  This interaction was 
identified through a yeast two hybrid screen and confirmed by coimmunoprecipitation 
and in vitro binding assays.  The interaction between MTG8 and SHARP localized  
 32 
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broadly to the N-terminal portion of MTG8 and MTG8 bound to the promoters of the 
Notch target genes Hes1 and Nrarp by Chromatin Immunoprecipitation (ChIP). In 
addition to an indirect interaction through SHARP, MTG16 also interacts directly with 
CSL through the NHR3 region, further confirming the importance of MTGs in CSL 
repression complexes
43
 (Fig. 6A).  Interestingly, MTG8 increased the repression of Notch 
target genes by luciferase assay, while the AML1-ETO fusion protein, which was also 
capable of interacting with SHARP as part of the CSL complex, actually had the opposite 
effect and augmented expression of Notch targets when overexpressed.  Activation of 
Notch target genes by the AML1-ETO fusion proteins has previously been reported, 
though initial analysis suggested this increased expression of Notch targets was due to 
regulation of the expression of the Jagged2 Notch ligand by AML1-ETO
168
.   
More recently, an interaction between MTGs and the NICD was identified
43
.  This 
interaction occurred between Mtg16 and all four Notch receptors and localized to the 
very N-terminal portion of Mtg16, upstream of the conserved NHR1 region (Fig. 6B).  
Overexpression of the NICD disrupted the interaction between Mtg16 and CSL, 
suggesting a mechanism for active de-repression of CSL targets by the NICD (Fig. 6C).  
Loss of Mtg16 led to misregulation of some, but not all, Notch targets in hematopoietic 
stem and progenitor cells, including upregulation of the important Notch targets Hes1 and 
Nrarp.  Of note, these targets are also regulated by other transcription factors that interact 
with MTGs, including E2A, and changes to expression may not be attributed solely to 
disruption of Notch signaling
9
.     
  Notch signaling is a key regulator of hematopoiesis, most specifically T-cell 
development.  Expression of Notch ligands is an important component of the thymic 
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niche, and a strong Notch signal through ectopic expression of a constitutively active 
Notch1 is sufficient to drive T-cell development in the bone marrow
169,170
.  Conversely, 
absence of Notch signaling through deletion of either Notch1 or CSL led to a block to 
early T-cell development and ectopic B-cell development in the thymus
81,170,171
.  ETP 
formation from LMPP cells also required the strong Notch signal of the thymic 
microenvironment
80
.  Notch signaling is critical for the earliest stages of V(D)J 
recombination, and Notch-deficient cells were arrested at the DN3 stage due to lack of 
 T-cell receptor formation172,173.  This was partially due to the necessary function of 
Notch in activating the expression of Ptcra, a surrogate receptor chain that pairs with a 
rearranged TCR in immature T-cells174.  Enforced expression of Ptcra was not 
sufficient to drive Notch1-deficient cells through the DN3 checkpoint, confirming that 
additional targets must also be activated to fully restore the Notch signal necessary for T-
cell development.  Beyond the DN3 stage, Notch signaling is attenuated, at least in part 
by downregulation of Notch1 expression
175,176
.  
Deletion of a transcriptional corepressor that modulates Notch signaling 
highlights the importance of appropriate regulation of the Notch signal in T-cell 
development
177
.  Msx2-interacting nuclear target protein (Mint) is a CSL binding partner 
that competes with the NICD for binding and suppresses Notch-mediated transcriptional 
activation.  Deletion of Mint led to an increase in DN1 fetal thymocytes, as expected 
given the role for Notch in specifying ETP generation.  Surprisingly, this did not 
correspond to an overall increase in thymocytes, and instead coexisted with a relative 
decrease in DN2 cells, suggesting that an excess of Notch signal impairs the DN1 to DN2 
transition.  This impaired transition led instead to an overall decrease in developing 
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thymocyte cell number, supporting the idea that appropriate dosage of Notch signaling is 
critical for T-cell development. 
Overactive Notch signaling plays a significant role in most T-cell neoplasms
178
.  
In fact, mutations in the Notch receptor that lead to ligand-independent activation or 
mutations in the C-terminal PEST domain that produce a more stable Notch-ICD 
contribute to greater than 50% of human T-cell acute lymphoblastic leukemia (T-
ALL)
179
.  Overexpression of constitutively active N1, N2, and N3-ICDs was sufficient to 
induce T-ALL after bone marrow transplant in mouse models
180-182
.  More commonly, T-
ALL associated mutations in NOTCH1 activate Notch signaling less aggressively than 
constitutive NICD expression, and produced leukemia in mouse models only in the 
presence of a K-Ras oncogene
183
.  The resulting tumors were still addicted to the Notch 
signal and responsive to Notch inhibitors, though, further supporting the importance of 
Notch signaling in T-cell leukemia.  Targeting of the Notch transcription complexes is a 
current goal for T-ALL therapeutics, and a better understanding of the components and 
dynamics of activation complexes will be useful for future therapy design.  Therefore, the 
functional characteristics and consequences of Mtg16 interaction with Notch mediated 
transcription may help the targeting of Notch in T-ALL. 
Notch signaling plays a controversial role in hematopoietic stem cell maintenance 
which is of particular interest given that Mtg16
-/-
 stem cells have increased activation of 
Notch target genes
43
.  Deletion of Notch1 in mice had no effect on the long-term 
repopulating potential of hematopoietic stem cells, as Notch1
-/-
 marrow contributed 
normally to all lineages, with the exception of T-cells, 6 months after competitive bone 
marrow transplant
81
.  Alternate experiments suggested that Notch signaling expands 
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hematopoietic stem cells.  More specifically, retroviral overexpression of Hes1, a critical 
downstream mediator of Notch signaling, in mouse LSK cells led to increased long term 
repopulating capacity after transplant
184
.  Additionally, overexpression of the Notch1-
ICD in Rag1
-/-
 Lin
neg
sca-1
+
 cells led to an increase in hematopoietic stem cells, shown 
both by an increase in stem cell number in in vitro long-term culture initiating cell (LTC-
IC) assays and an increase in stem/progenitor pools (Lin
neg
sca-1
+
) in vivo after both 
primary and secondary bone marrow transplants
185
.  More recently, the effect of loss of 
Notch signaling in hematopoietic stem cells has been examined with alternate mouse 
models that used overexpression of a dominant negative mastermind protein (DNMAML) 
or deletion of CSL
186
.  Using the Mx-cre conditional activation system, this group 
showed that expression of DNMAML, and thus disruption of Notch signaling by all four 
Notch receptors, did not impair the ability of hematopoietic stem cells to maintain and 
self-renew long-term stem cells after transplant.  Similar results were obtained after 
deletion of CSL, further confirming that loss of Notch signaling has little effect on 
hematopoietic stem cells.   
While the role of Notch signaling in hematopoietic stem cells has been 
controversial, the impact of Notch on mature lineages other than T-cells is becoming 
more well defined.  Megakaryopoiesis is positively regulated by Notch signaling and 
expression of DNMAML leads to reduced megakaryocyte numbers after transplant
187
.  
Notch also plays a significant role in regulating mature B-cell development in the spleen.  
Immature circulating B-cells that that home to the spleen can develop into either marginal 
zone or follicular zone B-cells.  In the absence of CSL, there was a complete loss of 
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marginal zone B-cells with a corresponding increase in follicular zone cells and deletion 
of Notch2 or Delta-like 1 also led to reduced numbers of marginal zone B-cells
146,147,188
.   
 
E-proteins, Mtg16, and Hematopoiesis 
While Notch signaling is critical for T-cell development, it cooperates with 
another Mtg16 interacting protein in specifying T-cell fate, namely the E-protein E2A
9,97
.  
E-proteins are also critical for B-cell development and likely contribute to Mtg16 
functions in both contexts
189
.  The E-protein family is a family of basic helix-loop-helix 
transcription factors that includes E2-2 (Tcf4), HeLa E-Box binding protein (HEB) 
(Tcf12), and E2A (Tcf3).  E2A consists of dimers of two alternative splice forms, E12 and 
E47, encoded by the Tcfe2a or Tcf3 gene.  These proteins function in transcriptional 
regulation by binding to consensus CANNTG E-box motifs (Fig. 7).  They bind DNA as 
homo- or heterodimers with other E-proteins and can also bind as a heterodimer with 
other classes of bHLH proteins, including SCL/Tal-1 and Lyl1
190,191
.   
E-proteins have three conserved regions: N-terminal Activation Domain 1 (AD1) 
and Activation Domain 2 (AD2) and the C-terminal basic-Helix-Loop-Helix (bHLH) 
motif that facilitates DNA binding and dimerization with other HLH proteins
192
.  All 
three family members are highly homologous in their bHLH domains, with decreased 
homology in the AD1 and AD2 regions
193,194
.  E-proteins can be negatively regulated by 
four different Inhibitor of Differentiation (ID1-4) proteins, which consist of a bHLH 
domain alone and dimerize with E-proteins to impair their ability to bind DNA
195,196
.   
Traditionally thought of as transcriptional activators, E-proteins bind p300 and 
histone acetyl transferases (HATs) through both their AD1 and AD2 domains
31
.  Both 
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individual AD1 and AD2 domains activated expression of a luciferase construct in the 
context of gal4 fusion proteins
193,194
.  In the context of full-length E12, removal of each 
AD domain impaired the ability of E12 to activate an E-box luciferase construct, while 
removal of both AD domains had an additive effect
123
.  For full termination of E-box 
luciferase activation, though, the entire N-terminal region of E12 must be deleted. 
While E-proteins function as transcriptional activators in luciferase assays, they 
are also capable of interacting with transcriptional corepressors, namely MTG family 
members (Fig. 7).  Using immunoprecipitation followed by Mass-Spectrometry analysis, 
HEB was identified as one of two predominant ETO interacting proteins in HeLa cell 
lysates, with the other being Mtgr1
31
.  This interaction was unusually robust and could 
withstand high NaCl and detergent levels.  Overexpression of ETO family members 
converted HEB to a transcriptional repressor by reporter assay, suggesting a dual function 
for E-proteins in regulating transcription.  E-protein repression targets are under current 
investigation, and to date include genes such as Bcl2, Id2, Cebpb, Gata3, and Notch1 in 
early B-cells, though these genes have yet to be identified as direct MTG targets
121
.   
E2A is the primary family member implicated in regulating lymphoid 
development, playing a variety of roles throughout both B and T-cell development that 
coincide with the functions of Mtg16 identified in Chapters III and IV. Knockout mouse 
models of E2A led to decreased thymocyte number, due to a dose-dependent decrease in 
the production of LMPP cells and ETP cells and a partial arrest in vivo at the DN1 to 
DN2 transition
197-199
.  E2A also regulates the DN3 -selection checkpoint, and, in the  
 39 
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absence of E47, thymocytes escaped to the DP and CD8
+
 stages of development even in 
the absence of Rag1 expression and V(D)J recombination
200
.  As part of this DN3 -
selection checkpoint, E2A negatively regulated the ability of non-TCR DN3 expressing 
cells to cycle
201
. 
Using in vitro assays that present a strong Notch signal from the Delta-like1(DL1) 
ligand engineered on OP9 stromal cells (OP9-DL1 cells), in concert with the lymphoid 
cytokine IL7, E2A
-/-
 progenitors were unable to produce T-cells at all, magnifying in vivo 
phenotypes
9,74
.  E2A functions in T-cell specification in part by cooperating with 
activated Notch signaling.  Notch and E2A share common activation targets in early T-
cells, including the critical T-cell modulators Hes1 and Ptcra
9
.  E2A also activates 
expression of Notch1 itself, and defects in in vitro T-cell specification from E2A
-/-
 
progenitors were bypassed by expression of the NICD
9,202
.   
  As previously mentioned, E2A is one of the initiating factors in specifying B-
cell fate, in large part due to induction of B-cell specific genes including EBF1 and 
Pax5
97,189
.  In the absence of E2A virtually no mature B-cells developed, though some 
early Hardy Fraction A B-cells were produced
189,203
.  Concurrent with the absolute arrest 
in Fraction A in E2A
-/-
 mice were decreases in the common lymphoid progenitor cells and 
LMPP cells that precede B-cell commitment
198,203
.   
In addition to regulating expression of the B-cell lineage program, E2A regulates 
several parts of V(D)J recombination, including, but not limited to, expression of Rag1 
and Rag2, D to J rearrangement of the Ig Heavy chain locus, and Ig light chain 
rearrangement.  In fact, E-proteins were first identified due to their ability to bind an Ig 
enhancer element
204
.  In the absence of E2A, Rag expression was decreased relative to 
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wild-type controls as early as the CLP population, and no D to J rearrangement occurred 
in either these early cells or later Fraction A B-cells
189,203
.  Ectopic expression of Rag1 
and Rag2 in concert with E2A was sufficient to induce Ig and D to J IgH rearrangements 
in non-lymphoid cells, further suggesting E2A controls access to and rearrangements of 
Ig germline DNA
205
.     
As E2A is necessary for B-cells to develop in vivo, in vitro assays to assess B-cell 
development and survival are not possible from E2A
-/-
 mice.  Therefore, primary pre-B 
cell cultures can only be generated using transformation methods such as the expression 
of Abelson Murine Leukemia Virus
206
.  These E2A
-/-
 pre-B cultures exhibited a slight 
G0/G1 arrest by Propidium iodide staining
207
.  More strikingly, treatment with STI-571, 
which inhibits the v-Abl transforming oncogene and induces cell cycle arrest and 
differentiation, caused a strong increase in apoptosis.  Therefore, E2A is also necessary 
for the in vitro growth and survival of developing B-cells. 
E2A plays minor roles in mature B-cells of the spleen that have been discovered 
using conditional deletion models.  E2A regulates the marginal zone vs. follicular zone 
cell fate decision, and deletion of E2A favored marginal zone development
137,148
.  
Germinal center development was also perturbed in the absence of E2A, though germinal 
centers could still form
137
.  These germinal centers were smaller and fewer in number, 
and while decreased proliferation could be ruled out, the mechanism for E2A function in 
germinal centers is unknown.   
In both B- and T-cell in vitro assays, E2A regulates myeloid versus lymphoid cell 
fate decisions.  In OP9-DL1 T-cell development assays, E2A
-/-
 progenitors failed to give 
rise to T-cells and instead develop into Natural Killer (NK) and granulocyte/monocyte 
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cells
9
.  In B-cell development assays, E2A was necessary to suppress Mac1
+
 macrophage 
development from MPP cells, and this function localized to the MTG interacting AD1 
domain
123
.  E2A
-/-
 LMPP cells also preferentially developed along granulocyte/monocyte 
lineages in cultures that support multilineage myeloid potential, further supporting the 
hypothesis that E2A functions in part to restrict granulocyte/monocyte potential
198
.  In in 
vivo competitive transplant assays, E2A
-/-
 hematopoietic progenitors gave rise to a 
slightly increased proportion of Gr1
+
 granulocytes, with little to no contribution to 
lymphocyte lineages
208
.   
In addition to the well-characterized roles in lymphoid development, it is 
becoming increasingly apparent that, like Mtg16, E2A also functions to regulate stem cell 
populations
208,209
. Long-term reconstitution after competitive transplant was defective in 
the absence of E2A, a phenotype that was exacerbated after secondary transplant
208
.  
Stem cell exhaustion in the E2A
-/-
 mice was associated with an increase in cell cycling in 
LT-HSCs
198,208
. E2A
-/-
 mice were sensitive to treatment with 5-Fluorouracil (5-FU), a 
cytotoxic drug that kills rapidly cycling cells.  It is possible that normally quiescent LT-
HSCs were also susceptible to 5-FU treatment due to an increase in active cell cycling.  
Additionally, the LT-HSCs may have been susceptible to stem cell exhaustion due to 
aberrantly increased cycling of HSCs as they repopulated hematopoietic cells
209
.  The cell 
cycle regulator CDKN1A (p21) is a potential target of E2A in regulating stem cell 
cycling, and loss of E2A led to a 50% reduction in p21 transcript levels, a phenomenon 
that could be reverted by re-expression of E47 
209
.   
HEB is the second E-protein family member to play a role in T-cell development.  
Deletion of HEB led to a five-to-ten fold reduction in total thymocytes due to an 
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accumulation of both DN3 cells and immature single positive cells that exist between the 
DN4 and DP populations
210
.  HEB and E2A form heterodimers in developing thymocytes  
and together regulate a number of genes including the CD4 locus and Ptcra
211,212
.  
Conditional double deletion of both HEB and E2A resulted in a more severe thymocyte 
phenotype than individual HEB and E2A deletions, with a complete block to T-cell 
development in the DN population
213
.  This block could not be localized to one particular 
subset, but nonetheless very few DP cells developed. 
E2-2 is perhaps the least studied family member, and its best understood function 
is as a determinant of plasmacytoid dendritic cell development
214
.  While E2A is the 
family member most commonly implicated in regulating B-cell development, E2-2 also 
appears to play a role.  Mice double heterozygous for E2A and E2-2 or HEB were 
deficient in B-cell development, with reduced early B-cell number
215
.  Adoptive transfer 
of E2-2
-/-
 fetal liver cells into Rag2
-/-
 mice exposed a defect in early B-cell development 
in the absence of E2-2, with a two-fold reduction in both B220
+
CD43
-
 early B-cells and 
B220
+
CD43
+
 late B-cells
216
.  This relatively minor defect was much more severe in the 
context of a competitive transplant and in vitro differentiation assays.  Furthermore, these 
mice had altered marginal zone vs. follicular zone cell fate choice, with a relative 
increase in marginal zone mature B-cells.  The role of E2-2 in thymocyte development 
was also subtle, with a slight DN3 block and decreased Ptcra expression in E2-2
-/- 
thymocytes, though expression profiles suggest the HEB and E2A are the critical E-
proteins in the thymus
217
 . 
Increased expression of ID family members also has deleterious effects on E-
protein function and lymphocyte development.  Overexpression of Id1 led to an increase 
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in myelopoiesis at the expense of lymphopoiesis, increased apoptosis in early DN 
thymocytes, and decreased V(D)J recombination in developing B-cells, which impairs the 
number of mature B-cells
218-221
.  Overexpression of Id2 impaired T-cell development 
both in vivo and in vitro, with a block in early thymopoiesis and diversion from the T-cell 
lineage towards Natural Killer cells
222,223
.  Deletion of Id2 led to an increase in B-cell 
development and increased expression of Id2 impaired B-cell development, confirming a 
negative regulatory role for Id2 in B-cell development
224
.  This defect localized to the 
pro-B or fraction C stage.  Id3 also plays a role in lymphocyte development, and 
overexpression of Id3 impaired B-cell development by inducing apoptosis
225
.  Therefore, 
E-proteins and their negative regulator Id proteins regulate a variety of stages in 
lymphocyte development. 
 
MTG16 and Hematopoiesis 
 
 As detailed in the previous section, Mtg16 interacts with transcription factors that 
regulate a variety of hematopoietic stages.  Subsequently, deletion of Mtg16 has a 
significant impact on multiple facets of hematopoiesis (Fig. 8).  While the transcription 
factors disrupted by loss of Mtg16 vary according to the lineage, common targets exist 
and some of the effects are consistent across lineages.  Therefore, an understanding of the 
consequences of Mtg16 deletion on other hematopoietic lineages informed and 
contributed to the analysis in Chapters III and IV. 
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Figure 8. Effect of deletion of Mtg16 on hematopoiesis Deletion of Mtg16
leads to changes in several different hematopoietic populations, depicted in
red.
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Mtg16 and Erythroid and Myeloid Development 
Mtg16 interacts with critical regulators of erythrocyte and megakaryoctye 
differentiation, including Stem Cell Leukemia (SCL) and GATA1
30,32,226
.  In both Murine 
Erythroid Leukemia (MEL) cells and L0857 (Megakaryoblastic) cells, Mtg16 could be 
found in a complex with LMO2 and LDB1 that was nucleated by SCL, a critical regulator 
of both erythropoiesis and megakaryopoiesis
227,228
.  This complex, which also includes 
GATA1 and Gfi1b in MEL cells, was readily found in immature erythrocytes but 
dissociated with erythroid differentiation
30
.  Over-expression of Mtg16 impaired the 
activation of -Globin and band 4.2 as a part of erythroid differentiation and band 4.2 is 
a direct repression target of Mtg16 in early erythrocytes
30,226
.   
Mtg16 exhibited similar functions in L0857 megakaryoblastic cells where 
SCL/Mtg16 complexes repressed expression of megakaryocyte differentiation genes
32
.  
As a consequence, short-hairpin RNA (shRNA) knockdown of Mtg16 levels in L0857 
cells increased the production of mature megakaryocytes after 12-0 
tetradecanoylphorbol-13-acetate (TPA) induced differentiation.  This increase in 
differentiation was associated with increased expression of megakaryocyte specific genes 
such as acetycholine esterase.  Together, this over-expression and knockdown data 
created a strong precedence for Mtg16 to regulate erythroid and megakaryocyte 
differentiation through SCL complexes.  
At four weeks of age, Mtg16
-/-
 mice suffer from mild anemia and therefore 
exhibited an accompanying extramedullary hematopoiesis consistent with the increased 
need for red blood cell formation in maturing young mice
19
.  In addition, there was an 
increase in circulating reticulocytes and Howell-Jolly bodies, immature red blood cells 
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that carry nuclear remnants.  The anemia, increased reticulocyte count and 
extramedullary hematopoiesis defects corrected by 8 weeks of age, or the onset of 
adulthood, suggesting that after the stress period of early growth, Mtg16
-/-
 mice were 
capable of reaching a homeostatic condition of sufficient red blood cell production.  
Despite the correction of anemia, Mtg16
-/-
 mice still showed decreased erythroid lineage 
commitment by flow cytometry, as confirmed by decreased Ter119 and CD71 labeling of 
total bone marrow.  While overall decreases in Ter119 labeling persisted, cells that did 
commit to the erythroid lineage were capable of differentiating normally, suggesting that 
the major defect in erythropoiesis in the absence of Mtg16 is not in erythrocyte lineage 
development, but rather in lineage commitment. 
Consistent with the finding of decreased erythrocyte commitment in vivo, Mtg16
-/-
 
bone marrow had an absolute inability to produce erythrocyte colonies in in vitro 
methylcellulose assays supplemented with erythropoietin
19
.  This result suggests two 
things: one, commitment to the erythroid lineage is impaired in the absence of Mtg16 and 
two, a subtle phenotype under homeostatic conditions of the Mtg16
-/-
 mouse can become 
much more dramatic in response to stress.  This second suggestion is a common theme in 
the Mtg16
-/-
 mouse, as many of the phenotypes that occur under homeostasis, including 
those identified in Chapters III and IV, are magnified in response to stress.   
As a further example of the impact of stress on erythropoiesis in the absence of 
Mtg16, these mice rapidly succumbed to treatment with the erythro-lytic drug 
phenlyhydrazine
19
.  This drug lyses red blood cells and is well tolerated by wild-type 
mice that are capable of activating their stem and progenitor cells to proliferate and 
differentiate to repopulate the lost erythrocytes.  In fact, five days after the first drug 
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administration wild-type mice had a 2-fold decrease in red blood cell number and 
hematocrit and a corresponding four-fold increase in the weight of the spleen as the 
hematopoetic system responded with extramedullary hematopoiesis.  This extramedullary 
response rapidly repopulated the missing erythrocytes in wild-type mice.  In contrast, 
Mtg16
-/-
 mice were significantly more sensitive, with a near 10-fold decrease in red blood 
cell number and hematocrit.  These mice were not capable of mounting a hematopoietic 
response, bone marrow or extramedullarly, as evidenced by a lack of increase in spleen 
size and absence of BFU-E colonies from both the bone marrow and spleen of treated 
mice.  They could not survive the significant loss of red blood cells. 
In addition to the defects in erythropoiesis, Mtg16
-/-
 mice have changes to lineage 
allocation (Fig. 8)
19
.  Adult null mice under homeostatic conditions have increases in 
Gr1
+
/Mac1
+
 myeloid cells; these increases were further confirmed by methylcellulose 
assay, as Mtg16
-/-
 marrow produced increased granulocyte and granulocyte/monocyte 
colonies in both complete methylcellulose supplemented with stem cell factor, IL3, IL6, 
and erythropoietin, and myeloid specific methylcellulose supplemented with stem cell 
factor, IL3, and IL6.  While there were not increased monocyte colonies, normal numbers 
of this colony type formed.  Likewise, normal megakaryocyte colonies formed in a 
megakaryocyte specific assay.  This result was in contrast to previous reports of increases 
in megakaryopoiesis in the absence of Mtg16 by shRNA knockdown
32
.  Overall 
decreases to B220
+
 B-cell number were also observed; this phenotype will be explored in 
more detail in Chapter III.  Collectively, initial analysis of the Mtg16
-/-
 mouse suggested 
commitment to erythroid and lymphoid lineages were decreased in favor of an increase in 
the default myeloid pathway. 
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One potential contributor to the increase in myeloid Gr1
+
/Mac1
+
 cells was the 
aberrant production of a CD34
hi
FCRlo myeloid progenitor population19.  This c-kit+ 
population rarely occurs in wild-type mice, but accounts for roughly 20% of myeloid 
progenitors in Mtg16
-/- 
mice.  Methylcellulose analysis of sorted populations of these 
abnormal cells revealed granulocyte and monocyte potential.  In addition, Mtg16
-/-
 mice 
have increases in common myeloid progenitors (CMPs) and granulocyte/monocyte 
progenitors (GMPs) but decreases in megakaryocyte/erythrocyte progenitors (MEPs) that 
reflect the decreased erythroid but increased granulocyte/monocyte production under 
homeostasis.  Changes within the myeloid progenitor populations therefore contributed to 
the increase in Gr1
+
/Mac1
+
 cells and decreased erythroid cells.   
Progenitor cell function was also altered in the absence of Mtg16 in the setting of 
the colony-forming unit spleen (CFU-S) assay
19
.  This assay determines the function of 
hematopoietic stem and progenitor cells in repopulating a lethally irradiated recipient 
mouse by the expansion of colonies in the spleen.  At day 8 after transplant, these 
colonies are derived from MEP cells, while at day 12 they are derived from ST-HSCs and 
MPP cells.  While 50,000 wild-type cells leads to the development of robust colonies 
both 8 and 12 days after transplant, Mtg16
-/- 
bone marrow produced virtually no colonies 
at either time point.  This deficit in colony formation can be rescued by re-introduction of 
Mtg16 through retroviral infection.  Furthermore, overexpression of the cell-cycle 
regulator c-Myc also rescued colony formation from Mtg16
-/-
 bone marrow, suggesting 
that reduced cell cycling is the cause of absence of colonies.  This data provides the first 
example of Mtg16 as important for cell cycling. 
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Gene expression profiling of both myeloid progenitor populations and overall 
immature hematopoietic precursors, or lineage negative cells, provided many clues to the 
important targets and transcription factor binding partners for Mtg16.  Consistent with the 
function of MTGs as transcriptional corepressors, many interesting genes were 
upregulated in Lin
neg
 cells in the absence of Mtg16, though a similar number were 
downregulated, perhaps through off-target effects.  Some of the most interesting 
upregulated genes were also upregulated in myeloid progenitor populations, suggesting 
these are common and important targets of Mtg16.  Among these are cell cycle regulators 
such as cyclin D1 and hematopoietic differentiation factors like Id1, Gfi1, and Cebpb.  
This gene expression data further confirms Mtg16 as an important regulator of 
hematopoietic development and the cell cycle. 
 
Mtg16 and Hematopoietic Stem Cell Function 
 Loss of Mtg16 also has severe effects on stem cell function (Fischer et al, in 
prep).  In the absence of Mtg16 long-term hematopoietic stem cells are decreased in both 
relative percentage and absolute number, a phenotype that becomes more pronounced 
with age.  Stem cell function is also compromised, as assessed by bone marrow 
transplant.  Due to the defects in erythropoiesis seen in the absence of Mtg16, recipient 
mice transplanted with Mtg16
-/-
 marrow fail the transplant and die within 30 days; 
increasing the amount of marrow transplanted five-fold extends life to 50 days post-
transplant, but is not sufficient to overcome the defect in stress erythropoiesis (Fig. 9A).   
To bypass this defect and assess stem cell function, competitive bone marrow 
transplants were used.  In this assay, 90% CD45.2
+
 test marrow is supplemented with  
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Figure 9. Defects in stem cell function in Mtg16-/- mice (A) Mtg16-/-bone
marrow fails to reconstitute a lethally irradiated recipient mouse, even  with a
five-fold increase in donor cells injected.  Survival curves shown. (B) Wild-
type CD45.2+ bone marrow contributes to peripheral blood at a consistent
90% level up to a year after transplant.   CD45.2+Mtg16-/-bone marrow cannot
compete with CD45.1+ wild-type bone marrow in a competitive transplant.
Adapted with permission from Melissa Fischer and Scott Hiebert.
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B
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10% CD45.1
+
 wild-type marrow that is capable of providing all the necessary mature 
hematopoietic cells for survival.  This system also allows for a baseline level of 
hematopoiesis and therefore removes the stress on stem cells that causes extra cycling 
and differentiation of hematopoietic stem cells.  Instead, CD45.2
+
 test stem cells are 
allowed to self-renew and repopulate the stem cell compartment.  In these assays, 
CD45.2
+
 Mtg16
-/-
 bone marrow contributed at a much lower level to hematopoiesis than 
CD45.2
+
 wild-type marrow, as assessed by the percent of CD45.2
+
 cells contributing to 
both the peripheral blood and the bone marrow (Fig. 9B).  This defect was more 
pronounced in the peripheral blood than associated bone marrow, due in part to decreased 
contribution to lymphoid lineages.  Nonetheless, the contribution of Mtg16
-/-
 stem cells to 
long-term hematopoietic stem cells after transplant was decreased which suggests a 
defect in self-renewal.   
This hypothesis is further confirmed using serial replating and long-term colony-
initiating cell (LT-CIC) in vitro stem cell assays.  In both of these assays, Mtg16
-/-
 
hematopoietic stem cells exhausted much sooner than their wild-type counterparts, 
potentially due to either decreased self-renewal or decreased growth and survival.  Other 
assays to directly test self-renewal were therefore performed.  The most specific stem cell 
self-renewal assay is the secondary bone marrow transplant that assesses the repopulation 
capacity of stem cells after a primary transplant.  Bone marrow was harvested from 
primary competitive transplant recipients and re-transplanted into new recipient mice.  
Wild-type marrow repopulated the hematopoietic system of recipients, including the 
production of more long-term hematopoietic stem cells after self-renewal.  In contrast, 
Mtg16
-/-
 marrow, regardless of the initial amount transplanted, did not contribute to 
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hematopoiesis in secondary recipients at all, particularly to the maintenance and 
expansion of LT-HSCs.  Even a short time after secondary transplant, no CD45.2
+
 Mtg16
-
/-
 LT-HSCs existed, suggesting that any LT-HSCs transplanted differentiated instead of 
self-renewing.  These phenotypes could be accounted for, at least in part, by an increase 
in cell-cycle entry of Mtg16
-/-
 HSCs that leads to stem cell exhaustion and precocious 
differentiation in vitro.  Mtg16 regulates a number of important cell cycle genes, 
including E2F2, and increased expression of E2F2 can lead to increased cell cycle entry.  
Mtg16 was localized by chromatin immunoprecipitation to a regulatory region in intron 1 
of E2F2 that is bound by E2A, implicating E2F2 as a direct repression target for Mtg16. 
Collectively, this data highlights the importance of Mtg16 in regulating 
hematopoietic differentiation and the cell cycle of hematopoietic cells, particularly after 
stress.  Given that most of the transcription factor interacting partners for Mtg16 act in 
multiple stages of hematopoiesis, we hypothesized that defects in hematopoiesis in the 
absence of Mtg16 would extend beyond erythropoiesis and stem cell function.  In 
particular, we were interested in how the interaction with important regulators of 
lymphoid development such as Notch signaling and E2A affected Mtg16
-/-
 phenotypes.  
Combined with preliminary data on lineage allocation, this question led directly to the 
work presented in Chapters III and IV. 
 
AML1-ETO Fusion Protein Leukemogenesis 
 
 The ultimate goals for studying Mtg16 function are twofold: one, to provide an 
increased understanding of basic hematopoiesis and the role of Mtg16 transcriptional 
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regulation in this process and two, to inform the understanding of how AML1-ETO and 
AML1-ETO2 fusion proteins function in cancer.  While the work presented here focuses 
on the first aim, knowledge of AML1-ETO function informed our understanding of how 
endogenous MTGs function.  Additionally, we hope to extend the new information 
generated by this dissertation to new theories on AML1-ETO function, and my 
hypotheses on the potential implications for fusion protein understanding will be a topic 
covered in Chapter V. 
The AML1-ETO fusion protein results from a t(8;21) that fuses the DNA-binding 
Runt-homology domain (RHD) of the Runx1/AML1 transcription factor to nearly all of 
ETO
4
.  Runx1 is a component of the Core-binding factor (CBF) complex as a 
heterodimer with CBF and binds DNA through the RHD at conserved (TGT/cGGT)  
sites found in many hematopoietic genes
229,230
.  Runx1 binds transcriptional activators 
such a p300 through its C-terminus to activate transcription
14,229
.  On its own, Runx1 is a 
weak activator of transcription, but Runx1 also facilitates the formation of much stronger 
transcriptional activation complexes with other transcription factors, including CEBP 
and the ETS family member PU.1
231,232
. Runx1 also represses transcription through 
interactions with mSin3a and HDACs, and this was the dominant function of Runx1 by 
transcriptional reporter assay when Runx1 was expressed by itself
233,234
.  The fusion 
protein replaces the C-terminal activation domain with the vast majority of the ETO 
protein.  AML1-ETO recruits ETO-bound corepressors to Runx1 target sites in place of 
coactivators, ultimately both repressing Runx1 downstream transcription and disrupting 
ETO function
23,235
.   
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It is notable that the t(8;21) fusion protein forms stable hetero-tetramers with 
native MTG family members
14,31
.  This raises the possibility that the fusion protein 
recruits endogenous MTG proteins or impairs the function of endogenous MTG family 
members via the NHR2 domain.  The NHR2 domain is the only domain of ETO within 
the context of the AML1-ETO fusion protein that is necessary for leukemogenesis, 
highlighting the importance of MTG dimerization, potentially with endogenous wild-type 
MTGs, to fusion protein function
236
.  Given that Mtg16 is the dominant member of the 
MTG family expressed in hematopoietic stem cells and Mtg16 is the only family member 
with a knock-out hematopoietic phenotype, we are particularly interested in how 
disruption of Mtg16 may contribute to AML1-ETO mediated leukemia
19,48
.  Furthermore, 
overexpression of the AML1-ETO fusion protein impaired the ability of Mtg16 to 
interact with NCoR, disrupting the endogenous functions of Mtg16
237
.  Restoring an 
excess of Mtg16 by overexpression in concert with AML1-ETO overexpression disrupted 
the ability of the fusion protein to impair granulocyte differentiation, returning cells to 
normal and suggesting that the effects of AML1-ETO on hematopoietic differentiation 
are due, at least in part, to disruption of Mtg16 function.  Therefore, understanding the 
normal function of Mtg16 is critical for fully understanding how the t(8;21) and t(16;21) 
cause AML. 
 
AML1-ETO Fusion Protein Targets 
 Overexpression of AML1-ETO leads to immortalization of hematopoietic 
precursors, with increased self-renewal and a block to terminal granulocyte 
differentiation.  In addition, the fusion protein causes an increase in DNA damage and 
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alters cellular growth and survival with increases in apoptosis and a G0/G1 arrest
20,238-241
.  
One hypothesis for the mechanism of AML1-ETO fusion protein function is disruption of 
Runx1 function by AML1-ETO repression of Runx1 targets.  Contributing to this 
hypothesis is the fact that Runx1
-/-
 mice develop a mild myelo-proliferative disorder
103
.  
Evidence also exists that AML1-ETO has a variety of activation targets that result from 
disruption of both Runx1 binding partners and ETO binding partners.     
One important target for AML1-ETO mediated repression is the p14(ARF) tumor 
suppressor, which is otherwise activated by Runx1
242
.  Repression of p14(ARF) facilitates 
loss of the p53 checkpoint and therefore allows immortalization of hematopoietic 
precursors.  Neurofibromatosis type 1 (NF-1) is another such target activated by Runx1 
and repressed by AML1-ETO, and NF-1 serves as a negative regulator of proliferation of 
myeloid progenitors in response to Granulocyte-Macrophage Colony Stimulating Factor 
(GM-CSF)
243
.  Loss of NF-1 sensitizes cells to GM-CSF, leading to a myeloproliferative 
disorder even in NF-1
+/-
 mice.  Repression of NF-1 levels by AML1-ETO may contribute 
to leukemogenesis by increasing proliferation in response to cytokines. 
In addition to direct repression of Runx1 targets, the AML1-ETO fusion protein 
also interacts with other transcription factors and interferes with their ability to function.  
CEBP is one such target, as it interacts directly with both Runx1 and the AML1-ETO 
fusion protein through the RHD domain
240,244
.  While Runx1 and CEBP act 
synergistically at promoters to enhance transcription, the AML1-ETO fusion protein 
impaired the ability of CEBP to activate downstream transcription. CEBP plays a 
critical role in terminal myeloid differentiation and overexpression of the fusion protein 
impaired the ability of granulocytes to differentiate, likely by impairing CEBP 
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function
245
.  One direct genetic target for CEBP activation that is repressed by the 
expression of AML1-ETO is CEBP itself, and AML1-ETO patient samples had reduced 
levels of CEBP when compared to other types of AML246.  Overexpression of CEBP 
rescued differentiation of Kasumi-1 cells, a cell line that carries the t(8;21).  Similarly, 
AML1-ETO interacted with PU.1, another AML1 binding partner and a critical 
transcription factor for hematopoiesis, and disrupted its functions as a transcriptional 
activator
247
.  PU.1 exerts many of the same functions as CEBP in hematopoiesis, and 
restoration of PU.1 function through overexpression also restored differentiation of 
Kasumi-1 cells.   
Runx1 targets are not the only casualties of AML1-ETO expression; the fusion 
protein also interacts with many of the ETO-directed transcription factors and disrupts 
their function. AML1-ETO exerted inhibitory effects on PLZF, an ETO interacting factor 
and BTB/POZ transcriptional repressor that negatively regulates proliferation and 
differentiation of myeloid cells
248
.  AML1-ETO blocked the function of this 
transcriptional repressor, partially through its ability to cause PLZF mislocalization and 
inhibit PLZF DNA binding, potentially leading to increased proliferation
27
.  Additionally, 
AML1-ETO interacts with the E-protein HEB through the NHR1 domain of ETO, which 
led to repression of E-protein mediated transcription in luciferase assays
31
.  Expression of 
the fusion protein caused mislocalization of HEB at new promoter targets and an overall 
increase in HEB protein levels
249
. This interaction had varied effects on AML1-ETO 
mediated leukemogenesis, as point-mutants that decrease the ability of AML1-ETO to 
repress E-protein mediated transcription had little impact on the ability of AML1-ETO to 
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repress terminal granulocyte differentiation, but did impair the ability of AML1-ETO to 
increase self-renewal
250
.  
AML1-ETO also induces upregulation of some targets indirectly, including 
CDKN1A (p21)
251
.  Expression of AML1-ETO in human CD34
+
 cord blood cells led to 
the accumulation of DNA damage foci (H2Ax foci), an effect that can cause 
upregulation of p21
241,252
.  This increase in p21 has controversial effects.  It may have 
deleterious effects for the ability of the fusion protein to induce leukemia: expression of 
AML1-ETO in mouse models does not induce leukemia, but, in the absence of p21, the 
fusion protein was sufficient to produce disease
251
.  This data suggests that the cell cycle 
arrest induced by increased p21 expression inhibited leukemia progression.   
Alternatively, expression of p21 may have protective effects in stem cell populations, 
with p21-mediated cell cycle arrest protecting against accumulation of excessive DNA 
damage and preventing exhaustion of leukemia stem cells
252
.  The DNA damage that 
accumulates in AML1-ETO expressing cells accumulates gradually, and is hypothesized 
to result from defects in DNA damage repair that occur as a result of repression of repair 
genes, such as OGG1 and POLE.  Alternative hypotheses driven by a potential direct role 
for MTG family members in DNA damage and repair are currently under investigation. 
Finally, AML1-ETO can activate some target genes indirectly by disrupting the 
ability of transcription factors to interact with NCoR and other corepressors (Moore et al 
in revision).  Over-expression of AML1-ETO activates a Tcf4 dependent transcription 
assay (TOP-FLASH) and does so by impairing the ability of Tcf4 to interact with co-
repressors.  Similar interaction data is obtained with Gfi-1, as expression of AML1-ETO 
impairs its ability to bind NCoR as well.  AML1-ETO blocks the ability of Mtg16 to 
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interact with NCoR, a function that affects AML1-ETO’s ability to repress granulocyte 
differentiation.   
 
Effect of AML1-ETO Expression on Hematopoiesis and Leukemogenesis 
To better understand how AML1-ETO expression leads to leukemia, several 
groups have developed knock-in mouse models for AML1-ETO expression.  Knock-in of 
AML1-ETO in the Runx1 locus produced a phenotype much like Runx1 knockout mice 
with embryonic lethality from lack of definitive hematopoiesis
253,254
.  Given the absolute 
requirement for Runx1 in definitive hematopoiesis, this phenotype is likely just an 
alternate form of a Runx1
-/-
 mouse.  Using an alternative locus for knock-in shows that 
expression of AML1-ETO alone is not sufficient to induce leukemia.  A tetracycline-off 
system driving AML1-ETO expression in mice shows no formation of leukemia as a 
result of the expression of AML1-ETO
239
.  AML1-ETO expressing bone marrow cells 
were grossly normal, with normal hematopoietic lineage allocation by both flow-
cytometry and methylcellulose colony assays.  However, AML1-ETO bone marrow cells 
had increased replating efficiency by methylcellulose serial replating assays, producing 
colonies through at least 13 rounds of replating, compared to 3 for wild-type controls.  
The colonies were composed of immature myeloid cells, and showed a delay in myeloid 
maturation that could be reverted by loss of AML1-ETO expression, which caused 
differentiation of the immature myeloid cells and loss of replating ability.  Collectively, 
this data indicates an effect on general hematopoiesis short of leukemia by the presence 
of AML1-ETO.  
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Mice that express the fusion-protein under the direction of the human MRP8 
promoter, and therefore in myeloid (neutrophil and monocyte) lineages, also do not 
develop leukemia as a result of AML1-ETO expression
255
. When these mice were treated 
with the DNA-alkylating agent N-ethyl-N-nitrosourea (ENU) to provide second-hit 
mutagenesis, though, both transgenic and wild-type controls developed leukemia and 
were sacrificed within seven months after initiating ENU treatment.  However, wild-type 
mice and half of the AML1-ETO transgenic mice developed acute lymphocytic leukemia 
(ALL) while only AML1-ETO transgenic mice developed acute myeloid leukemia.  
These leukemias were comprised of immature myeloid cells and had an increased latency 
when compared to ALL disease.  With lower doses of ENU, transgenic mice developed 
an accumulation of immature myeloid progenitors skewed away from the 
Megakaryocyte/Erythrocyte Progenitor (MEP) population, suggesting an expanding 
precursor cell population with granulocyte/monocyte skewing prior to the development of 
full-blown myeloid leukemia.  Similar results were obtained with a different AML1-ETO 
expression model
256
. 
 Retroviral overexpression of the AML1-ETO fusion protein in bone marrow cells 
prior to transplant likewise does not lead to leukemia, but does have a strong effect on 
lineage allocation and differentiation
257,258
.  The presence of the fusion protein reduced 
development of transduced B and T lymphocytes to 13% and 3% of control cells, 
respectively, in one model
257
.  Contributing to this phenotype was a block of B-cell 
development from immature to mature recirculating B-cells (Fractions E to F).  AML1-
ETO expressing cells also showed defects in erythropoiesis and increases in 
granulopoiesis, a phenotype similar to the loss of Mtg16.  The increased granulocytes 
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were of an immature type, lacking terminal differentiation
258
 . Finally, overexpression of 
AML1-ETO affected the self-renewal potential of hematopoietic stem cells, as AML1-
ETO expressing marrow showed a strong increase in HSC number, but a decrease in 
contribution to mature cells after transplant
258
.        
Perhaps the most faithful model of AML1-ETO mediated leukemogenesis is one 
where AML1-ETO expression is targeted to hematopoietic stem cells using the Sca-1 
promoter for knock-in
259
.  Studies of samples from patients who were in remission 
confirmed that the fusion protein is present in hematopoietic stem cells that can give rise 
to multiple lineages, suggesting that the stem cell compartment is the place of origin for 
t(8;21) mediated leukemia
260
.  Like similar overexpression models, lymphopoesis was 
affected by the presence of AML1-ETO expression in stem cells from the Sca-1 
promoter; in this model, though, surviving developing lymphocytes reduced expression 
of AML1-ETO significantly to bypass the deleterious effects of AML1-ETO of B and T-
cell development.  Granulocyte skewing was also seen with AML1-ETO expression.  
Ultimately this increase in granulopoiesis led to a myeloproliferative disorder, 
highlighting the importance of cell-type specific expression in recapitulating in vivo 
models.   
 
Structure/Function Analysis of AML1-ETO 
  Structure function analysis of AML1-ETO has identified important functions for 
many conserved regions of the protein in inducing leukemogenesis. C-terminal NHR3 
and NHR4 are not only dispensable for leukemogenesis, but may also be inhibitory, as 
AML1-ETO truncation mutants that removed these regions were capable of inducing 
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leukemia in the absence of a second hit
261
.  C-terminal deletion of AML1-ETO negatively 
affected the ability of the fusion protein to induce cell-cycle arrest in G0/G1, suggesting 
that NHR3 and/or NHR4 play a role in cell cycle regulation.  Cyclin D3, Cyclin A, and 
Cyclin Dependent Kinase 4 levels were decreased by the presence of full-length AML1-
ETO but not by the c-terminal truncation form, providing possible targets for differential 
regulation that contribute to the different phenotypes seen by the two isoforms of AML1-
ETO.   
Further deletion analysis showed that removal of NHR4 alone was sufficient to 
increase the leukemogenic potential of AML1-ETO and in fact mutation of a single 
residue in NHR4 (C663S) that abrogates the Zn-chelating structure of NHR4 conferred 
the same enhanced potential on AML1-ETO
262
.  This region and, specifically, this 
mutated residue facilitate interaction with SON, a protein that facilitates RNA splicing
263
.  
SON is nuclear protein that is necessary for cell cycle progression, as knockdown of SON 
led to cell cycle arrest in mitosis due to spindle defects.  Therefore, the full-length 
AML1-ETO isoform may interact with SON and block it’s ability to enhance cell cycle 
progression, leading to the cell cycle arrest seen in the presence of the fusion protein.  
Deletion of this interacting domain reversed this phenomenon, restoring cell growth even 
in the presence of the rest of AML1-ETO. 
An alternative splice isoform of AML1-ETO was identified in 2006 that removes 
the 9th through 11th exons of Mtg8 by introducing a stop codon after the 8
th
 exon
264
.  The 
alternative fusion protein, termed AML1-ETO9a, is 575 amino acids, as opposed to the 
752 amino acids of the full-length fusion protein, and no longer contains NHR3 or 
NHR4.  Found in patient samples alongside full-length AML1-ETO at varying ratios, 
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AML1-ETO9a induced acute myeloid leukemia in mice within 16 weeks post-transplant.  
This is particularly interesting given that expression of full-length AML1-ETO was not 
capable of inducing leukemia in the absence of a secondary mutation and corresponds 
with reports that a C-terminal truncation mutant of AML1-ETO that artificially removes 
the NHR3 and NHR4 regions also induced leukemia without a secondary hit 
255,261
. Co-
expression of both full length and 9a isoforms, mimicking the physiologic conditions 
found in most patient samples, was strongly leukemogenic, and even more effective in 
inducing leukemia than expression of each construct alone.  Co-expression shortened the 
leukemia latency from 16 weeks for AML1-ETO9a alone to just five weeks.  The cell 
types comprising the leukemia differed according to the isoforms of AML1-ETO 
expressed.  AML1-ETO9a alone leukemias were 30% myeloid progenitor cells, or 
Lin
neg
sca1
-
c-kit
+
, and fell within an abnormal FCRII/IIImedCD34- population.  AML1-
ETO9a and AML1-ETO co-expressing leukemias were more like patient samples, with 
over 60% myeloid progenitor cells contained diffusely across normal myeloid progenitor 
populations (FcRII/IIIlo-highCD34+) and also contained a higher amount of hematopoietic 
stem/progenitor cells (20% Lin
neg
sca-1
+
c-kit
+
).  While deletion of NHR3 and NHR4 is 
known to delete interaction with SON and corepressors such as NCoR, other regions of 
MTGs can also recruit NCoR, and therefore corepressor function is retained.  Alternative 
binding partners for the C-terminal NHR3 and NHR4 regions that may contribute to this 
phenotype are under current investigation. 
In the context of the AML1-ETO9a isoform that produces leukemia in vivo the 
contribution of other conserved regions to leukemia initiation and progression can be 
assessed. DNA binding by the AML RHD domain and oligomerization by the NHR2 
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dimerization domain were both necessary for AML1-ETO9a to induce leukemia while 
the presence of NHR1 was dispensable for leukemia formation
236
. Furthermore, CBF 
binding and DNA binding are critical for AML1-ETO to function in disrupting 
hematopoiesis and inducing leukemia in concert with the TEL-PDGFβR fusion protein as 
a second hit
265
.  Therefore, NHR3 and 4 contribute to the function of AML1-ETO in a 
negative regulatory role, while NHR2 and the RHD are indispensable for AML1-ETO 
leukemia.  The contribution of NHR1 has yet to be determined.   
  
Associated Mutations in AML1-ETO Leukemia 
Mouse models of AML1-ETO leukemia show that AML1-ETO expression alone 
is not sufficient to induce leukemia.  Furthermore, second-hit mutations generated by 
ENU treatment in the presence of AML1-ETO can help induce myeloid leukemia.  
Therefore, several groups have investigated the nature of cooperating mutations in 
AML1-ETO driven AML.  The second-hit necessary in vivo to produce AML in the 
presence of the fusion protein is not p53 mutation, as p53 was not found to be mutated in 
primary t(8;21) AML samples
266
.   This result is surprising given that deletion of p21 
allowed AML1-ETO to induce leukemia in mouse models
251
.  The most common type of 
second-hit mutation occurs in signal transduction pathways, including receptor tyrosine 
kinases Flt3 and Kit
267
.  In a study of 135 patients with AML1-ETO translocation 
associated AML, 18.5% carried activating mutations in Flt3 or Kit.  Another 9.6% had 
activating mutations in NRAS.  Mouse bone marrow transplant models expressing 
AML1-ETO or mutant Flt3 alone did not develop leukemia, while all recipients who 
received AML1-ETO
+
/Activated-Flt3
+
 bone marrow developed an acute leukemia, 
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confirming that AML1-ETO and Flt3 activating mutations can cooperate in the 
pathogenesis of AML.  This leukemia was not a 100% faithful recapitulation of AML, 
though, as half of the recipient mice developed ALL instead of AML.  Further analysis of 
patient samples with the AML1-ETO fusion protein showed expression of some 
lymphocyte markers, though, suggesting that immature AML cells from AML1-ETO 
patients may be a mixed myeloid/lymphoid lineage.  Recent evidence shows that classic 
Ras mutations (NRasG12D) can enhance transformation of AML1-ETO expressing cells, 
as evidenced by increased self-renewal and cytokine independent growth, though no 
evidence of leukemia in mouse engraftment models was shown
268
.  Activating C-kit 
mutations, which are frequently seen in AML1-ETO driven AML, can cooperate with 
AML1-ETO to induce myeloid leukemia in mouse models
269
.  Importantly, these myeloid 
leukemias were responsive to tyrosine kinase inhibitors, suggesting a potential 
therapeutic avenue for AML1-ETO AML with cooperating c-Kit mutations.   
 
Conclusions 
 
 Mtg16 is a transcriptional corepressor that does not bind DNA directly, but 
instead binds DNA-binding transcription factors, many of which are important for 
hematopoiesis.  Among the list of transcription factor binding partners for Mtg16 are 
many that are involved in B- and T-cell development, including CSL and the NICD of the 
Notch signaling cascade, E-proteins such as E2A, HEB, and E2-2, and Bcl6.  Disruption 
of Mtg16 in knockout mouse models led to altered lineage allocation with increased 
granulopoiesis, decreased lymphopoiesis, and impaired erythropoiesis.  Mtg16 also 
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regulates hematopoietic stem cell function, and loss of Mtg16 impaired the ability of LT-
HSC cells to self-renew.  These Mtg16
-/-
 phenotypes are more severe after stress and are 
often associated with alterations to cell growth and survival. 
 Disruption of MTG family members by chromosomal translocations leads to 
AML1-ETO fusion proteins and leukemia.  The function of the fusion protein requires 
the ability to dimerize with other MTG family members.  Furthermore, over-expression 
of AML1-ETO impairs lymphoid development and causes skewing towards immature 
granulocyte/monocyte lineages with increased self-renewal capacity.  Therefore, in an 
attempt to better understand Mtg16 contribution to AML1-ETO and AML1-ETO2 fusion 
protein mediated leukemia, we study Mtg16
-/-
 mouse models.  Given the number of 
transcription factors Mtg16 binds, particularly those that are involved in lymphoid 
development, and the precedence for targets of chromosomal translocations in leukemia 
to be involved with several different facets of hematopoiesis, we hypothesized that 
Mtg16 would play a role in regulating lymphoid development.  In Chapter III, the role of 
Mtg16 in T-cell development is explored: ultimately, Mtg16 is required for efficient 
murine T-cell development and it functions in part to regulate both Notch and E2A 
expression functions.  In Chapter IV, this analysis is extended to murine B-cell 
development, with the surprising finding that Mtg16 contributes to not only early B-
lineage fate decisions, but also mature immune function.  Hypotheses of the impact of 
these novel findings on understanding AML1-ETO function will be presented in Chapter 
V. 
 
 67 
CHAPTER II 
 
MATERIALS AND METHODS 
 
Mice 
 Generation of Mtg16-null mice was previously described 
19
.  For studies shown 
here, Mtg16-null mice were backcrossed into the C57Bl/6 background for ten 
generations.  Mouse genotyping was performed as follows: anesthetized mice were 
labeled by ear punch and the distal portion of the tail was removed.  The tail portion was 
placed in 500l of Jeffers Tail Mix (0.1M Tris, pH 8.0; 5mM EDTA, 0.2% SDS, and 
0.2M NaCl) supplemented with 250g Proteinase K over night at 55oC.  The digested tail  
remnants were collected by centrifugation and the supernatant was transferred to a new 
tube.  800l of ice cold isopropanol were added to the tail DNA solution and this 
suspension was placed on ice for 30 minutes.  The DNA was pelleted by a 10 minute 
centrifugation at maximum speed, followed by two 100% EtOH washes.  The pelleted 
DNA was allowed to air dry, then resuspended in 100l of TE.   
Genotyping Polymerase Chain Reactions (PCRs) were performed with two PCRs, 
one that identified a wild-type band between exons 8 and 9 of 704 base pairs (primer pair 
129T forward and 130B reverse) and one that identified a wild-type band spanning exon 
7 to 9 of 1.4kb and a null band of 280 base pairs that no longer contains exon 8 (primer 
pair 135T forward and 130B reverse).  The primer sequences are as follows:  
130B 5’-GTCCATGATGCAGTTCAGAAG-3’;  
129T 5’-CTGGGTCTCGACAAGAAGAAGTG-3’;  
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135T 5’-GATGCAAGAACTAGGCAGGGTT-3’.   
PCRs were performed with GoTaq Flexi Taq polymerase and the following cycle 
parameters: 1 Cycle 94
o
C 5 minutes, 55
o
C 1 minute, 72
o
C 1.5 minutes; 30 cycles 94
o
C 1 
minute, 55
o
C 45 seconds, 72
o
C 1.5 minutes; and 1 cycle 72
o
C 10 minutes.  PCR products 
were visualized on 1-2% agarose gels.  Sex and age matched wild-type and Mtg16
-/-
 mice 
were used between 6 and 8 weeks of age unless otherwise noted. 
 
Plasmids 
 The E-protein point mutant plasmids were generated using QuickChange II XL 
Site Directed Mutagenesis Kit (Agilent Technologies).  Primers were designed based 
upon the structure of the Eto-HEB interaction 
270
 to mimic the following mutations: 
F210A-F154A and R220A-R164A.  
F210A:  
Forward: 5’ CACTGAGGCCGTTTGTTATCCCTGCTCTGAAGGCTAATCTT 3’             
Reverse: 5’ AAGATTAGCCTTCAGAGCAGGGATAACAAACGGCCTCAGTG 3’ 
R220A:  
      Forward:  5’ CTTCCACTGCTGCAGGCTGAGCTCCTGCACTG 3’ 
       Reverse: 5’ CAGTGCAGGAGCTCAGCCTGCAGCAGTGGAAG 3’   
MSCV-Id1 and MSCV-Id2 were generous gifts of Dr. Jonathan Keller.  Fragments of 
Mtg16 deleted from the 5’- or 3’- ends were generated by PCR amplification and 
assembled in appropriate combinations to create interstitial deletion mutants NHR1, 
NHR2, NHR3, NHR4, PST2, and NHR1-PST2.  Fragments were subcloned into 
EcoR1/XhoI restricted MSCV or pCMV5 for use in terminal experiments.  The regions 
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deleted in each mutant were as follows: NICD deleted amino acids 1-85, NHR1 
deleted amino acids 145 to 242, NHR2 deleted amino acids 365 to 402, NHR3 deleted 
amino acids 460 to 510, NHR4 deleted amino acids 532 to 567, PST2 deleted amino 
acids 242 to 364, and NHR1-PST2 deleted amino acids 145 to 364. 
 
Cell Culture and Expression Analysis 
 Bosc23, Cos7, and 293T cells were cultured in Dulbecco’s modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 50 U/ml Penicillin, 
50 g/ml streptomycin, and 2mM L-glutamine. MEL cells are grown in DMEM 
supplemented with 10% FBS, 50 U/ml Penicillin, 50 g/ml streptomycin.  Plating 
densities for MEL cells ranged between 1x 10
5
 and 2 x 10
5
 and cells should not become 
more confluent than 2 x 10
6
.   OP9 and OP9-DL1 stromal cells were cultured in -MEM 
(GIBCO) supplemented with 20% heat-inactivated FBS, 50 U/ml Penicillin, 50 g/ml 
Streptomycin.  OP9 cells were passaged at less than 80% confluency to preserve 
expression of the DL1 ligand.  Expression from MSCV-IRES-GFP plasmids was 
confirmed after transfection of 3 µg of plasmid into Bosc23 viral producing cells with 
Polyfect (Qiagen). 48 hours post-transfection, cells were harvested into Radio-immune 
precipitation assay (RIPA) buffer (50mM Tris, 150mM NaCl, 1% NP-40, 0.25% Na-
deoxycholate, 1mM EDTA, pH 7.4) containing protease inhibitor cocktail (Roche) and 
diluted 1:2 in Laemmli’s Sample Buffer (Bio-Rad), sonicated, and subjected to 10% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis.  Immunoblots were 
performed using anti-Myc 9E10 antibody (1:2000), with GAPDH expression (AbCam) as 
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a loading control.  Expressed proteins were visualized using fluorophore-conjugated 
secondary antibodies (1:3000) and the Odyssey system (LiCor).   
 
Flow Cytometry and Cell Sorting 
 Single cell suspensions were formed after flushing the tibia and/or femur with 
PBS to collect bone marrow cells or mincing the spleen or thymus and passing the 
fragments through a 70 µM filter.  Erythrocytes were lysed with 1mL Buffer EL (Qiagen) 
for five to ten minutes on ice.  Antibody staining for flow cytometry was carried out on 1 
x 10
6 
cells in single wells of a round-bottom 96-well plate for 15 minutes at 4
0
C in the 
dark.  For lineage labeling, cells were stained with biotinylated antibodies directed 
toward lineage-specific cell surface markers (CD3, B220, Gr1, Mac1, and Ter119 
eBioscience), followed by fluorochrome-conjugated streptavidin.  For all other flow 
cytometry, cells were labeled with the appropriate combination of fluorochrome –
conjugated anti-c-Kit, anti-Sca-1, anti-FLT3, anti-IL7R, anti-CD44, anti-CD25, anti-
CD4, anti-CD8, anti-GR-1, anti-Mac-1, anti-B220, anti-CD43, anti-IgM, anti-BP-1, anti-
CD24, anti-CD21, and anti-CD23 (eBioscience).  Biotinylated anti-IgD, anti-AA4.1, and 
anti- T-cell Receptor were used followed by fluorochrome conjugated streptavidin 
(eBioscience).  Analysis was performed on a 3-Laser BD LSR II using FACSDiva 
software.  For rare populations of cells, bone marrow samples were first lineage-depleted 
using a lineage depletion kit and magnetic cell sorting (Miltenyi Biotec).  For rare 
thymocyte populations, thymi were lineage depleted using a biotinylated lineage panel as 
above supplemented with biotinylated anti-CD4 and anti-CD8 (eBioscience), followed by 
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anti-Biotin microbeads and magnetic cell sorting (Miltenyi Biotec).  Sorting of 
hematopoietic cell populations was performed on the BD FACSAria.   
 
Murine MTG Family Member Expression Analysis 
Expression of individual genes was measured using reverse transcriptase PCR, 
with total RNA isolated using the 5Prime PerfectPure RNA extraction kit from sorted 
populations of cells.  The Reverse Transcriptase step was carried out using 100-200ng 
total RNA per 20l iScript (BioRad) cDNA synthesis reaction; ¼ of the reaction was 
used for PCR using the iQ Sybr Green SuperMix (BioRad) with GAPDH as an internal 
control. PCR reactions were performed in duplicate.  
mMtg8F: 5’-ATTTACGCCAACGACATTAACGA-3’;  
mMtg8R: 5’-CTGAGTTGCCTAGCACCACA-3’;  
mMtgr1F: 5’-ACCTGGCCCAGCATGAGC-3’;  
mMtgr1R: 5’-AATGTCTTCTAGTGTATAGTGC-3’;  
mMtg16F: 5’-CCACGGCTGCTTAAAGTGGT-3’;  
mMtg16R: 5’-GTCATTGCCAAATTGCTGTAGG-3’ 
GAPDHF: 5’-GCCTTCCGTGTTCCTACCC-3’;  
GAPDHR: 5’-TGCCTGCTTCACCACCTTC-3’. 
 
In vitro Differentiation Assays 
 The indicated sorted populations of cells were plated on irradiated (20gy), 
confluent OP9-DL1 stromal cells in Alpha-MEM (GIBCO) supplemented with 20% FBS, 
50 U/ml Penicillin, 50 g/ml Streptomycin, 5 ng/ml IL-7 (Peprotech) and 5ng/ml Flt3L 
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(Peprotech.)  Initial plating densities ranged from 500-4000 cells per well of a 24-well 
plate.  The hematopoietic cells were collected by manual dissociation, counted, and 
passaged every 4-7 days onto a fresh stromal layer at concentrations less than 5 x 10
5
 
cells per well.  T-cell differentiation was assessed every 7 days for 4 weeks by flow 
cytometry. 
 
Cell Cycle Analysis 
 Cell cycle analysis of hematopoietic cells co-cultured with OP9-DL1 cells or in 
M3630 methylcellulose was performed using propidium iodide staining of genomic 
DNA.  Cells were collected from culture, washed with PBS, and counted.  Collected cells 
were fixed in 70% EtOH overnight at -20
o
 C.  The following day, samples were spun to 
collect and the EtOH was removed; a PBS wash was performed to remove residual 
ethanol.  Washed, fixed cells were treated with 0.1% Triton-X100, 20 µg/ml Propidium 
Iodide (Sigma), 0.1mg/ml RNase A (USB) in 500l Phosphate Buffered Saline (PBS)  
for 30 minutes at room temperature prior to FACS analysis.   
 
Annexin V Staining 
 Annexin V analysis on hematopoietic cells co-cultured with OP9-DL1 stromal 
cells or M3630 methylcellulose was performed using the Annexin V-FITC Apoptosis 
Detection Kit I (BD Pharmingen) per the manufacturer’s instructions.  Briefly, in vitro 
cells were collected from day 7 OP9-DL1 or methylcellulose cultures, washed in PBS, 
and counted.  Cells were resuspended in Annexin V Binding Buffer at a concentration of 
1 x 10
6
/mL and labeled with Annexin V FITC (5l per 100l sample) for 15 minutes at 
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room temperature in the dark then filtered through a filter cap tube and analyzed by flow 
cytometry.  Where possible, PI stain (5l per 100l sample) was added immediately prior 
to flow cytometry.   
 
Retroviral expression 
 MSCV-myc-Eto2-GFP and variants, MSCV-Id1-GFP, and MSCV-Id2-GFP were 
transfected into Bosc23 viral producing cells at a concentration of 3g per 60mm plate 
and supplemented with 1g of pCL to facilitate viral packaging.  Viral supernatant was 
collected 48 hours post-transfection and filtered through a 45 m syringe filter (Nalgene).  
Sorted LSK cells were centrifuged at 1500rpm for 1 hour at room temperature with viral 
supernatant prior to co-culture with OP9 or OP9-DL1 stromal cells.  Infection was 
monitored using flow cytometry to detect GFP expression. 
 
Transcription Assays 
 Luciferase reporter assays were performed in 293T cells transfected with the 
indicated plasmids. Luciferase values were assessed from an E-box reporter plasmid, a 
generous gift of Dr. Robert Roeder.  For each transfection, equivalent amounts of E-box 
luciferase and Renilla luciferase and the appropriate combinations of test plasmids or 
empty vector plasmids were mixed to achieve the same amount of total DNA transfected.  
Transfections were carried out using Polyfect (Qiagen).  48 hours post transfection, cells 
were lysed with Passive Lysis Buffer from the Promega Dual-Luciferase Reporter Assay 
System and luciferase activity was measured on a BD Pharmingen Monolight 3010 
luminometer using 10 second exposures for both the first reading (Firefly luciferase) and 
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the second reading (Renilla luciferase).  All values were performed in triplicate and 
normalized to a Renilla Luciferase internal control.  
 
Co-immunoprecipitation assays 
 Cos7 cells were transfected with the indicated combinations of plasmids and 40 hr 
later the cells were washed with PBS and harvested into HERR buffer (100mM KCl, 
0.02M Hepes pH7.9, 0.002M EDTA, 0.1% NP-40, 10% Glycerol) supplemented with a 
Protease Inhibitor Cocktail (Roche).  For Mtg16-E47 interactions, 600mM KCl HERR 
was used.  For Mtg16-NICD interactions, 100mM KCl HERR was used.  Lysates were 
sonicated with three short pulses at 4.5 watts and cleared by centrifugation for 10 minutes 
at 4
0
C at maximum speed.  Immunoprecipitation of lysates was performed for 2-3 hours 
nutating at room temperature using anti-Myc 9E10 for Mtg16-E47 interactions and the 
Flag M2 antibody (Sigma) for Mtg16-NICD interactions.  Immune complexes were 
collected using 30l of a 50% slurry of protein G sepharose 4B (Sigma). Co-precipitating 
proteins and whole cell lysates were subjected to 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis and identified by immunoblot analysis of immune 
complexes using anti-Myc 9E10 (1:2000), anti-Flag M2 (1:3000), and anti-E47 sc-763 
(1:400) (Santa Cruz). 
 
Bone marrow transplant-CFU-S 
 Bone marrow was harvested from two hind legs from wild-type and Mtg16
-/-
 mice 
and a sterile single cell suspension was created.  Red blood cells were lysed and total 
bone marrow cells were plated in DMEM supplemented with heat-inactivated ES-cell 
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FBS, 50 U/ml Penicillin, 50 g/ml streptomycin, and 2mM L-glutamine, 50ng/ml stem 
cell factor (SCF), 5ng/ml IL-6, and 10
3
U/ml leukemia inhibitory factor (LIF).  To ensure 
all conditions received the same Mtg16
-/-
 donor cells, multiple mice were pooled and 
equivalent numbers of cells were used for each condition. The next day, cells were 
transferred onto irradiated (30gy) Bosc23 cells transfected with the appropriate MSCV 
reconstitution plasmids or MSCV empty vector and incubated for 48 hours to allow for 
infection.  Bone marrow cells were collected, counted, and resuspended in PBS to allow 
for injection of 300l total volume by tail vein injection into lethally irradiated recipients 
(900 rads).  For wild-type controls, 5 x 10
4
 cells were injected.  For Mtg16
-/-
 cells of the 
various conditions, 4 to 5 x 10
5
 cells were injected, depending on the experiment.  Mice 
were placed on acidified water and monitored for twelve days.  On day 12, spleens were 
harvested and fixed in Tellesniczky’s’s Fixative (75% EtOH, 3.75% Acetic acid, and 
7.5% Formalin) to allow for visualization of spleen colonies. 
 
Competitive Bone Marrow Transplants 
For competitive reconstitution assays, a sterile single cell suspension of bone 
marrow cells was obtained from the tibia and femur, and the red blood cells were lysed 
with erythrocyte lysis buffer (Buffer EL, Qiagen).  Bone marrow cells were injected via 
the tail vein into lethally irradiated (900 rads) recipient C57Bl/6 CD45.1 congenic mice. 
The Mtg16
+/+
 or Mtg16
-/-
 donor cells were mixed with C57Bl/6 CD45.1 wild-type bone 
marrow cells (9:1) in PBS, with a final total of 1.8 x 10
6
 CD45.2
+
 test cells and 2 x 10
5
 
CD45.1
+
 competitive cells. Reconstitution potential of the donor (CD45.2) cells was 
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monitored by flow cytometry of the peripheral blood every two to four weeks and 
analysis of the bone marrow, thymus, and spleen at the end of the experiment. 
 
Chromatin Immunoprecipitation Assays.   
Chromatin Immunoprecipitation (ChIP) assays were performed using Murine 
Erythroleukemia (MEL) cells.  1 x 10
7
 cells per condition were crosslinked with 1% 
Formaldehyde (Sigma) for 20 minutes and the crosslinking reaction was quenched by the 
addition of glycine to a final concentration of 125mM for 5 minutes.  Cells were 
collected, washed, and resuspended in a low salt ChIP buffer (50mM HEPES KOH, 
ph7.5, 140mM NaCl, 1mM EDTA pH8.0, 1% Triton X-100, and 0.1% Sodium 
Deoxycholate).  Samples were sonicated and cleared by centrifugation for 15 minutes at 
maximum speed at 4
0
C.  Protein estimations were performed using the DC Protein Assay 
(BioRad) per the manufactures instructions and equivalent amounts of protein were 
allocated to each antibody conditions.  5% of each sample was saved overnight at -20
0
C 
for input controls, then subjected to reverse crosslinking and all subsequent steps. 
Samples were then precleared with the addition of Protein G Sepharose 4B (Sigma).  
Samples were incubated over-night with 6g either Goat IgG (Santa Cruz) or anti-Eto2 
G20 (Santa Cruz).  Immune complexes were collected by incubation with a 50% slurry of 
Protein G Sepharose 4B (Sigma) then washed with a low salt ChIP buffer, a high salt 
ChIP buffer (50mM HEPES KOH pH7.5, 500mM NaCl, 1mM EDTA pH8.0, 1% Triton 
X-100, and 0.1% Sodium Deoxycholate) and Lithium Chloride/NP40 buffer (10mM 
TrisCl, pH8.0, 250mM LiCl, 0.5% NP-40, 0.5% Sodium Deoxycholate).  DNA-antibody 
complexes were eluted with elution buffer (1% SDS and 100mM Sodium Bicarbonate) 
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and the crosslink was reversed with 200 µM NaCl at 65
o
C
 
for 5 hours.  DNA was 
precipitated with the addition of 100% EtOH and incubation over-night at -20
0
, RNase 
treated (Macherey-Nagel), Proteinase K (Sigma) treated, and isolated using the Qiagen 
PCR Purification kit.  RT-PCR was performed with 2 µl of each sample in duplicate 
using SybrGreen (BioRad) and the BioRad ICycler and normalized to input.  Primer 
sequences are as follows:  
E2F2 Intron 1: F- 5’-GGACTCTGGAGGGCTAATGTTG-3’  
R-5’-GCAATGTCTTCACTCGGCTCGG-3’ 
E2F2 Intron 2: F-5’TCAGACAGATGAGCGGGGAGGTG-3’  
R-5’-GCCTCTGCCAGCCGCTTGAAA-3’ 
E2F2 3’ UTR F-5’-TGGTTTCCCCTCCCTGTGAGGC-3’  
R-5’-AGACCTGTAGCCACCACGGTCC-3’ 
CCND1 TCF F-5’-CTGCCCGGCTTTGATCTCT-3’  
R-5’-AGGACTTTGCAACTTCAACAAAACT-3’ 
CCND1 EBox/CSL F-5’-CTGGTCTGGCATCTTCGG-3’  
R-5’-GAGAATGGGTGCGTTTCCG-3’ 
NMyc F-5’-CCCGAATGCCTACATAATTCT-3’  
R-5’CCTTGGAAGGGTGGCTCA-3’  
Mtg16 F-5’-AATATTCACAGGGCCTGACCAA-3’  
R-5’-AAATGCCTGCAAGCGGATTA-3’ 
 
LPS Stimulation 
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B220
+
 populations were created by labeling total spleen suspensions with B220-
biotin (eBioscience) followed by anti-Biotin magnetic microbeads and magnetic cell 
separation (Miltenyi Biotec). Total splenic cell populations or B220
+
 positively-selected 
populations were cultured in 96-well round bottom dishes at 100,000 cells/well in a total 
volume of 200l in Roswell Park Memorial Institute (RPMI) media, 10% FBS, 50 U/ml 
Penicillin, 50 g/ml streptomycin, and 2mM L-glutamine.  Wells were supplemented 
with LPS (Sigma) at 20g/mL for three days.  At 24 hour intervals, alamar blue 
(Invitrogen) was added to the wells at 10% of total well volume, incubated for 4-6 hours, 
and read using a Biotek plate reader and the Gen5 program (Biotek) to assess cell 
viability.   
 
V(D)J Recombination PCR 
V(D)J recombination was assessed by PCR in total bone marrow B220
+
 cells 
collected by magnetic cell sorting.  Total genomic DNA was collected using the DNeasy 
Blood and Tissue Kit (Qiagen) per the manufacturer’s instructions and equivalent 
amounts of DNA (500ng) were used for each of 4 PCRs: DH to JH, VH558 to JH , VH7183 to 
JH, and CMu heavy chain loading control.  PCR primers are as follows: 
DH Forward: 5’-TTCAAAGCACAATGCCTGGCT-3’ 
VH558 Forward: 5’-CGAGCTCTCCARCACAGCCTWCATG-3’ 
VH7183 Forward: 5’-CGGTACCAAGAASAMCCTGTWCCTG-3’ 
JH Reverse: 5’-GTCTAGATTCTCACAAGAGTCCGATA-3’ 
Cmu Forward: 5’-TGGCCATGGGCTGCCTAGCCCGGGA-3’ 
Cmu Reverse: 5’-GCCTGACTGAGCTCACACAGGGAGG-3’ 
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Where R= A,G; W=A,T; S=C,G; and M=A,C. PCRs were performed with GoTaq Flexi 
Taq polymerase and the following cycle parameters: 1 Cycle 95
o
C 5 minutes; 30 cycles 
95
o
C 30 seconds, 60
o
C 1 minute, 72
o
C 2.25 minutes; and 1 cycle 72
o
C 10 minutes.  PCR 
products were visualized on 1-2% agarose gels. 
 
Peripheral Blood Analysis 
Complete Blood Counts were performed after tail-vein bleeds on the Hemavet 
HV950FS blood analyzer (Drew Scientific, Inc.) 
 
Methylcellulose Assays 
Total bone marrow was harvested into a single-cell suspension in Iscove’s 
Modified Dulbecco’s Medium (IMDM) from one femur of either Wild-type or Mtg16-/- 
mice.  Red blood cells were lysed with Erythrocyte Lysis Buffer (EL Buffer; Qiagen) and 
cells were counted.  7.5 x 10
4 
total bone marrow cells were plated in methylcellulose 
supplemented with 10ng/ml IL-7 (M3630 methylcellulose; Stem Cell Technologies) in 
1.1mL per plate on methylcellulose specific plates (Stem Cell Technologies).  Colonies 
were allowed to grow for 14 days and were counted manually at day 7 and 14.  A positive 
colony was judged as containing greater than 30 cells.  A Nikon Eclipse T5100 inverted 
scope was used and pictures of colonies were taken at day 7 and day 14 using a Nikon 
Coolpix P5100 camera.  To trace total cell counts and for flow cytometric analysis, 
methylcellulose plates were harvested by washing plates three times with Phosphate 
Buffered Saline (PBS) then collected by centrifugation and counted using a 1:2 dilution 
with trypan blue (Cellgro).  IL-7 titration in methylcellulose was performed using varying 
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degrees of IL-7 (Peprotech) and M3234 methylcellulose without cytokines (Stem Cell 
Technologies.) 
 
Germinal Center Assay 
 Wild-type and Mtg16
-/-
 mice were injected with phosphate buffered saline (PBS), 
Alum, or Alum + NP-CGG intraperitoneally.  NP(59)-CGG (Biosearch Technologies) 
was dissolved at 1mg/mL in sterile PBS then mixed in a 1:2 solution with Alum 
(Thermofisher) and 200l total solution was injected.  7 days later, spleens were 
harvested, weighed, and frozen in Optimal Cutting Temperature (OCT) Compound 
(Tissue-Tek).  5m sections were cut and frozen sections were warmed to room 
temperature and fixed in ice-cold acetone for 10 minutes.  Slides were dried and 
endogenous peroxidases were blocked with 3% H2O2  (Sigma) in MeOH for 30 minutes.  
Slides were washed in TBS-T and blocked with normal horse serum from the RTU 
vectastain kit (Vector), followed by Avidin-Biotin blocking (Vector).  Slides were 
incubated in biotinylated peanut agglutinin (PNA) (Vector) at a concentration of 8g/mL 
for 5 hours at room temperature, washed with TBS-T, and incubated with biotinylated 
anti-PNA (EyLab) for 45 minutes at room temperature at a concentration of 8g/mL.  
Slides were washed and incubated with streptavidin-Horseradish peroxidase (HRP) 
(Dako) for 30 minutes at room temperature using a 1:300 dilution, washed, and 
developed using SIGMA FAST 3,3’-Diaminobenzidine tablets dissolved immediately 
before use per the manufacturer’s instructions and applied for 90 seconds, followed by 
washing with tap water.  Slides were mounted with cytoseal (Richard-Allan Scientific) 
and imaged using a Nikon Eclipse T5100 microscope and pictures were taken with a 
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Nikon Coolpix P5100.  Germinal centers positive follicles were counted manually and 
depicted as the percent of total follicles. 
 
Microarray Analysis 
 Fraction A B-cells were sorted from pooled wild-type and Mtg16
-/-
 mice per cell 
sorting procedures detailed above.  RNA was collected using the 5’-Prime PerfectPure 
RNA Kit.  RNA was amplified using the NuGen WT Pico RNA Amplification Kit and 
hybridized to Affymetrix Exon/Gene (WT) arrays.   
 
Intracellular H2aX Flow Cytometry 
 Methylcellulose plates were collected and cells were resuspended in PBS and 
counted.  Equivalent numbers of cells were fixed and permeablized using the BrdU 
intracellular staining kit (BD Pharmingen).  Briefly, cells were fixed with for 15 minutes 
at room temperature with Cytofix/Cytoperm buffer, washed, and permeablized with 
Cytoperm Plus.  After permeablization, cells were re-fixed with Cytofix/Cytoperm then 
labeled with 1:1500 dilution of anti-H2aX (Milipore) for one hour at room temperature 
in the dark.  Secondary antibody labeling was performed for 30 minutes at room 
temperature in the dark using an anti-mouse conjugated to AlexaFluor488 (Invitrogen) 
and analyzed by flow cytometry. 
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CHAPTER III 
 
MYELOID TRANSLOCATION GENE 16 (MTG16) CONTRIBUTES TO  
MURINE  T-CELL DEVELOPMENT 
 
Abstract 
 
 Mtg16/Eto2 is a transcriptional co-repressor that is disrupted by the t(16;21) in 
acute myeloid leukemia.  Using mice lacking Mtg16, we find that Mtg16 is a critical 
regulator of T-cell development.  Deletion of Mtg16 led to reduced thymocyte 
development in vivo and after competitive bone marrow transplantation there was a 
nearly complete failure of Mtg16
-/-
 cells to contribute to thymocyte development.  This 
defect was recapitulated in vitro as Mtg16
-/-
 Lineage
-
/Sca1
+
/c-Kit
+
 (LSK) cells of the 
bone marrow or DN1 cells of the thymus failed to produce CD4
+
/CD8
+
 cells in response 
to a Notch signal. Complementation of these defects by re-expressing Mtg16 showed that 
3 highly conserved domains were somewhat dispensable for T cell development, but 
required the capacity of Mtg16 to suppress E2A-dependent transcriptional activation and 
to bind to the Notch intracellular domain.  Thus, Mtg16 integrates the activities of 
signaling pathways and nuclear factors in the establishment of T-cell fate specification. 
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Introduction 
 
The progeny of hematopoietic stem cells receive external signals and integrate 
them into altered transcriptional programs that direct multi-potent progenitor cells to 
become lineage committed and generate all the mature cell types found in the peripheral 
blood
53,271
.  Development along these distinct lineages requires that the external cues be 
faithfully interpreted at the transcriptional level to activate and repress lineage-specific 
gene expression programs
59,96
.  Transcriptional co-activators and co-repressors are ideally 
situated to integrate the activities of multiple DNA binding transcription factors and 
signaling pathways to alter gene expression programs and regulate lineage allocation 
119,272
.   
 Myeloid translocation gene (MTG) 16 is disrupted by the t(16;21) in acute 
myeloid leukemia (AML)
12
.  MTG16 (gene name CBFA2T3; also known as ETO2) is a 
member of a family of transcriptional co-repressors that also includes MTGR1 and 
MTG8 (also known as ETO), which is targeted by the t(8;21)
4,11,14
.  These translocations 
fuse the DNA-binding domain of RUNX1 to nearly all of either MTG16 or MTG8 to 
repress the transcription of RUNX1-regulated genes
4,11,12,21
.  As expected for co-
repressors, MTG16 binds to both DNA binding proteins and chromatin modifying 
factors
20,28,30,43,226,273
.  Four highly homologous domains within MTGs are evolutionarily 
conserved in the Drosophila factor Nervy and mediate some of these contacts.   
The action of E proteins and Notch signaling are critical to T-cell development 
and a potential role for Mtg16 in lymphopoiesis was further suggested by the 
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identification of an association between MTGs and these pathways
29-31,43,226,273
.  Upon 
ligand binding, the Notch receptor is cleaved and the intracellular domain of Notch (ICD) 
moves to the nucleus and binds the transcription factor CBF1-Suppressor of Hairless-
Lag1 (CSL) to activate transcription
274
.  MTGs appear to act as co-repressors for CSL, 
and independent of CSL, Mtg16 also associates with the Notch ICD, suggesting that 
Mtg16 mediates some aspects of Notch functions
29,43
.   
Likewise, Mtg16 associates with transcriptional activation domain-1 (AD1) in E-
proteins to impair E-protein-dependent transcription, and E2A instructs lymphoid 
development while inhibiting myelopoiesis
31,97,123,189,198,270
.  E2A-null mice have 
decreased numbers of thymocytes due to reduced lymphoid-primed multi-potent 
progenitor (LMPP) and early thymocyte progenitor (ETP) production and impaired 
progression from the earliest CD4
-
CD8
-
CD44
+
CD25
-
 Double Negative (DN) 1 
thymocytes to the subsequent CD4
-
CD8
-
CD44
+
CD25
+
 DN2 thymocytes
97,197-199
.  
Furthermore, E2A-null progenitor cells fail to produce T-cells in in vitro cell fate 
specification assays initiated by Notch signaling
9,74
. Here, we show that inactivation of 
Mtg16 impairs the development of T-lineage thymocytes, indicating that Mtg16 has the 
capacity to interact with key factors that specify the T-lineage, potentially serving as a 
master regulator of this cell fate decision. 
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Results 
 
Mtg16 is required for thymopoiesis after bone marrow transplantation 
Mtg16-null mice are able to produce all of the hematopoietic lineages, though 
myeloid development is enhanced with increased numbers of Gr1
+
/Mac1
+
 myeloid cells 
in the spleen and bone marrow (Fig. 10).  However, there was a two-fold decrease in total 
thymocyte number that was visible upon gross dissection (Fig. 11A), which caused us to 
examine T-cell development in more detail.  Using flow cytometry, all populations were 
decreased in absolute number in the absence of Mtg16 (Fig. 11B) with a small relative 
decrease in CD4
+
CD8
+
 cells and a slight relative increase in CD4
-
CD8
-
 cells and both 
CD4
+
 and CD8
+
 mature thymocytes as a percent of total thymocytes.  When the earliest 
thymocytes of the CD4
-
CD8
-
 DN population were further subdivided using CD44 and 
CD25, there was a substantial decrease in both CD25
-
CD44
+
 DN1 cells and 
CD25
+
CD44
+
 DN2 cells in the absence of Mtg16 (Fig. 11C). Consistent with the lower 
level of thymocytes, there were somewhat fewer  T cells (Fig. 12). 
Our interest in the role of Mtg16 in T-cell development was heightened when we 
noted that after competitive bone marrow transplantation using 90% Mtg16
-/-
 CD45.2
+
 
bone marrow cells and 10% control CD45.1-expressing cells, there was a dramatic loss of 
T-cell production from the null bone marrow (Fig. 13A).  As measured by flow 
cytometry, control CD45.2
+
 bone marrow showed robust reconstitution, which was 
similar to the percentage of CD45.2
+
 WT marrow transplanted.  By contrast, only 2-3% 
of the thymocytes were derived from the Mtg16
-/-
 bone marrow (Fig. 13B).  Thus, when  
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Figure 10.  Increased development of myeloid lineages in the Mtg16-/-
mouse.  (A) Increased production of Gr1+/Mac1+ cells in Mtg16-/- bone
marrow, both as a percentage of total cells and as an absolute number in 2
hind limbs (both femur and tibia). An unpaired, two-tailed t-test shows *
p<0.05, *** p<0.001. Shown are data from a representative experiment from
one of two independent exper iments performed with 3 mice of each genotype,
for a total N=7 mice. (B) Increased population of Gr1+/Mac1+ cells in Mtg16-/-
spleens shown both as a percentage of total cells and as an absolute number
per spleen. An unpaired, two-tailed t-test shows ** p<0.01.  N=3. Shown are
data from a representative experiment from one of two independent
experiments, for a total N=7 mice.
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Figure 11. Analysis of the Mtg16-null thymus. (A) Left panel shows a photo
of a representative thymus from a 6-8 week old wild type and Mtg16-null
mouse.  The right panel shows a graph of the average of the total numbers of
WT and Mtg16-null thymocytes, +/- standard deviation (SD).  An unpaired,
two-tailed t-test shows ** p<0.01. Shown are data from a representative
experiment with 5 mice of each genotype, with a total N= 17. (B) Left panels
show flow cytometric plots of CD4 and CD8 expression in the WT and Mtg16-
null thymus.  Graphs in the right panels depict both the average percentage of
total thymocyte number (top) and the average absolute cell number (bottom)
in each population, +/- SD.  Shown are data from a representative experiment
with 5 mice of each genotype, with a total N=17.  An unpaired, two-tailed t-
test shows * p<0.05,  ** p<0.01, ***p<0.001 (C) Flow cytometric analysis of
CD4-CD8- thymocytes for expression of CD44 and CD25 of the double
negative population shown in B.  Graphs depict both the average of the
percentage of total CD4 -CD8- number (top) and the absolute cell number
(bottom) in each population, +/- SD. Shown are data from a representative
experiment with 5 mice of each genotype, with a total N= 17. An unpaired,
two-tailed t-test shows * p<0.05, ** p<0.01, ***p<0.001. For (A-C) a minimum
of three independent experiments were performed with at least three pairs of
age-matched WT and Null mice.
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Figure 13. Mtg16 is required for thymopoiesis after bone marrow
transplantation.  Mtg16-/- cells fail to repopulate the thymus in competitive
transplant.  Shown are representative CD45.2 FACS plots six weeks after
bone marrow transplantation using 10% wild type CD45.1 cells and 90%
control or Mtg16-/- CD45.2 cells.  Representative FACS plots of cells
harvested from the bone marrow (A) and thymus (B).  These data are from
one of two experiments with total N = 5 WT recipients and N=9 Mtg16-null
recipients.
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homeostasis was disrupted and the null cells placed in a competitive environment, Mtg16 
was required for T-cell formation in vivo. 
To better interpret the defects in Mtg16-null early T-lineage progenitor cells, we 
measured the expression of Mtg16 and the other MTG family members, Mtg8 and Mtgr1, 
by quantitative RT-PCR in wild-type mice across several hematopoietic populations.  The 
highest levels of Mtg16 expression were seen in early stem/progenitor cell populations 
(LSK cells), common myeloid progenitors (CMPs), and bone marrow B220
+
 cells (Fig. 
14), whereas Mtgr1 was widely expressed and Mtg8 was poorly expressed, with 
undetectable expression in some populations.  In the thymus, Mtg16 expression was 
generally lower, with the highest levels in the CD4
+
CD8
+
 cells and lower levels of Mtg16 
expression in the early T-cell progenitor cells. These data suggested that the defect in T-
cell development might lie in the earliest T-cell progenitor cells of the bone marrow. 
Flow cytometric analysis supported this hypothesis, and indicated that the “lymphoid-
primed multi-potent progenitor” cells (LMPP) of the bone marrow and the CD4-/CD8-
/CD25
-
/c-Kit
+
 “early thymocyte progenitor” cells (ETP) that seed the thymus were 
reduced in the absence of Mtg16 (Fig. 15A, B).  The two-fold reduction in progenitors 
observed was consistent with the two fold-reduction in thymocytes (Fig. 11).  
 
Mtg16 is required for T-cell commitment in vitro  
To directly assess the T-cell potential of Mtg16-null bone marrow progenitor cells 
and early thymocytes, we cultured wild type and Mtg16-null bone marrow stem cells and 
thymus double negative cells in the presence of Flt3 ligand and IL-7 on OP9 stromal cells 
expressing the Delta-like 1 Notch ligand, which triggers T-cell development
74
. We  
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Figure 14.  Relative expression of Mtg family members across murine
hematopoiesis. The indicated populations were isolated by flow cytometry and the
mRNA levels determined using qRT-PCR.  For each population, at least two
independent samples were collected and analyzed in duplicate.  The average
relative expression is shown +/- SD.
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Figure 15.  Loss of Mtg16 leads to decreased early thymocyte progenitor
cells in the thymus and lymphoid primed progenitor cells in the bone
marrow.  (A) Decreased presence of Lin -CD25-c-Kit+ ETPs in the Mtg16-null
thymus shown both as percentage of total thymocytes and absolute number
per thymus +/- SD. Representative FACS plots are shown from one of three
independent experiments with 4 mice of each genotype, with a total N=12.
An unpaired, two-tailed t-test yielded * p<0.05, ** p<0.01.  (B) Decreased Lin -
Sca-1+c-Kit+Flt3hi LMPPs in Mtg16-/- bone marrow shown both as percentage
of LSKs and absolute number per hind limb (both femur and tibia), +/- SD.
Shown are data from a representative experiment with 5 mice of each
genotype, with a total N=15.  An unpaired, two-tailed t-test shows ***p<0.001.
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the thymus and assessed their ability to develop into CD4
+
CD8
+
 T-cells using flow 
cytometry
74
. Between day 21 and 28, wild-type LSK and DN1 cells produced CD4
+
CD8
+
 
T-cells.  As DN2 cells have already begun the process of committing to the T-lineage, 
CD4
+
CD8
+
 T-cells developed between day 7 and 14 (Fig. 16A). By contrast, Mtg16-null 
LSK and DN1 cells failed to develop into CD4
+
CD8
+
 T-cells (Fig. 16A).  However, 
Mtg16-null DN2 cells developed into CD4
+
CD8
+
 T-cells within 7 to 14 days of culture 
on OP9-DL1 stroma, albeit at a reduced rate (Fig. 16A, right panels).  The reduced 
numbers of T-cells could reflect reduced proliferative capacity or increased cell death, as 
the null cells failed to expand to the levels of wild type DN2 cells (Fig. 17).  Together, 
these data indicate that Mtg16 is required for efficient T-cell development in vivo and in 
vitro and that this defect precedes lineage commitment into DN2 T-cells of the thymus 
(Fig. 16A).   
Given that the Mtg16-null LSK cells failed to develop into T-cells, we determined 
their lineage fate in this in vitro system.  Seven days after the initiation of the cultures, 
there was an exaggerated production of Gr1
+
/Mac1
+
 myeloid cells in the absence of 
Mtg16 (Fig. 16B). These data suggest that Mtg16-null stem cells are incapable of 
developing along T-cell lineages in vitro and prefer to develop along the myeloid 
lineages, even in conditions favorable for lymphoid development. 
 
Ex vivo complementation of the Mtg16
-/-
 defect in T-cell Development 
To begin to define how Mtg16 functions in regulating T-cell development, we 
sought to complement the Mtg16-deficient T-cells by exogenous expression of Mtg16.  
Recombinant Murine Stem Cell Virus (MSCV) expressing Mtg16 and GFP was used to  
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Figure 16.  Mtg16-null LSK and DN1 progenitor cells fail to develop into
T-cells in vitro.  (A) FACS sorted LSK, DN1, and DN2 populations were
plated on OP9-DL1 cells and CD4+CD8+ T-cell development was assessed at
day 21 for LSK and DN1 cells and day 7 for DN2 cells. Representative FACS
plots are shown from one of at least two experiments. Shown are data from a
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(LSK) N=7 (DN1) and N=4 (DN2).   (B) Mtg16-null LSK cells display
enhanced myelopoiesis. FACS plots for Gr1 and Mac1 7 days after culturing
LSK cells with OP9/DL1 stromal cells. Shown are data from a representative
experiment from one of five independent experiments performed with 2 mice
of each genotype, for a total N=10 mice.
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from a representative experiment from one of two independent experiments performed
with 3 mice of each genotype, for a total N=6 mice.
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infect FACS purified LSK cells followed by culture with OP9-DL1 cells.  Re-expression 
of Mtg16 yielded T-cell differentiation typically producing from 7-30% CD4
+
CD8
+
 cells 
in numerous biological replicates when compared to the Mtg16-null cells infected with 
control MSCV (e.g., Fig. 18A, 18B). Therefore, the failure to differentiate into T-cells 
was dependent on Mtg16 rather than an off target effect of the deletion. 
Next, we utilized a panel of deletion mutants that removed each of the Nervy 
Homology Regions (NHRs) in Mtg16.  Each of these domains is highly conserved 
between MTG family members and facilitates interaction with different proteins, thereby 
allowing the identification of the crucial interactions that contribute to Mtg16 functions.  
Mtg16-null LSK cells were infected with MSCV-IRES-GFP, MSCV-Mtg16-IRES-GFP, or 
deletion mutants of the conserved domains and the cells were cultured on OP9-DL1 
stroma in the presence of IL-7 and Flt3L (see Fig. 19 for the levels of expression). The 
Mtg16 deletion mutant lacking NHR1 failed to complement the null phenotypes, whereas 
deletion of NHR2, NHR3 and NHR4 allowed reconstitution of T-cell development (Fig. 
18B), but with somewhat lower efficiencies. Like the ∆NHR1, deletion of a domain just 
upstream of NHR1, which mediates association with the Notch intracellular domain, 
NICD, also failed to restore T-cell development. These results suggest that Mtg16 must 
be able to associate with the NICD and specific transcription factors via NHR1 to fully 
regulate cell-fate decisions.  
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Figure 18. Reconstitution of Mtg16-/- LSK cells with Mtg16 and Mtg16
deletion mutants.   (A) Representative FACS plots from day 21 cultures of LSK
cells infected with MSCV or MSCV-myc-Mtg16-GFP co-cultured with OP9-DL1
stroma to assess T-cell development using cell surface expression of both CD4
and CD8.  GFP+ events are shown. Shown are data from a representative
experiment from one of four independent experiments performed with 2 mice of
each genotype, for a total N=8 mice.  (B) Mutant analysis of Mtg16 and
contribution to T-cell development. Representative plots from day 21 cultures of
LSK cells expressing MSCV or MSCV-myc-Mtg16-GFP on OP9-DL1 stroma
assessing T-cell development by the cell surface expression of both CD4 and
CD8.  GFP+ events are shown.  Shown are data from a representative
experiment from one of two independent experiments performed with 2 control
Wild-Type mice and 4 Mtg16-/- mice pooled into two samples, for a total N=8
mice.  A schematic diagram of the deletion mutants is shown in the lower right
hand portion.  ÆNH1=Æ145-242; ÆNH2=Æ365-402; ÆNH3=Æ460-510;
ÆNHR4=Æ532-567; ÆNICD=Æ1-85.
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Figure 19.  Expression of MSCV-myc-Mtg16-GFP mutant proteins.
Immunoblot analysis is shown of cell lysates expressing the indicated
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 100 
The defect in Mtg16
-/-
 T-cell development cannot be overcome by ectopic NICD 
expression 
 Given that deletion of the NICD interacting domain removed the ability of Mtg16 
to rescue in vitro T-cell development, we asked whether overexpression of the activated 
form of the Notch1 receptor, the NICD, could rescue T-cell development from Mtg16
-/-
 
LSK cells in the OP9-DL1 assay.  This approach has the added benefit of bypassing the 
cell-to-cell contacts and the cytoplasmic events required to propagate a Notch signal. 
LSK cells from wild type or Mtg16-null mice were isolated by flow cytometry and 
infected with MSCV-NICD-GFP and plated on OP9-DL1 stromal cells.  In control LSK 
cells, the Notch ICD enhanced the formation of T-cells on OP9-DL1 stroma (Fig. 20A, 
B).  Mtg16
-/-
 LSK cells did not respond fully to the strong Notch signal, though a minor 
increase in T-cell development occurred in some samples (Fig. 20B).  Furthermore, 
overexpression of the NICD had a strong growth advantage in wild-type cells, as 
evidenced by expansion of the GFP
+
 population that did not occur in Mtg16
-/-
 cells (Fig. 
20C).  These results suggest that the NICD is not capable of exerting its full potential in 
instructing T-cell development in the absence of Mtg16.  This could be due to either 
defects in other pathways that prevent T-cell development even in the presence of NICD 
overexpression or direct impairment of  NICD function in the absence of Mtg16.  Given 
that Mtg16 interacts with both CSL and the NICD, it is possible that it facilitates removal 
of repression complexes and activation of Notch-mediated transcription, though this 
hypothesis is still under investigation. 
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Figure 20. Expression of the Notch Intracellular Domain  cannot rescue
Mtg16-/- T-cell development in vitro (A) Representative plots show
CD4/CD8 labeling of wild-type and Mtg16-/-LSK cells infected with MSCV-
IRES-GFP or MSCV-IRES-GFP-NICD and cultured in the OP9-DL1 system.
(B) A small level of T-cell development occurs  from Mtg16-/- LSK cells
expressing the NICD.  Graphical depiction of CD4+CD8+ percentage from all
replicates. Data from three independent experiments (C) Expression of the
NICD confers a growth advantage on wild-type cells as shown by GFP +
expansion that does not occur in Mtg16-/- cells.  Representative data from one
of three independent experiments.
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Structure/Function analysis of Mtg16 in alternate progenitor cell assays 
 To assess whether defects seen in Mtg16 deletion mutants were specific to T-cell 
development, we utilized the same panel of mutants in another Mtg16 reconstitution 
assay, namely the Colony-Forming Unit Spleen (CFU-S) assay.  In this context, the 
impaired ability of Mtg16
-/-
 progenitors to proliferate leads to a loss of spleen colony 
formation after bone marrow transplant.  Retroviral expression of wild-type Mtg16 
rescues colony formation and the NICD interacting domain is dispensable in this assay, 
confirming that this portion of Mtg16 contributes specifically to T-cell development (Fig. 
21).  The NHR panel of deletion mutants shows that NHR3 is dispensable for CFU-S 
reconstitution, a similar result to that seen in the OP9-DL1 T-cell assay (Fig. 22).  
Deletion of NHR1, 2, and 4 impairs the ability of Mtg16 to rescue colony formation, 
though the quanitative effect of this impairment is difficult to determine.  
 
E-protein regulation is necessary for the function of Mtg16 in T-cell development 
 One of the interactions disrupted by the deletion of NHR1 is the interaction 
between this portion of Mtg16 and activation domain 1 (AD1) of HEB
31
.  Given that the 
Mtg16-null phenotype is similar to that of E2A-deficient mice 
97,197,198,275
, we mined gene 
expression data from Mtg16
-/-
 LSK cells (Fischer et al., in preparation) and found that 
E2A expression was slightly decreased, while Id1 and Id2, negative regulators of E-
protein DNA binding and T-cell development
195,196,218-221,223
, were increased 4-8 fold.  
Expression of Id1 in in vitro culture systems designed to permit B-cell development 
favored myeloid development over B-cell commitment and similar results were seen in 
vivo
218,220
.  Because double shRNA-mediated knockdown of Id1 and Id2 was inefficient  
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Figure 21. NICD binding is dispensable for Mtg16 function in the CFU-S
assay  Wild-type and Mtg16-/- total bone marrow were infected with MSCV-
IRES-GFP, MSCV-IRES-GFP-myc-Mtg16, or MSCV-IRES-GFP-myc-Mtg16 
NICD and transplanted into lethally irradiated mice.  Day 12 colonies shown
from one of two experiments for a total N=4-5 recipients.
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Figure 22. Contribution of Nervy Homology Regions to Mtg16 function in
the CFU-S assay.  Day 12 spleen colony formation from wild-type or Mtg16-/-
total bone marrow infected with MSCV-IRES-GFP or MSCV-IRES-Myc-Mtg16
and associated deletion mutants.  Data from one of two experiments for a
total N=8 recipients per condition.
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(data not shown), we asked whether expression of Id1 or Id2 was sufficient to enhance 
myelopoiesis and block T-cell development in the OP9-DL1 system.  MSCV-Id1-GFP 
and MSCV-Id2-GFP infected wild-type LSK cells were plated on OP9-DL1 stroma and 
FACS analyzed at day 7 to test for increased Gr1
+
Mac1
+
 production, which was seen in 
the absence of Mtg16.  Both Id1 and Id2 over expression led to increased myeloid 
production at day 7, suggesting that the increased expression of Id1 and Id2 in Mtg16-
null LSK cells contributes to this phenotype (Fig. 23A).  Over-expression of Id2 
inhibited, but did not completely abolish, CD4
+
CD8
+
 T-cell development in the OP9-DL1 
assay 
222
.  Similarly, we noted that Id1-expressing LSK cells also yielded some T-cell 
differentiation (Fig. 23B).  Therefore, increases in Id1 and Id2 expression likely 
contribute to the enhanced myelopoiesis observed in the absence of Mtg16 (Fig. 16B), 
but are unlikely to completely explain the block in T-cell differentiation. 
The E proteins E2A and HEB are critical for T-cell development
97,210
.  The 
structure of the NHR1 domain of MTG8 in association with the HEB AD1 domain 
identified residues that mediate this contact
270
. While HEB binds to MTG8 through 2 
sites, mutations within the NHR1 domain of MTG8 were sufficient to disrupt repression 
of E-protein-mediated transcriptional activation
270,276
.  Therefore, to define the 
contributions of E-protein functions to the role of Mtg16 in T-cell development, we 
engineered a point mutation in Mtg16 that is homologous to changes that abrogated the 
binding of the MTG8 NHR1 domain to HEB AD1.  F210A in Mtg16 mimics the F154A 
MTG8 mutant to eliminate E-protein AD1 binding, whereas a control R220A mutation 
mimics the R164A mutant that retained the ability to bind to HEB AD1
270
.  The F210A 
and R220A mutants were reintroduced into Mtg16-null LSK cells using  
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Figure 23.  Over expression of Id1 and Id2 enhanced myelopoiesis. (A)
LSK cells infected with MSCV-Id1-GFP or MSCV-Id2-GFP phenocopy Mtg16-
/- LSK cells with increased production of Gr1+/Mac1+ cells.  Representative
FACS plots of GFP+ populations 7 days after co-culture on OP9/DL1 stromal
cells. Shown are GFP+ data from a representative experiment from one of
two independent experiments performed with 2-3 mice of each genotype, for
a total N=5 mice.  The average of the percentage of the cells that were
Gr1+Mac1+ that were obtained from 2 experiments are shown graphically in
the panel below.  An unpaired, two-tailed t-test shows * p<0.05, ** p<0.01.
(B) WT LSK cells infected with MSCV-Id1-GFP retain the capacity to generate
CD4+CD8+ T-cells after co-culture on OP9/DL1 cells.  Shown is GFP+
representative data from one of three experiments.
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MSCV-IRES-GFP, and both Mtg16 and the R220A mutant were capable of rescuing T-
cell development (Fig. 24A).  However, the F210A point mutant failed to rescue T-cell 
development (Fig. 24A). Therefore, the appropriate regulation of E-protein activity is a 
necessary function of Mtg16 in T-cell development. 
As E-proteins also function in regulating hematopoetic stem and progenitor cell 
populations, we included these mutants in the CFU-S assay as well.  The R220A mutant 
functioned like wild-type Mtg16 (Fig. 25).  F210A Mtg16 was impaired in this assay as 
well, suggesting that the Mtg16-E-protein interaction also contributes to Mtg16
-/-
 stem 
cell phenotypes, a hypothesis that is under current investigation. 
Given that deletion of the Notch ICD contact site and mutation of the E protein 
binding motif both impaired T-cell production, we probed the molecular contacts that 
these mutants retain.  We confirmed that the point mutants in NHR1 did not disrupt E-
protein binding and found that further deletion of a region between NHR1 and NHR2 (the 
PST2 domain) was necessary to completely abrogate E-protein binding (Fig. 24A, B). 
The NHR1 domain of MTGs also contacts NCoR
277
, but we found normal levels of 
repression by mutant GAL4-Mtg16 fusion proteins using a Gal-reporter assay (Fig. 24D).  
In addition, the F210A mutant retained the ability to bind to the Notch ICD (Fig. 24C), 
yet failed to properly respond to a Notch signal.  Finally, we used a luciferase construct 
carrying E-box binding sites in the promoter to show that Mtg16 and Mtg16(R220A) 
suppressed E47-dependent transcriptional activation, while the F210A mutant was 
deficient in repression (Fig. 24B). Importantly, deletion of the N-terminal NICD binding 
region did not affect the ability of Mtg16 to repress E47-mediated transcriptional 
activation (Fig. 24B), indicating that suppression of E protein-dependent transcription  
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Figure 24.  Suppression of E-protein mediated transcriptional activation is necessary
for Mtg16 to reconstitute T-cell development.   (A) Retroviral introduction of wild-type
MSCV-myc-Mtg16-GFP and the R220A mutant rescues CD4+/CD8+ T-cell development, but
F210A does not. Representative day 21 FACS plots using anti-CD4 and anti-CD8 are shown,
with GFP+ cells shown and GFP percentage at day 21 listed under each plot. Shown are data
from a representative experiment from one of three independent experiments performed with 2
mice of each genotype, for a total N=6 mice.   (B) An F210A point mutant in Mtg16 abrogates
the ability of Mtg16 to repress transcription from an E-box promoter activated by the
expression of E47, while the NICD deletion mutant suppresses E-protein functions .  Graph
shows the average relative luciferase values +/- SD from an E-box reporter plasmid co-
transfected with vector control or vector expressing E47 and the indicated Mtg16 or mutant
thereof.  The values were normalized to a renilla-luciferase plasmid to control for specificity
and transfection efficiency.  The experiment was performed twice in triplicate.   (C) Venn
diagrams are shown that display the i ntersection between genes up-regulated in Mtg16-/- LSK
cells relative to wild-type controls and genes up -regulated by activated Notch signaling in OP9-
DL1 co-culture and E47 expression  left panel or E2A-deficient thymic lymphoma cells that
were complemented by re-expressing E2A .
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was not sufficient to trigger T-cell development (Fig. 16) and that Mtg16 must associate 
with the Notch ICD to restore function.  
 MTG family members function in transcriptional repression, and therefore these 
results implied that E-protein-mediated repression contributes to T-cell development.  By 
comparing gene expression profiles from Mtg16
-/-
 LSK cells (Fischer et al., submitted) to 
genes that were repressed by over-expression of E47 
9,278
, we identified 19 genes that 
were repressed by E47 in hematopoietic progenitor cells, but up regulated upon Mtg16 
inactivation in LSK cells (Fig. 26C and Table 1). In addition, we compared the changes 
in Mtg16
-/-
 gene expression profiles to genes regulated by over-expressed E47 in the 
context of Notch signaling from OP9-DL1 cells (Table 2). 44 genes that were up 
regulated by loss of Mtg16 were also co-activated by Notch signaling and E47 
expression. Most importantly, key regulatory genes were found within this group 
including Gata3, Id2, Socs3, Hes1, and Tle6, which were also regulated by E47 in thymic 
lymphoma cells
278
 (Tables 3, 4).   Of note, the expression of Mtg16, but not Mtg8 or 
Mtgr1, was activated by E47
9
, suggesting a possible regulatory loop between these 
proteins.  Collectively, these data indicate that Mtg16 plays a key role in integrating 
Notch signals and E protein actions to suppress myelopoiesis and direct T-cell 
differentiation. 
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Figure 25. E-protein regulation is necessary for Mtg16 function in the CFU-S assay
Wild-type and Mtg16-/- total bone marrow were infected with MSCV-IRES-GFP, MSCV-IRES-
GFP-myc-Mtg16, MSCV-IRES-GFP-myc-Mtg16 R220A or MSCV-IRES-GFP-myc-Mtg16
F210A and transplanted into lethally irradiated mice.  Day 12 colonies shown from one of two
experiments for a total N=4-5 recipients.
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Figure 26.  Mtg16 associates with E47 and the Notch Intracellular
Domain.  (A) Mtg16 F210A retains binding to E47  by co-immunoprecipitation.
The indicated proteins were co-expressed and association measured by
immunoprecipitation followed by western blot analysis.  Positions of molecular
weight markers are indicated to the right.  (B) Deletion of NHR1 is not
sufficient to remove the interaction between Mtg16 and E47. The indicated
proteins were co-expressed and association measured by
immunoprecipitation (IP) followed by western blot analysis (WB).  Positions of
molecular weight markers are indicated to the right.   (C) Mtg16 F210A and
R220A retain associating with the Notch1-Intracellular Domain by co-
immunoprecipitation, while the DNICD no longer binds. The indicated proteins
were co-expressed and association measured by immunoprecipitation (IP)
followed by western blot analysis (WB).  Positions of molecular weight
markers are indicated to the right.    (D) F210A, R220A, and NICD do not
affect Mtg16-dependent repression.  Mtg16 and the indicated mutants were
fused in frame with the GAL4 DNA binding domain and tested for repression
using a Gal4-luciferase reporter construct. Graph shows the average relative
luciferase values from an Gal4 reporter plasmid co-transfected with vector
control or the indicated Mtg16 or mutant thereof.  The values were normalized
to a renilla-luciferase plasmid to control for specificity and transfection
efficiency.  The experiment was performed twice in triplicate.
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Table 1. Genes Upregulated in Mtg16
-/-
 LSK and 
Repressed in E47ER Hematopoietic Progenitor Cells 
Asb7 Dntt Hip1 Myom1 
Calcrl Entpd4 Il18r1 Phf7 
Ccl3 Fmn2 Itga6 Sytl4 
Ctla2a Gcnt2 Loxhd1 Tex15 
Dlk1 Gem Lypla3  
 
Table 2. Genes Upregulated in Both Mtg16
-/-
 LSK and 
OP9-DL1/E47ER Hematopoietic Progenitor Cells  
Arhgef3 Gadd45b Kif5a Rassf4 
Atp13a2 Galnt2 Ltb Rps6ka6 
Atp2a3 Gata3 Map3k8 Sgsh 
CD52 Hcls1 Nnt Sla 
CD80 Hemgn Nox4 Slc45a4 
Celsr1 Hes1 Olfml1 Slco4a1 
Csf2rb2 Hsd11d1 P2ry14 Smad7 
Ctsl Id2 Pcmtd2 Socs3 
Dcx Il10ra Pik3cd Tcf7l2 
Esr1 Il1r1 Plaur Tcrb-V13 
Fyn Itgam Ptprc Tle6 
 
Table 3. Genes Upregulated in Mtg16
-/-
 LSK and 
Repressed in E47ER 1F9 Thymoma Cells 
Adarb1 Gata3 Mbl1 Rasgef1b 
Brd8 Gem Mdga1 Rgs1 
Cav2 Hhex Myom1 Slc16a9 
Col18a1 Hivep3 Nrxn1 Tex15 
Dlk1 Hoxb2 Pik3r1 Ttr 
Dusp18 Lonrf3 Plaur Xlr3a 
 
Table 4. Genes Upregulated in Mtg16
-/-
 LSK and 
Activated in E47ER 1F9 Thymoma Cells 
Bcl2l1 Galnt2 Irf6 Sytl4 
Ctsl Gimap6 Itga6 Tcfec 
Cyfip2 Hemgn Itpr3 Tle6 
Dhx9 Hes1 Jag2 Tmem35 
Ebi3 Id1 Mxd4 Tnfrsf22 
Efhc2 Id2 Nnt Tnfrsf23 
Esr1 Il10ra Nsg2 Vegfa 
Gadd45b Il21r Socs3 Wfdc2 
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Discussion 
 
Our work indicates that Mtg16 is required for lymphopoiesis after bone marrow 
transplantation and that it acts in the LSK and DN1 populations (Fig. 13, 16).  
Surprisingly, 3 highly conserved domains, when deleted individually, were somewhat 
dispensable for Mtg16 function in T-cell differentiation, even the oligomerization domain 
(NHR2, Fig. 18).  In contrast, the Notch ICD binding domain and the motif that is 
required for suppression of E protein transactivation within NHR1 were required for 
Mtg16 action (Fig. 18, 24).  Given the intersection between Notch signaling and E 
protein function in T-cell differentiation, our data suggest that Mtg16 is a key regulator of 
this process that contributes to maintaining the correct level of several key genes that 
control lineage allocation and that are coordinately regulated by Notch signaling and E47 
activation, including Gata3, Id2, and Hes1 (Tables 1-4). 
 Although the Notch ICD association motif was important for Mtg16 function in T 
cell development (Fig. 18), it is intriguing to note that Mtg16
-/-
 mice display many of the 
hallmarks of E2A-deficiency.  In addition to defects in T cells, mice lacking E2A contain 
reduced numbers of B cells, fewer long-term hematopoietic stem cells and multi-potent 
progenitor cells, and fewer erythropoietic progenitor cells.  In addition, stem cells lacking 
E2A showed a considerable defect in competitive repopulation assays
208,279
.  Likewise, 
Mtg16
-/-
 mice show defective stress erythropoiesis with few erythropoietic progenitors as 
measured by colony forming assays
19
 and defects in stem cell competitiveness (Fischer et 
al., submitted).  Chromatin immunoprecipitation assays also suggest that the association 
between Mtg16 and E proteins play an important role in the action of these factors during 
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hematopoiesis, as the most robust signal for Mtg16 was found near E protein binding 
sites in E2F2 when probing for direct Mtg16 targets amongst cell cycle genes (Fig.  27).   
 While the NHR1 domain was essential, the NHR2 domain was not absolutely 
required for Mtg16 function in the OP9-DL1 assay.  NHR2 forms strong homo- and 
hetero-oligomers with MTG family members
14,40,280
.  In fact, other MTG family members 
were the major associating proteins when MTGs or RUNX1-MTG8 were purified
14,31
.  
Our analysis suggests that Mtg16 monomers retain function and the observation that 
∆NHR1 and ∆NICD impaired Mtg16 functions (Fig. 18), suggests that hetero-oligomers 
that might be formed with endogenous, wild type Mtgr1 (the other MTG family member 
widely expressed in hematopoietic cells, Fig. 14) were unable to exert the same functions 
as Mtg16 and thereby complement this defect.  NHR2 is more essential for multipotent 
progenitor reconstitution after transplant in the CFU-S assay, as the ∆NHR2 construct 
could not reconstitute Mtg16
-/-
 bone marrow function.  Similar to NHR2, the NHR3 and 
NHR4 domains were not absolutely required for Mtg16 to rescue T-cell development 
(Fig. 4). NHR4 mediates the weaker of the two contacts between Mtg16 and 
NCoR/SMRT, but is not required for associating with N-CoR or for transcriptional 
repression
20,23
, whereas the NHR3 domain contributes to binding the regulatory subunit 
of protein kinase A (PKA RII) 
42,281
.  The NHR3 domain is the most consistently 
dispensable, as it was not required for reconstitution of the CFU-S assay (Fig. 22).  
Rather than contributing to the formation of acute leukemia, deletion of these domains 
has been associated with increasing the activity of the t(8;21) fusion protein
264
, 
suggesting that these domains play a negative regulatory role. 
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Figure 27. Mtg16 binds an E2A site in the 1st Intron of E2F2 (A) Mtg16
associates with the first intron of E2F2.  Chromatin immunoprecipitated with
either control IgG or anti-Mtg16/Eto2 from lysates of MEL cells was amplified
with primers specific to two regions encompassing an E2A binding site in the
first intron of E2F2, or as a control, the 3Õ untranslated region (UTR) of E2F2
using quantitative PCR.  Graph shows the level of signal relative to IgG set to
Ò1Ó.  The panel at the right shows ChIP using anti-E47 with the same E2F2 1st
intron primers.  The ethidium bromide stained agarose gel shows a
representative PCR reaction stopped after 30 cycles; In., input; 1 and 2
designate the duplicate PCR samples from the ChIP reaction using primer set
#2 flanking the E2A. (B) Mtg16 associates with a GATA-E-box in the Mtg16
promoter, but not an E2A/CSL site in the CCDN1 promoter or Tcf4 sites in the
CCND1 or N-Myc promoters.  Experiments performed as in (A) and shown
relative to an IgG value of Ò1Ó.
A
B
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 Notch signaling is a key determinant in instructing T-cell development, and when 
coupled with IL7 is sufficient to induce T-lineage development in vitro
74,81
.  The Notch 
ICD binds to CSL and recruits Mastermind to activate transcription
274
.  The association 
of MTGs with CSL suggested that Mtg16, like MTG8, acts as a co-repressor to suppress 
the expression of downstream target genes such as Hes1
29
.  The discovery of an 
association between the Notch ICD and Mtg16 furthered this model by suggesting a 
mechanism by which the Notch ICD impairs the association between Mtg16 and CSL, 
perhaps allowing Mastermind to bind to CSL
43
.  The high levels of expression of the 
canonical Notch target genes Hes1 and Nrap in Mtg16-null LSK cells
43
 and the failure of 
the Mtg16 mutant that lacks the Notch ICD binding motif to complement the null 
phenotype (Fig. 16), even though this mutant impaired E-protein-dependent 
transcriptional activation (Fig. 24B), are consistent with this interpretation. Importantly, 
our mutation data indicate that the loss of Mtg16 perturbs the function of other necessary 
factors in T-cell development (e.g., E proteins) that allow the proper integration of Notch 
signals.  Thus, Mtg16 plays a critical role in integrating Notch signals and E protein 
functions in T cell development, perhaps in the earliest bone marrow progenitor cells. 
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CHAPTER IV 
 
MYELOID TRANSLOCATION GENE 16 (MTG16) CONTRIBUTES TO MURINE B-
CELL DEVELOPMENT 
 
Abstract 
 
 Myeloid translocation gene 16 (Mtg16) is a target of the t(16;21) that produces 
acute myeloid leukemia.  Like many targets of leukemia-associated chromosomal 
translocations, Mtg16 regulates several stages of hematopoiesis, including lineage 
allocation and stem cell function.  Decreased B220
+
 B-cells in the bone marrow of 
Mtg16
-/-
 mice have previously been reported, and we show that this defect is due to 
decreased B-lineage commitment and an associated decrease in the numbers of Common 
Lymphoid Progenitor (CLP) cells.  The defect in B-cell commitment is magnified after 
stress such as competitive bone marrow transplant and IL7-dependent methylcellulose 
colony formation assays.  Mtg16
-/-
 pre-B colonies have striking growth and survival 
defects that can be reverted by deletion of p53.  Defects in B-cell function in the absence 
of Mtg16 extend to mature B-cells of the spleen and Mtg16
-/-
 splenic B-cells have 
marginal zone skewing, decreased response to lipopolysaccharide (LPS) in vitro, and 
defective germinal center responses.  Therefore, Mtg16 regulates both early B-cell 
development and mature B-cell function.   
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Introduction 
 
 Chromosomal translocations that lead to leukemia and lymphoma disrupt master 
regulators of hematopoietic transcription.  Originally identified by their role in 
chromosomal translocations, many of these factors have been subsequently identified as 
important for facets of hematopoiesis beyond leukemia.  One such factor that is emerging 
in importance in leukemia and general hematopoiesis is Myeloid Translocation Gene 16 
(Mtg16) or Cbfa2t3, which is a target of the t(16;21) that produces acute myeloid 
leukemia when translocated to Runx1 or AML1
12
.  Myeloid Translocation Gene 16 is a 
critical regulator of murine hematopoiesis and affects stem cell function, erythroid 
development, and lineage fate specification
19
 (Chapter III, Fischer et al, in prep).  In the 
absence of Mtg16 lymphoid lineages are decreased, including a global decrease in B220
+
 
cells in the bone marrow and a striking defect in T-cell development
19
 (Chapter III).  
Concurrently, granulocyte/monocyte myeloid lineage commitment is enhanced.   The 
defects seen in T-cell development are attributed to stem and progenitor cell dysfunction, 
with decreased numbers and impaired function of early T-cell progenitors, including both 
the Lymphoid Primed Multipotent Progenitor (LMPP) fraction and early thymocyte 
progenitor (ETP) fraction.   
All Mtg16
-/-
 phenotypes are subtle under homeostasis, but become more 
pronounced after stress such as bone marrow transplant or phenylhydrazine 
administration
19
. Associated with this stress-related exacerbation is the ability of Mtg16 
to regulate cell cycling and survival, which contributes to many of the phenotypes seen 
after the loss of Mtg16
19
.  For example, Mtg16
-/-
 hematopoietic progenitor cells were 
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deficient in spleen colony formation after transplant, but this defect was bypassed with 
over expression of the cell cycle regulator Myc, suggesting that proliferation defects in 
the absence of Mtg16 plays a key role in the lack of colony formation
19
.  In early 
developing T-cells, growth and survival defects were seen in OP9-DL1 in vitro assays, 
where increases to apoptosis contribute to decreased cellular expansion in response to IL-
7 and Flt3-ligand (Chapter III).   
Mtg16 functions by interacting with a number of transcription factors and 
recruiting transcriptional co-repressors, such as NCoR and HDACs, to repress 
downstream transcription
20,273
.  The transcription factor interacting partners for Mtg16 
include many factors that act during hematopoiesis, including Tcf4, CSL, GFI-1, E2A, 
and Bcl6
25,26,28,31,43
.  The interaction between Mtg16 and E2A is exceedingly robust and 
has been well characterized structurally, though the importance of this interaction was not 
realized until a novel role for Mtg16 in regulating lymphocyte development, and T-cell 
development in particular, was discovered
31,270
 (Chapter III).  E-proteins such as E2A 
facilitate specification of B-cell fate as well as T-cell fate, and also regulates the function 
of mature B-cells, including marginal zone vs. follicular zone decisions and germinal 
center reactions
97,122,148,149,189,198,203
.    
BCL6, another important transcription factor binding partner for Mtg16, also 
regulates both immature and mature B-cell development
25,142,282-284
.  While the most well-
understood role for Bcl6 in hematopoiesis is in regulating the germinal center response 
associated with mature B-cell immune function, it also regulates immature B-cell survival 
during V(D)J recombination
142,282-284
.  Histone deacetylases, such as HDAC3, also 
regulate lymphocyte development and conditional deletion of Hdac3 in early B-cells 
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(using Mb1-Cre) led to an accumulation of early B220
+
CD43
+
 cells at the expense of 
mature cells (Bhaskara et al, in prep).  This defect appears to be due to defects in V(D)J 
recombination, though the mechanism is under further investigation.  Recent data 
suggests that conditional deletion Hdac3 in later B-cells using CD19-Cre bypasses the 
defect in early B-cell development.  Mature Hdac3
-/-
 B-cells were defective in germinal 
center reactions as well, likely reflecting the capacity of Hdac3 to facilitate Bcl6 
mediated repression (Bhaskara in prep).  Therefore, multiple Mtg16 interacting partners 
regulate B-cell development and do so at a variety of stages. 
Given that Mtg16 is highly expressed in murine B220
+ 
populations in both the 
bone marrow and spleen, that it associates with transcription factors and co-repressors 
that are important to B-cell development, and that Mtg16
-/-
 display decreased percentages 
of B220
+ 
cells, we further explored the role of Mtg16 in regulating B-cell 
development
19,25,31
 (Chapter III).  Mtg16
-/-
 mice showed decreases in cell numbers 
throughout early B-cell development, with the most striking changes coming in early 
progenitor populations including Common Lymphoid Progenitors  (CLPs) and in mature 
re-circulating cells.  The progenitor defects were made more severe under stress using 
both bone marrow transplant and in vitro methylcellulose colony formation assays 
supplemented with 10 ng/ml IL-7.  Methylcellulose assays also unearthed a striking 
deficit in cell growth and survival in early B-cells in the absence of Mtg16.  Furthermore, 
Mtg16 appears to be critical for mature B-cell function, with altered marginal zone vs. 
follicular zone cell fate decisions, defective LPS stimulation responses, and impaired 
germinal center formation in Mtg16
-/-
 mice.  Therefore, Mtg16 is a critical regulator of 
multiple stages of B-cell development.   
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Results 
 
Mtg16
-/-
 mice are lymphopenic 
Initial analysis of Mtg16
-/-
 mice showed changes across hematopoiesis in response 
to stress, including profound defects in erythropoiesis
19
.  In addition, Mtg16
-/-
 
hematopoiesis produces decreased total thymocytes as well as decreases in total bone 
marrow B220
+
 developing B-cells
19
.  To assess whether this decrease in developing 
lymphoid cells affects peripheral lymphocytes, we began with complete blood counts and 
found that these mice are significantly lymphopenic throughout early adulthood (Fig. 
28A).  Surprisingly, flow cytometric analysis of peripheral hematopoietic organs from 6-
8 week old adult mice showed that CD3
+
 T-cells did not contribute significantly to the 
peripheral lymphopenia, and, while they do show a decrease in total cell number, CD3
+
 
T-cells are not decreased as a percentage of total splenic cells (Fig. 28B).  This suggests 
that while T-cell development in the thymus is severely impaired, by 6 weeks of age and 
under homeostatic conditions, T-cell development can achieve near-normal levels in the 
peripheral blood system.   
On the other hand, Mtg16
-/-
 mice showed decreased B220
+
 B-cells in the spleen, 
both as a percentage of total splenic cells and as a total number of cells, likely accounting 
for the peripheral lymphopenia (Fig. 28B).  As previously published, myeloid 
development was enhanced, as Mtg16
-/-
 mice have increased absolute and relative 
numbers of Gr1
+
/Mac1
+
 myeloid cells in the spleen (Fig. 28B). Flow cytometric analysis 
of the bone marrow showed decreases in total B220
+
 cells in both relative and absolute  
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Figure 28.  Mtg16-/-mice are lymphopenic (A) Complete blood counts of wild-type
and Mtg16-/-mice from peripheral blood throughout adulthood.  Graph depicts
lymphocytes per (B) Flow cytometric analysis of total splenocytes from wild-type
and Mtg16-/-mice show increased Gr1+/Mac1+myeloid cells and decreased B220+
B-cells.  Graphs depict Mean +SD from one of two experiments.  *, p<0.05,
**p<0.01, ***,p<0.001.  (C)Representative plots from flow cytometric analysis of
total bone marrow B220+ populations.  Graphs depict mean + SD from one of three
independent experiments. *, p<0.05
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numbers of total bone marrow cells per femur (Fig. 28C.)  The increase in Gr1
+
/Mac1
+
 
cells in the absence of Mtg16 persisted in the bone marrow as well (Chapter III).   
 
Lymphopenia is more severe after competitive bone marrow transplant 
 Given that many of the Mtg16
-/-
 phenotypes are more severe after stress, we 
sought to assess lymphopenia and lineage allocation after competitive bone marrow 
transplantation.  Mtg16
-/-
 defects in erythropoiesis make traditional bone marrow 
transplant lethal, so all bone marrow transplant assays to assess stem cell function and 
differentiation were performed with 90% CD45.2
+
 wild-type or Mtg16
-/-
 marrow 
supplemented with 10% CD45.1
+
 wild-type bone marrow to provide the necessary 
erythrocytes for survival (Fischer et al, in prep).  By following CD45.2
+
 cell surface 
labeling of peripheral blood, competitive reconstitution was monitored.  Peripheral 
reconstitution by Mtg16
-/-
 CD45.2
+
 cells was severely impaired over time (Fischer et al, 
in prep and Fig. 29A).  The defect seen in the peripheral blood was more severe than the 
defect seen in total bone marrow and hematopoietic stem cells, and given that peripheral 
blood is comprised primarily of lymphocytes, we hypothesized that the lymphopenia seen 
in the absence of Mtg16 was an exacerbated after transplant (Fig. 29A).  When lineage 
contribution in the peripheral blood was assessed following competitive transplant 
bleeds, most of the wild-type CD45.2
+
 cells were B and T-cells, while Mtg16
-/-
 CD45.2
+
 
peripheral blood showed decreased B-cells and a higher relative proportion of myeloid 
cells (Fig. 29A).  
We next assessed the contribution of CD45.2
+
 Mtg16
-/-
 cells to B-cell 
development and myeloid development in the bone marrow of recipient mice.  Within the  
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CD45.2
+
 population, there was little to no contribution to B-cell lineages and an 
exaggerated Gr1
+
/Mac1
+
 myeloid population (Fig. 29B).  This corresponds well with the 
defect in thymus reconstitution seen in the absence of Mtg16, where virtually no CD45.2
+
 
thymocytes remained from Mtg16
-/-
 donor cells (Chapter III).  Much like other 
phenotypes, the lymphopenia and decreased B-cell development seen in the absence of 
Mtg16 becomes much more dramatic under stress, highlighting the importance of Mtg16 
in regulating B-cell development. 
 
Defects in early B-cell development in the absence of Mtg16 
To analyze B-cell development in greater detail and pinpoint the mechanism for 
Mtg16 involvement, we used flow cytometry to detect cells expressing the B220, CD43, 
BP-1, CD24, IgM, and IgD cell surface markers to identify seven distinct stages labeled 
A through F
120
.  Mtg16
-/-
 developing B-cells show little change in early B-cell stages, or 
“Hardy Fractions” A through C (Fig. 30.)  The most striking changes were in the more 
mature, CD43
+
 fractions D, E, and F, with a significant relative increase in non-Ig 
expressing Fraction D at the expense of more mature Ig-expressing B-cells, or Hardy 
Fractions E and F (Fig. 30).  When taking into account the overall decrease in B220
+
 
cells, though, the percent of total bone marrow cells in each stage remained lower in the 
absence of Mtg16.  As the decrease in mature cells is not accompanied by an increase in 
immature cells, we ruled out an overt block to development.  Instead, it is likely that the 
decrease seen in Fraction F reflects the decrease in re-circulating peripheral lymphocytes, 
as they will return to the bone marrow as Fraction F cells.   
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To further confirm the absence of blocks in early maturation of B-cells in the 
absence of Mtg16, we probed V(D)J IgH recombination in total B220
+
 populations.  
Using three different sets of primers to assess DH to JH recombination and both proximal 
and distal VH to DJH recombination, we found normal V(D)J recombination in Mtg16
-/-
 
B220
+
 cells when compared to wild-type controls (Fig. 31).  While inactivation of Hdac3, 
an Mtg16 binding partner, impaired V(D)J recombination, this phenotype is likely due to 
a more global effect on chromatin structure (Bhaskara et al, in prep). 
Given the small changes seen in B-cell development, the absence of a block to 
development in the more mature stages of lymphopoiesis after lineage commitment, and 
the increase in myeloid development, we hypothesized that the source of the 
lymphopenia preceded lineage commitment into stem and progenitor stages of 
hematopoiesis.  This has previously been characterized in the context of T-cell 
development, as Mtg16
-/-
 cells show enhanced granulocyte and monocyte development in 
in vitro T-cell assays (Chapter III).  To address this hypothesis, we first turned to flow 
cytometric analysis of B-cell progenitors, namely the Lin
-
IL7-R
+
Sca-1
lo
c-Kit
lo
 Common 
Lymphoid Progenitor (CLP) that is though to contribute primarily to B-cell 
development
62,66
.  We observed a significant though relatively subtle decrease in CLPs as 
a percentage of total bone marrow (Fig. 32).  This corresponded to the two-fold decrease 
seen in the lymphoid primed multipotent progenitor (LMPP) cells that precede CLP 
development and further confirms decreased lymphoid commitment from early 
progenitor populations.   
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Mtg16 is required for  normal B-cell methylcellulose colony formation 
 To assess the functional quality of Mtg16
-/-
 progenitor cells in the formation of B-
cell lineages, we used in vitro differentiation assays.  One of the most commonly used 
assays is the Methylcellulose assay which determines the relative number and quality of 
progenitor cells by their ability to produce clonogenic colonies of mature cells when 
plated in a semi-solid media with specific growth factors.  To address the ability of 
Mtg16
-/-
 bone marrow to produce early pre-B-cell colonies, we plated 7.5 x 10
4
 total bone 
marrow cells from either wild type or Mtg16
-/-
 mice in M3630 methylcellulose containing 
10ng/ml rhIL-7.  The Mtg16
-/-
 colonies were distinctly smaller by visual inspection (Fig. 
33A). As expected from the decrease in CLPs and early B-cells in the Mtg16
-/-
 marrow, 
we found a significantly decreased number of pre-B cell colonies at day 7 (Fig. 33B).   
While it is recommended that the colony number be counted at day 7, we also 
allowed our plates to incubate until day 14 to further assess cell growth in what should 
become nutrient depleted conditions.  The wild-type colonies continued to respond to the 
presence of IL-7, and expanded in size from day 7 to day 14, while the Mtg16
-/-
 colonies 
failed to expand, and in fact appeared to contract in size (Fig. 33A). Colony formation 
appeared to be complete by day 7, as wild-type plates contained the same or fewer 
numbers of colonies at day 14 (Fig. 33B).  Harvesting the plates and counting total 
numbers of cells per plate confirmed that Mtg16
-/-
 colonies failed to expand over this 14-
day period as compared to wild type colonies, leading to a disparity in the total number of 
cells per plate by day 10; this disparity was significantly larger by day 14 (Fig. 33C).   
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Figure 33. Decreased Mtg16-/- Pre-B colony number associated with an
expansion deficit (A) Representative pictures of wild-type and Mtg16-/- M3630
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The natural culprit for the decreased expansion of pre-B colonies in IL7-containing 
methylcellulose would be decreased cell proliferation.  To assess the cell cycle status of 
pre-B colonies, methylcellulose plates were harvested at day 7 and the DNA stained 
using propidium iodide to identify cells as 2N (Go/G1), 4N (G2/M), or S-phase.  While 
wild type cells were actively cycling, Mtg16
-/-
 pre-B cells accumulated in the 2N G0/G1 
stage (Fig. 34A). To investigate changes to cell death within the Mtg16
-/-
 colonies, 
methylcellulose plates were harvested and total cells were stained with Annexin V, which 
showed a statistically significant increase in Annexin V
+ 
cells in the absence of Mtg16 
(Fig. 34B).  Lack of cell-cycle entry and increased apoptosis likely accounts for the small 
size and decreased expansion of these more mature, B-lineage committed cells. Lack of 
response to IL-7 driven growth is a possible mechanism for the lack of cell-cycle entry, 
but colonies do form, and thus Mtg16
-/-
 progenitor cells are able to respond to IL-7 and 
contribute to B-cell development, albeit in a reduced capacity.  Furthermore, increasing 
the concentration of IL-7 had a similar dose-dependent effect on WT and Mtg16
-/-
 colony 
expansion, confirming that Mtg16
-/-
 progenitor cells are capable of responding to IL-7 
cytokine stimulation (Fig. 34C). 
 
Altered DNA damage in IL7-dependent colonies in the absence of Mtg16 
Increased DNA damage has been found in several Mtg-deficient cell populations, 
most notably Mtg8
-/-
 murine embryonic fibroblasts (MEFs) and Mtg16
-/-
 hematopoietic 
progenitor cells, particularly those that are rapidly cycling in in vitro culture assays 
(DeBusk et al, in prep, Fischer et al, in prep).  Collectively, these data suggest a role for 
Mtg family members in regulating DNA damage and/or DNA damage responses.  
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 Given the cell cycle arrest and increased apoptosis seen in Mtg16
-/-
 B-cell colonies, we 
asked if an increase in DNA damage contributed to the defect in growth and survival in 
colonies grown in IL7-dependent methylcellulose.  Using intracellular H2aX staining, 
we found a two-fold increase in cells with a high level of H2aX staining by flow 
cytometry (Fig. 35).  
To further probe the importance of DNA damage in the absence of Mtg16, we 
crossed the Mtg16
-/-
 mice with p53
-/-
 mice, with the hypothesis that removing a critical 
DNA damage checkpoint would restore cell cycle entry, block apoptosis, and increase 
colony growth and formation.  In the IL7-containing methylcellulose assays deletion of 
p53 in the context of wild-type Mtg16 caused an increase in colony size and number and 
an overall decrease in apoptosis, consistent with changes in early B-cell development in 
the absence of p53 (Fig. 36A, B).  Mtg16
-/-
p53
-/-
 bone marrow had a subtle increase in 
colony formation relative to Mtg16
-/-
p53
+/+
, but a more dramatic increase in the size and 
cell number of colonies (Fig. 36A, B) that surpassed Mtg16
+/+
p53
+/+
 controls at day 7, 
but did not approach the changes seen in Mtg16
+/+
p53
-/-
.  The Mtg16
-/-
p53
-/-
 colonies 
displayed a decrease in Annexin V staining that restored the levels to those of 
Mtg16
+/+
p53
-/-
 colonies, further confirming that decreased cell survival contributed to the 
changes in colony number and size seen in the absence of Mtg16 (Fig. 36C).  Given the 
relatively subtle increase in DNA damage seen in the Mtg16
-/-
 colonies, we hypothesize 
that these changes seen in Mtg16
-/-
p53
-/- 
primarily reflect a decrease in apoptosis and that 
other functions of Mtg16, such as lymphoid progenitor specification through transcription 
factors like E2A, may lead to an intermediate phenotype compared to wild-type and p53
-/-
 
control cells. 
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Mtg16 regulates gene expression in early B-cells 
To further probe the important molecular functions of Mtg16 that contribute to 
initial B-cell commitment, we performed microarray analysis on wild type and Mtg16
-/-
 
B220
+
CD43
+
CD24
-
BP-1
-
 Fraction A cells, or the earliest cells of the B-cell lineage.  
Many common Mtg16 targets were up regulated, such as E2F2 and Id2, further 
confirming these as critical Mtg16-regulated genes (Table 5).  Increased expression of 
Id2 suggests that E-protein mediated transcription may be disrupted, not only by 
inactivation of Mtg16, but also by the inhibitory action of Id2, as over expression of Id2 
disrupted early B-cell development
139
. 
Also up regulated in the absence of Mtg16 were several genes that are myeloid 
specific, such as myeloperoxidase(Mpo) and Itgam, or Mac1, suggesting that Mtg16 is 
necessary to repress certain myeloid gene expression programs.  Perhaps most interesting 
were the changes to cell growth and survival genes, including Ccnb1 (Cyclin B1), which 
was one of the most affected targets, Myc, and Bcl2.  Several Bcl6 regulated genes were 
up regulated, including p21 and Bcl6 itself, which was particularly interesting given that 
Bcl6 was more recently found to play a role in early B-cell survival
142
. 
 
Altered cell fate decisions in mature Mtg16
-/-
 B-cells 
Decreases in early B-cell development and lymphoid lineage commitment 
contribute to peripheral B-cell lymphopenia in Mtg16
-/-
 mice, and the factors that we 
hypothesize contribute to this phenotype, such as Bcl6 and E2A, also regulate mature B-
cell development and function in the periphery
148,149
.  Therefore, we measured the  
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Gene Fold Up 
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distribution of B-cell populations in mature splenocytes in wild type and Mtg16
-/-
 mice.   
As B-cells exit the bone marrow and travel to the spleen, they arrive as immature 
transitional T1 B-cells
144
.  These cells gain the expression of IgD and the ability to 
recirculate and become T2 transitional cells.  T2 cells then make a cell-fate decision that is 
regulated by Notch signaling and E-proteins, choosing between a marginal zone and a 
follicular zone fate
146
.  Marginal zone cells function in innate immune responses and 
remain in the spleen throughout their lifespan, undergoing self-renewal but not entering 
the circulation.  On the other hand, follicular zone cells are re-circulating B-cells that are 
the critical mediators of the adaptive immune response.   
In the absence of Mtg16, more splenic B-cells adopt a marginal zone fate (Fig. 
37).  All B-cell populations in the Mtg16
-/-
 spleen are decreased as a percentage of total 
splenocytes, except for marginal zone cells.  In fact, there are equivalent or slightly 
elevated numbers of marginal zone B-cells in the absence of Mtg16.  This is not 
surprising given the roles for Mtg16 in both Notch signaling and E-protein mediated 
transcription and the consistent up regulation of Id2 in multiple hematopoietic 
populations, a protein whose expressions favors the marginal zone fate
148,149,188
. 
Interestingly, follicular populations are not correspondingly decreased as a proportion of 
total B-cells (Fig. 37, lower panel).  Collectively these data suggest that decreases in 
mature B-cells in the spleen and the peripheral lymphopenia are exacerbated due to cell 
fate choices towards non-circulating marginal zone B-cells. 
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Figure 37. Altered lineage allocation of Mtg16-/- splenic B-cells Representative
flow cytometry plots depicting populations of B220 + B-cells in the spleen.  B220+
cells were divided into Immature CD24 hiAA4.1hi and mature CD24 loAA4.1lo
populations.  Middle plots depict Immature cells and are divided into T1
CD21hiCD23hi and T2 CD21loCD23lo cells.  Lower plots depict mature cells divided
into B1 CD21loCD23lo, Follicular CD21hiCD23hi and Marginal Zone CD21hiCD23lo
populations.  Graph shows the percent of total splenocytes from one of two
experiments for a total N=7. **p<0.01, ***p<0.001
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Defective response to LPS following In Vitro stimulation of Mtg16
-/-
 B-cells 
Given the decrease in peripheral B-cells, we next assessed mature B-cell function 
as the decrease in cell number could have effects on immune function.  To investigate the 
capacity for Mtg16
-/-
 mice to respond to infection, we first began with in vitro mitogen 
response assays using LPS stimulation. Total splenic populations were responsive to LPS 
at higher levels in Mtg16
-/-
 samples (Fig. 38A).  This response may primarily reflect the 
increased proportion of Gr1
+
/Mac1
+
 cells in Mtg16
-/-
 spleens, as macrophages respond 
robustly to LPS stimulation.  Indeed, isolation of B220
+
 populations showed that  Mtg16
-
/-
 B-cells failed to respond (Fig. 38B).  This likely reflects a global impairment of Mtg16
-
/-
 cells to rapidly proliferate in response to stress, though other mechanisms are possible. 
 
Decreased germinal center response in the absence of Mtg16 
LPS stimulation in vitro provides a measure of the ability of cells to proliferate in 
response to a mitogen, which is a critical part of the immune response, but does not 
replicate an immune challenge.  Therefore, we performed in vivo germinal center assays.  
Bcl6 is a critical determinant of the germinal center reaction, and forms a complex with 
Mtg family members and Hdac3 to repress the DNA damage response in activated B-
cells that are undergoing somatic hypermutation and antibody class-switch 
recombination.  Both Bcl6
-/-
 and Hdac3
-/-
 mice have defects in germinal center formation.  
Wild-type and Mtg16
-/-
 mice were injected with PBS, Alum, and 4-Hydroxy-3-
nitrophenylacetyl Chicken gamma globulin (NP(59)-CGG) supplemented with Alum to  
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initiate a germinal center response.  Seven days after injection, spleens were harvested 
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Figure 38. Defective in vitro LPS response from Mtg16-/- splenic B-cells
(A) Alamar blue cell viability readings from wild-type and Mtg16-/- total spleen
cells after 72 hours of culture untreated or stimulated with LPS.  Mean + SD
from one of two experiments for a total N=6.  (B) Alamar blue cell viability
readings from wild-type and Mtg16-/- B220+ splenocytes after 72 hours of
culture untreated or stimulated with LPS.  Mean + SD from one of two
experiments for a total N=6.
144
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and stained with Peanut Agglutinin to visualize activated germinal centers.  In the 
absence of Mtg16, there were decreased total follicular B-cells in the spleen, providing 
fewer cells capable of mounting a reaction (Fig. 39).  The B-cells that were present did 
not contribute to the immune response in this context, as germinal centers were 
dramatically decreased after injection of NP-CGG + alum (Fig. 39). Decreased 
proliferative capacity may contribute to this phenotype, and this hypothesis is under 
further investigation.  Ultimately, Mtg16 plays a crucial role in the development of 
immature B-cells as well as the function of mature splenic B-cells, likely through the 
interaction with both E-proteins and Bcl6.   
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Figure 39. Decreased germinal center response after immunization in the
absence of Mtg16  Representative pictures of total spleen sections from wild-
type or Mtg16-/- mice injected with Alum or Alum + NP-(CGG) stained with Peanut
Agglutinin to identify germinal centers.  Positive germinal centers denoted by
arrow head.  2x magnification.  Germinal centers were quantified manually and
graphed as a percent of total follicles.  Data from three experiments with a total
NP-CGG injected of N=9 for wild-type and  N=10 for Mtg16-/-***p<0.001
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Discussion 
 
 Mtg16 has been identified as the critical myeloid translocation gene family 
member in hematopoiesis, as it is the most highly expressed family member and the only 
family member to exhibit hematopoietic defects in knock-out mouse models
19,47,48
. Much 
like other targets of chromosomal translocations that produce leukemia, Mtg16 functions 
across hematopoiesis and serves as a master regulator of lineage commitment and 
survival. Previous studies have shown defects in Mtg16
-/-
 hematopoietic cell development 
and lineage allocation, particularly in myeloid versus lymphoid cell fate decisions.  Here, 
we show that B-cell development was impaired in the absence of Mtg16 and this 
impairment led to lymphopenia (Fig. 28).  This defect was more severe after stress, such 
as bone marrow transplant or in in vitro differentiation assays, and Mtg16
-/-
 B-cells have 
deficits in growth and survival in vitro (Fig. 29, 33, 34).  In addition to impaired 
development of maturing B-cells, Mtg16
-/-
 mice displayed immune function defects, 
including decreased proliferation in response to a mitogen and a defect in germinal center 
reactions (Fig. 38, 39).  Collectively, these data suggest that Mtg16 is a critical regulator 
of not only immature B-cell development, but also mature immune function. 
 Decreases to early B-cells are not surprising, given that immature progenitor cells 
with lymphoid potential, namely LMPP cells (Chapter III) and CLP cells (Fig. 32), are 
consistently decreased in the absence of Mtg16.  Microarray analysis of early B-cell 
progenitors showed increased expression of myeloid specific genes such as Itgam and 
MPO.  In T-cell specific assays, myeloid development occurred at the expense of 
lymphoid development, and Mtg16
-/-
 stem cells preferentially gave rise to Gr1
+
/Mac1
+
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cells after competitive bone marrow transplant (Fig. 29).  Very little myeloid 
development can occur in the context of IL7-containing methylcellulose and these assays 
do not directly test the potential of sorted stem cell populations, but instead reflect the 
decrease in total progenitor cells with B-cell potential from Mtg16
-/-
 bone marrow.  
Nonetheless, increased myeloid commitment and decreased lymphoid commitment 
contributed to the loss of B-cells in the absence of Mtg16.   
Much like the phenotype seen in T-cell development, the phenotypes shown here 
are also likely related to disruption of the bHLH E-protein family.  While expression of 
E-proteins such as E2A are not disrupted in early Mtg16
-/-
 B-cells, Id2 expression was 
increased.  Id2 functions as a negative regulator of E-proteins, and its expression impairs 
the ability of E2A to function in early B-cell specification
224
.  Furthermore, over-
expression of Id2 leads to increased marginal zone commitment, a phenotype seen in the 
absence of Mtg16 as well
149
.  Id2 expression is regulated by E2A and Gfi1, which are 
both binding partners of Mtg16.  Moreover, Gfi1
-/-
 mice have increased expression of Id2 
across several hematopoietic populations, much like Mtg16
-/-
 mice.   Deletion of one 
allele of Id2 rescued B-cell development from Gfi1
-/-
 mice, and it is possible that it would 
have similar effects in the context of Mtg16
285
.  
 One of the most striking phenotypes seen in the Mtg16
-/-
 mouse is an impaired 
response to stress, such as the replication stress associated with rapid proliferation in in 
vitro assays.  While Mtg16
-/-
 mice are capable of making the necessary erythrocytes for 
survival, they cannot make any BFU-E colonies methylcellulose supplemented with 
erythropoietin
19
.  Similarly, B-cell development occurred at a reduced rate in the absence 
of Mtg16, but was severely impaired in IL7-containing methylcellulose colony formation 
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assays.  This defect was associated with a severe impairment in cell proliferation and 
survival (Fig. 34) that was alleviated by deletion of p53 (Fig. 36).  Data is accumulating 
that suggests MTGs are necessary for appropriate cell cycle control, cell survival, and 
DNA damage control, potentially through indirect transcriptional effects or potentially 
from a to-be-determined direct role in cell cycle progression.  
 The work shown here is the first report of Mtg16 functioning in mature immune 
responses.  Inactivation of Mtg16 led to a significant lymphopenia, and we hypothesized 
that decreases to peripheral lymphocytes caused impaired immune function.  The two-
fold decrease in splenic B-cells was unlikely to cause a significant decrease in germinal 
center response, though, and it is possible that Mtg16 plays a direct role in the germinal 
center.  The loss of a germinal center reaction in the absence of both Bcl6 and Hdac3, 
suggests that at least three of the components of the Bcl6-Mtg-NCoR-Hdac3 complex are 
necessary for germinal centers to form.  Bcl6 is capable of interacting with several 
different co-repressors, but it appears that the NCoR/SMRT interaction is primarily 
responsible for repression of DNA damage targets such as p53
156
.  Future work will focus 
on locating Mtg16 at Bcl6-regulated promoters in the spleen and identifying direct targets 
of Mtg16-dependent repression. CDKN1A (p21) is an attractive target, as it is up 
regulated in early Mtg16
-/-
 B-cells and repression of p21 is an important function for Bcl6 
in the germinal center.   
 
 
 
 
 
 150 
 
 
CHAPTER V 
 
DISCUSSION 
 
 Myeloid translocation genes are uniquely situated as transcriptional corepressors 
to regulate multiple different transcription factors that are critical for hematopoiesis.  As 
such, they can act as master regulators of growth and development, integrating signals 
into transcriptional programs that define cell fate and growth/survival.  Previous work 
had defined roles for Mtg16 in regulating transcription in erythropoiesis and stem cell 
homeostasis and, for the first time, we have shown that Mtg16 regulates transcription in 
the context of lymphoid development.  Therefore, much like other targets of 
chromosomal translocations that lead to leukemia, Mtg16 is an important modulator of 
hematopoiesis including and beyond the myeloid progenitor population that results from 
leukemic transformation.   
In the absence of Mtg16 both B- and T-cell development are perturbed.  Given 
that B- and T-cell development diverge beyond the LMPP population and rely upon 
different combinations of transcription factors to facilitate lineage commitment, we 
divided our analysis into two parts.  It is likely, though, that changes to early lymphoid 
commitment up to and including the LMPP population affect B- and T-cell development 
equivalently.  Therefore, the work in Chapter III that suggests increased myeloid 
commitment in the absence of Mtg16 also affects our interpretation of the data in Chapter 
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IV.  Single-cell lineage potential assays, where sorted single cells are cultured in the 
presence of IL7, Flt3L, and SCF to support both myeloid and lymphoid commitment 
would help address the possibility that Mtg16
-/-
 LT-HSCs or LMPP cells have increased 
myeloid and decreased lymphoid potential
51
.  Ultimately, gene expression analysis of 
LMPP cells at the single cell level would define the relative percentage of myeloid and 
lymphoid primed cells and the relative percentage of priming within a given cell
59
.  
Given that myeloid lineage genes are upregulated in early B-cells and Mtg16
-/-
 cells have 
increased myeloid capacity after transplant, I hypothesize that more Mtg16
-/-
 LMPP cells 
will be strictly myeloid primed.   
In Chapter III, we show that Mtg16 can regulate T-cell development and does so 
by interacting with both the Notch intracellular domain and E2A, two factors that are 
known to intersect in critical regulation steps for T-cell development.  While previous 
data suggested that Notch and E-proteins regulate many of the same targets, this is the 
first work that shows that they share a common interacting partner that facilitates their 
ability to regulate T-cell development
9
.  While NICD and E-protein interaction are 
necessary functions for Mtg16 in regulating T-cell development, Mtg16 is capable of 
interacting with other factors that play important roles in T-cell development, namely 
Gfi1, and the list of Mtg16-interacting factors continues to expand
26,98
.  Given that Mtg16 
can interact with Gata factors such as Gata1 in erythroid and megakaryocyte 
development, it is interesting to hypothesize that it can also interact with Gata3 and 
regulate that T-cell specific factor, though no such interaction has been previously 
demonstrated
32
.  Nonetheless, Mtg16 potentially serves as a master regulator of early T-
cell development through the NICD, E-proteins, and Gfi1. 
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In addition to regulating early T-cell development, Mtg16 can affect both early 
and late B-cell development and function.  In Chapter IV, we show that the role of Mtg16 
in early B-cell development is twofold: one, regulating early cell fate choices towards 
lymphoid lineages and the concurrent production of early B-cell progenitors, namely 
LMPP cells and CLP cells and two, regulating the growth and survival of early B220
+
 
cells under the stress conditions of in vitro differentiation assays.  Mtg16 also regulates 
the expansion and survival of immature T-cells in culture, adding further evidence to the 
hypothesis that MTGs are important regulators of cell growth.   
One question raised for ongoing analysis is how mechanistically MTGs are 
regulating cellular expansion.  There are several hypotheses to be tested, and it is likely 
that they are inter-related and not mutually exclusive.  The most obvious answer is that 
MTGs directly regulate the expression of specific genes that are involved in cell growth 
and survival, further supported by expression changes in genes such as p21 and Bcl2 in 
Mtg16
-/-
 B-cells.  This hypothesis has been difficult to test directly in B-cell assays, as in 
vitro complementation or rescue experiments cannot be performed in the context of the 
methylcellulose assay as the infection conditions disrupt development within this very 
sensitive experiment.   
Therefore, our next step will be to attempt to generate pre-B cultures.  These 
cultures allow expansion and development of B-cells through the full range of early B-
cell populations.  In the absence of both E2A and Bcl-6, two Mtg16 interacting proteins, 
pre-B cells cannot grow in culture without transformation by an oncogene such as v-
Abl
142,207
.  Even in the context of transformation, E2A
-/-
 and Bcl-6
-/-
 pre-B cultures have 
deficits in cell growth and survival.  While Mtg16
-/-
 pre-B colonies are generated in 
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M3630 methylcellulose, they exhibit many of these same growth and survival defects.  
Therefore, while we do not anticipate needing to transform early B-cells to facilitate 
culture initiation, we do anticipate that Mtg16
-/-
 pre-B cultures will exhibit growth 
defects.  Complementation of these defects with retroviral reintroduction of Mtg16 will 
allow structure-function analysis and we anticipate that both E2A and Bcl6 will 
contribute to Mtg16 function in early B-cell survival. 
Alternatively, it is becoming apparent that MTGs may function outside of the 
canonical role in transcriptional repression.  For example, MTGs may regulate 
transcriptional elongation, most likely of specific genes involved in cell differentiation 
but potentially as part of a global phenomenon.  We and others have data that shows 
MTGs are capable of binding components of the transcriptional elongation machinery, 
including MLL, Tif1, and Dot1L, and phenotypes generated by the loss of other 
components of the transcriptional elongation machinery match well with some Mtg16
-/-
 
phenotypes
286
.  It is possible that by disrupting transcriptional elongation, loss of MTGs 
leads to stalled RNA Pol II, which stalls replication forks and increases DNA damage, 
producing cell cycle arrest and apoptosis.  This idea is further supported by data from 
both Chapter IV and Mtg8
-/-
 MEFs that show increases in DNA damage in the absence of 
MTGs.   
Additionally, in Chapter IV we show for the first time an important role for 
Mtg16 in regulating the immune response, and specifically the germinal center response.  
Mtg16 interacts with Bcl6, a critical determinant of germinal center reactions, and, like 
Bcl6
-/-
 mice, Mtg16
-/-
 mice have drastically decreased germinal center formation
282,283
.  
This result was somewhat surprising given that Bcl6 interacts with several different 
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corepressors in regulating the germinal center reaction
156
.  The impact of Mtg16 on 
germinal centers may be magnified due to its ability to regulate proliferation of splenic B-
cells in response to a mitogen and its ability to interact with E2A, which also contributes 
to the germinal center response
137
. Repression of the p53 DNA damage response is an 
important mediator of Bcl6 function in germinal centers, and in the absence of Bcl6, 
increases to DNA damage lead to apoptosis and loss of germinal centers
151
.  Given that 
deletion of p53 rescues in vitro methylcellulose colony formation from Mtg16
-/-
 bone 
marrow, we hypothesize that it will also rescue formation of the germinal center 
response.  
The interaction between Mtg16 and E-proteins is one of the most robust and 
reproducible interactions of Mtg family members, but prior to this work, a function for 
this interaction was unknown.  Recent work by our group suggests that the interaction 
between Mtg16 and E-proteins is also an important component of stem cell regulation.  
E2A
-/-
 mice have decreased stem cell self-renewal, a phenotype that matches closely with 
the loss of Mtg16
208,209
.  Both phenotypes result from increased cell cycle entry, and 
Mtg16 binds to an E2A binding site in the first intron of E2F2, potentially providing a 
target for repression.  The E2A binding site in E2F2 was identified as positively regulated 
in early B-cells but it is possible that in the context of LT-HSCs that need to restrict cell 
cycle entry, E2A functions as a repressor for this specific gene
121
.  Alternatively, Mtg16 
can negatively regulate E2A activation targets as a mechanism for more precise 
modulation of E2A mediated gene expression.  The F210A mutant generated in Chapter 
III fails to reconstitute Mtg16
-/-
 cell function in not only the CFU-S assay, but also in 
stem cell self-renewal assays such as the LTC-IC assay (Fischer et al, in prep).  
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Therefore, the Mtg16-E-protein interaction is important for T-cell development, 
hematopoietic stem cell function, and potentially B-cell function as well. 
MTGs were first discovered for their role in chromosomal translocations that lead 
to Acute Myeloid Leukemia.  In attempting to better understand how these translocations 
lead to leukemia, we and other groups have created knock-out mouse models for each of 
the three family members.  Initial hypotheses theorized that Mtg8 would serve a critical 
role in regulating hematopoiesis, as this is the family member that is most frequently 
disrupted with the AML1-ETO fusion protein translocation.  Surprisingly, Mtg8
-/-
 mice 
have no discernable hematopoietic phenotypes
45
.  Instead, Mtg16 appears to be the 
critical family member for regulating hematopoiesis.  Not only is it the most highly 
expressed, but it also has the most severe hematopoietic phenotypes
19,47
.  These 
phenotypes overlap with some of the phenotypes found with over-expression of the 
AML1-ETO fusion protein, including increased granulocyte/monocyte skewing and 
impaired lymphoid development
257,258
.  Both AML1-ETO and Mtg16 regulate cell 
growth and survival, though the effect of Mtg16 deletion on cell cycle status appears to 
be population specific
238
. 
Dimerization with other Mtg family members is a critical function of the AML1-
ETO fusion protein
236
.  When combined with the emerging role for Mtg16 in 
hematopoiesis, this fact suggests that disruption of Mtg16 by the fusion protein, 
effectively creating Mtg16
-/-
 hematopoietic cells, is a significant mechanism of action for 
the AML1-ETO fusion protein.  In fact, previous work has shown that the fusion protein 
acts in part by disrupting the ability of Mtg16 to interact with NCoR and our own group 
has shown that the fusion protein is capable of activating transcription by certain factors 
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primarily by titrating away repressors such as NCoR
237
 (Moore in revision).  This 
information leads to a new model for AML1-ETO mediated disruption of transcription 
(Fig. 40).  In this model, the fusion protein tethers ETO to Runx1 targets, recruiting other 
MTG family members to repress Runx1 transcription (Fig. 40B).  In addition, AML1-
ETO de-represses MTG targets, potentially by titrating away NCoR and other 
corepressors from MTGs bound at their appropriate promoters (Fig. 40C).  Alternatively, 
AML1-ETO may disrupt the ability of Mtg16 to bind target transcription factors, 
effectively creating an Mtg16
-/-
 cell (Fig. 40D).  In the absence of normal Mtg16 function, 
differentiation patterns are disrupted, with loss of lymphoid lineages and skewing 
towards myeloid development.  DNA damage increases, by a to-be-determined 
mechanism, and cell cycle kinetics are disrupted, common features in Mtg16
-/-
 
populations identified here.  Ultimately, in the presence of a second hit mutation, 
leukemia develops.   
Future studies addressing the localization of Mtg16 on chromatin in the presence 
of the fusion protein will be very useful in addressing this hypothesis.  Does Mtg16 travel 
to Runx1 targets as a dimerization partner of AML1-ETO, removing it from endogenous 
targets?  Does the presence of the fusion protein impair the ability of Mtg16 to interact 
with other binding partners, namely transcription factors such as E2A?  We have very 
preliminary results to suggest that expression of AML1-ETO may impair the ability of 
Mtg16 to repress E-protein mediated transcription, though the effect is subtle by 
luciferase assay.  Finally, work is currently underway to determine if loss of Mtg16 itself 
is sufficient to predispose cells to transformation.  The incidence of Mtg16 mutations in 
other cancers would suggest that such a phenomenon is likely. 
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